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Diffuse gliomas are highly lethal central nervous system malignancies which, unfortunately, 
are the most common primary brain tumor and also the least responsive to the very few 
therapeutic modalities currently available to treat them.  IGFBP2 is a newly recognized 
oncogene that is operative in multiple cancer types, including glioma, and shows promise 
for a targeted therapeutic approach. Elevated IGFBP2 expression is present in high-grade 
glioma and correlates with poor survival. We have previously demonstrated that IGFBP2 
induces glioma development and progression in a spontaneous glioma mouse model, 
which highlighted its significance and potential for future therapy. However, we did not yet 
know the key physiological pathways associated with this newly characterized oncogene.  
We first evaluated human glioma genomics data harnessed from the publicly available 
Rembrandt source to identify major pathways associated with IGFBP2 expression. Integrin 
and ILK, among other cell migration and invasion-related pathways, were the most 
prominently associated.  We confirmed that these pathways are regulated by IGFBP2 in 
glioma cells lines, and demonstrated that 1) IGFBP2 activates integrin α5β1, leading to the 
activation of key pathways important in glioma; 2) IGFBP2 mediates cell migration 
pathways through ILK; and 3) IGFBP2 activates NF-κB via an integrin α5 interaction. We 
then sought to determine whether this was a physiologically active signaling pathway in vivo 
by assessing its ability to induce glioma progression in the RCAS/tv-a spontaneous glioma 
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mouse model. We found that ILK is a key downstream mediator of IGFBP2 that is required 
for the induction of glioma progression. Most significantly, a genetic therapeutic approach 
revealed that perturbation of any point in the pathway thwarted tumor progression, 
providing strong evidence that targeting the key players could potentially produce a 
significant benefit for human glioma patients.  The elucidation of this signaling pathway is a 
critical step, since efforts to create a small molecule drug targeting IGFBP2 have so far not 
been successful, but a number of inhibitors of the other pathway constituents, including ILK, 
integrin and NF-κB, have been developed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
Table of Contents 
Approval Sheet .................................................................................................................... i 
 
Title page ............................................................................................................................ ii 
 
Acknowledgments ............................................................................................................ iii 
 
Abstract .............................................................................................................................. v 
 
Table of Contents ............................................................................................................. vii 
 
List of figures ..................................................................................................................... x 
 
List of tables ..................................................................................................................... xii 
 
List of abbreviations ....................................................................................................... xiii 
 
CHAPTER 1: Introduction .................................................................................................. 1 
 
Glioma ................................................................................................................................. 1 
 
Introduction ............................................................................................................... 1 
 
Common molecular alterations ................................................................................. 4 
 
Therapeutics ........................................................................................................... 10 
 
Mouse models of glioma ......................................................................................... 12 
 
Insulin-like growth factor binding protein 2 ......................................................................... 18 
 
Introduction ............................................................................................................. 18 
 
Role in IGF system ................................................................................................. 18 
 
IGF-independent functions ..................................................................................... 20 
 
IGFBP2 in cancer ................................................................................................... 21 
 
Integrins ............................................................................................................................. 25 
 
Introduction ............................................................................................................. 25 
 
Integrin ligands ....................................................................................................... 25 
 
viii 
 
Integrin signaling pathways .................................................................................... 26 
 
Integrin activation ................................................................................................... 28 
 
Integrins in cancer .................................................................................................. 31 
 
Therapeutic inhibition ............................................................................................. 32 
 
Integrin-linked kinase ......................................................................................................... 34 
 
Introduction ............................................................................................................. 34 
 
Kinase or pseudokinase? ....................................................................................... 36 
 
ILK in cancer .......................................................................................................... 38 
 
Therapeutic inhibition ............................................................................................. 41 
 
NF-κB ................................................................................................................................ 43 
 
Introduction ............................................................................................................. 43 
 
NF-κB regulation and activation .............................................................................. 44 
 
NF-κB and cancer .................................................................................................. 47 
 
NF-κB in glioma ...................................................................................................... 49 
 
Therapeutic inhibition ............................................................................................. 50 
 
Hypothesis ......................................................................................................................... 53 
 
CHAPTER 2: Materials and methods .............................................................................. 54 
 
CHAPTER 3: Results ........................................................................................................ 62 
 
IGFBP2 is clinically linked to the integrin and ILK pathways ............................................... 62 
 
IGFBP2 regulates downstream pathways via integrin activation......................................... 69 
 
ILK is required for IGFBP2-induced cell mobility ................................................................ 77 
 
IGFBP2 regulates an invasion-related NF-κB transcriptional program................................ 82 
 
Integrin, ILK, and NF-κB regulate IGFBP2-induced glioma progression ............................. 92 
 
CHAPTER 4: Discussion .................................................................................................. 98 
ix 
 
 
Summary ........................................................................................................................... 98 
 
The role of the IGFBP2 pathway in cell migration and invasion .......................................... 98 
 
Functional significance of the IGFBP2/integrin relationship .............................................. 100 
 
IGF-independent functions of IGFBP2.............................................................................. 101 
 
Integrin-linked kinase as a key mediator in glioma progression ........................................ 102 
 
The role of NF-κB and potential regulatory loop with IGFBP2 .......................................... 103 
 
IGFBP2 represents a physiologically active signaling pathway ........................................ 105 
 
Therapeutic implications................................................................................................... 105 
 
CHAPTER 5: Future directions ...................................................................................... 108 
 
Appendix ........................................................................................................................ 111 
 
Bibliography ................................................................................................................... 141 
 
Vita .................................................................................................................................. 201 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Figures 
 
Figure 1. Genomic alterations in glioma involve 3 key signaling pathways ........................... 9 
 
Figure 2. Schematic of integrin activation ........................................................................... 30 
 
Figure 3. ILK is a critical signaling molecule ....................................................................... 35 
 
Figure 4. Canonical and non-canonical NF-κB signaling pathways .................................... 46 
 
Figure 5. Proposed mechanism of IGFBP2-mediated glioma progression .......................... 53 
 
Figure 6. IGFBP2 is associated with integrin and ILK pathways in human glioma  ............. 64 
 
Figure 7. Integrin pathway genes cluster according to IGFBP2 and tumor grade  .............. 65 
 
Figure 8. ILK pathway genes cluster according to IGFBP2 and tumor grade  ..................... 66 
 
Figure 9. High expression of IGFBP2-related genes is associated with                            
poor prognosis  .................................................................................................................. 68 
 
Figure 10. IGFBP2 activates integrin β1  ............................................................................ 71 
 
Figure 11. Disruption of IGFBP2-integrin interaction alters genes in the                       
integrin pathway  ................................................................................................................ 73 
 
Figure 12. Disruption of IGFBP2-integrin interaction alters the actin                      
cytoskeleton pathway  ........................................................................................................ 74 
 
Figure 13. Disruption of IGFBP2-integrin interaction alters the ILK pathway ...................... 75 
 
Figure 14. Disruption of IGFBP2-integrin interaction alters the glioma                          
invasiveness pathway  ....................................................................................................... 76 
 
Figure 15. ILK is required for IGFBP2-induced cell motility  ................................................ 79 
 
Figure 16. ILK is required for IGFBP2-induced Rac activation  ........................................... 81 
 
Figure 17. Disruption of IGFBP2-integin significantly alters NF-κB                    
transcriptional activity  ........................................................................................................ 83 
 
Figure 18. IGFBP2 activates an NF-κB transcriptional program  ........................................ 86 
 
Figure 19. IGFPB2 induces NF-κB activity  ........................................................................ 89 
 
Figure 20. Elevated IGFBP2 expression sensitizes cells to NF-κB inhibition  ..................... 91 
xi 
 
 
Figure 21. Experimental procedure for mouse model studies  ............................................ 93 
 
Figure 22. IGFBP2 drives glioma progression by activating the                        
integrin/ILK/NF-κB network  ............................................................................................... 96 
 
Figure 23. Proposed mechanism of IGFBP2-mediated NF-κB activation  ........................ 110 
 
Appendix Figure A1. IGFBP2, ITGA5, ITGB1, and ILK Kaplan-Meier survival                      
plots according to glioma histology  .................................................................................. 112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
List of Tables 
 
Table 1. Differentially expressed NF-κB target genes resulting from                           
IGFBP2 overexpression ..................................................................................................... 84 
 
Table 2. Pearson correlation of NF-κB target genes with IGFBP2 in human glioma  .......... 87 
 
Table 3. Tumor distribution of Ntv-a mice ........................................................................... 97 
 
Appendix Table A1. Signaling pathways associated with IGFBP2 expression .................. 113 
 
Appendix Table A2. Pearson correlation of integrin pathway genes                                   
with IGFBP2 ..................................................................................................................... 123 
 
Appendix Table A3. Pearson correlation of ILK pathway genes with IGFBP2 ................... 125 
 
Appendix Table A4. Altered signaling pathways resulting from disruption of               
IGFBP2-integrin binding ................................................................................................... 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
Abbreviations 
 
CNS  central nervous system 
WHO  World Health Organization 
GBM  glioblastoma multiforme 
NF1/2  neurofibromatosis 1/2 
RB1  retinoblastoma 1 
IDH1/2  isocitrate dehydrogenase 1/2 
MGMT  O6-methylguanine-DNA methyltransferase 
RTK  receptor tyrosine kinase 
EGFR  epidermal growth factor receptor 
PDGFR platelet-derived growth factor receptor 
PI(3)K  phosphatidylinositol 3-kinase 
PTEN  phosphatase and tensin homolog 
TCGA  The Cancer Genome Atlas 
VEGF  vascular endothelial growth factor  
GEMM  genetically engineered mouse model 
GFAP  glial fibrillary acidic protein 
RCAS Replication-Competent Avian leukosis virus long terminal repeat with a 
Splice acceptor 
SVZ  subventricular zone 
ID  inhibitor of DNA-binding 
IGFBP2 Insulin-like growth factor (IGF) binding protein 2 
ECM  extracellular matrix 
HBD  heparin binding domain 
RGD  Arginine-Glycine-Aspartic acid 
MMP  matrix metalloproteinase 
MIIP  migration and invasion inhibitory protein 
HSC  hematopoietic stem cells 
FAK  focal adhesion kinase 
GFR  growth factor receptor 
xiv 
 
EGF  epidermal growth factor 
PIP2  phosphatidylinositol (4,5)-biosphosphate 
PyVmT polyoma virus middle T antigen 
NSCLC non-small cell lung cancer 
ILK  integrin-linked kinase 
ANK  ankyrin 
NF-κB  Nuclear factor-kappa B 
EMT  epithelial to mesenchymal transition 
TGFβ  tumor growth factor beta 
SIRE  Snail ILK responsive element 
RHD  Rel homology domain 
IκB  inhibitor of κ B 
TNF  tumor necrosis factor 
IKK  IκB kinase 
SASP  senescence-associated secretory phenotype 
 
 
 
 
1 
 
CHAPTER 1:  Introduction 
 
Glioma  
Introduction.  Gliomas are glial cell derived tumors of the brain and spinal cord, 
and are characterized by poor patient prognosis. Gliomas account for 31% of all primary 
Central Nervous System (CNS) tumors and 80% of all malignant primary CNS tumors (1). 
Current treatment regimens yield meager benefit, as patients with high grade, invasive 
glioma typically do not survive longer than a year following diagnosis (2). 
The CNS is composed of a variety of cell types, including neurons, glia, and 
vascular cells (3). Neurons are cells that transmit electrical signals throughout the body, 
allowing a superhighway of information to circulate within the CNS radiating out to the 
peripheral nervous system (PNS). Glial cells are neural helper cells responsible for a variety 
of functions depending on the glial subtype. Although it was previously accepted that glia 
outnumbered neuronal cells 10:1, recent research has revealed that there are nearly equal 
numbers of neuronal and non-neuronal cells (4). The relative number of cell types, 
however, differs in various regions of the brain, with the highest ratio of non-neuronal to 
neuronal cells residing in the cerebral cortex. This pattern correlates with the distribution of 
mass within the brain (4).  Glial cells are comprised of four cell types: astrocytes, 
oligodendrocytes, ependymal cells, and microglia. Glia perform various functions including 
supporting, protecting, and supplying nutrients to neuronal cells. Astrocytes are the most 
numerous type of glia in the brain and respond to inflammation by proliferating and 
migrating to the site of injury.  Astrocytes also connect neurons to the blood supply and 
protect neurons from glutamate-induced excitotoxicity by taking up excess transmitter from 
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the synapse (5). Oligodendrocytes perform the critical function of myelinating neuronal 
axons, forming an insulative layer that allows efficient propagation of electrical signals. 
Ependymal cells make and secrete cerebral spinal fluid and form the lining of ventricles. 
Finally, microglia are the major immune cell of the brain and are known as the resident 
macrophage (3). 
There are 4 main types of glioma: astrocytoma, oligodendroglioma, mixed 
(oligoastrocytoma), and ependymoma. The World Health Organization (WHO) has 
assigned a classification scheme that describes the tumors based on histopathological 
features, and separates the diffuse gliomas, including astrocytoma, oligodendroglioma, and 
oligoastrocytoma, into two major subtypes: 1) astrocytic tumors, including pilocytic 
astrocytoma, diffuse astrocytoma, and glioblastoma multiforme (GBM); and 2) 
oligodendroglial tumors, including oligodendroglioma and mixed oligoastrocytoma (6). 
Gliomas are further classified by WHO grade (I-IV): WHO Grade I is considered non-
malignant and includes pilocytic astrocytoma; WHO Grade II is a low-grade malignant, well-
differentiated tumor, including diffuse astrocytoma and oligodendroglioma; WHO Grade III 
is anaplastic, including anaplastic astrocytoma, anaplastic oligodendroglioma, and 
anaplastic oligoastrocytoma; WHO Grade IV includes GBM (6). Glioblastoma may be 
further subdivided into primary and secondary GBMs, with primary GBM forming de novo, 
with a short clinical history and no prior history of disease (includes >90% of GBM) (7), 
while secondary GBM is much less prevalent and develops from a previously diagnosed 
less malignant lesion (8). Astrocytoma and GBM comprise 76% of all gliomas (GBM alone 
comprises 53.7%), followed by oligodendroglioma and ependymoma, which account for 
6.5% and 5.9% of all gliomas, respectively (1).  
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Gliomas occur in individuals of all ages; however, the tumor histological spectrum 
varies according to age: pilocytic astrocytoma is the most frequent glioma in children, 
whereas GBM is most common in adults (median age of 64 years), and rare in children (7). 
Younger patients (age < 45) are more likely to develop low-grade tumors. The incidence 
rate of GBM increases significantly around age 45 and continues this trend until age 84 (1). 
Gliomas are slightly more prevalent in men than women (incidence rate of 7.17 versus 5.08 
per 100,000 person-years), and the incidence rate is significantly higher among blacks than 
whites (1).  
Patient prognosis is highly dependent on glioma histology type and grade, in 
addition to patient age, mental status, postoperative Karnofsky or WHO performance 
scores (assess patient’s overall condition), and extent of surgical resection (7). 
Oligodendroglial tumors have the most favorable prognosis, with one and five year survival 
rates of 94% and 79%, respectively. Patients with an anaplastic oligodendroglioma are 
typically faced with a 49% chance of surviving five years after diagnosis. Patients with 
either an astrocytoma or anaplastic astrocytoma are typically given 5-year survival rates of 
48% or 27%, respectively. Patients with GBM have a 34.6% chance of surviving one year 
after diagnosis, and a meager 4.75% chance of surviving five years after diagnosis (1). 
Although low-grade diffuse gliomas typically yield a more favorable prognosis than their 
high-grade counterparts, these tumors have a strong propensity to progress to secondary 
GBM within 2-5 years (8). 
The etiology of glioma is largely unknown (7, 9). Environmental agents have been 
examined, but ionizing radiation is the only agent that has been clearly associated with 
increased risk of glioma (9). Several studies have reported a familial link in glioma cases 
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(10-13), and it has been suggested that 5% of glioma cases are familial (11). Although 
infrequent, certain hereditary genetic syndromes predispose subjects to glioma 
development, including Li-Fraumeni (germline TP53 mutation), neurofibromatosis 1 (NF1 
truncation or deletion), neurofibromatosis 2 (NF2 germline mutations), and Turcot syndrome 
(APC, MLH1, MSH2, PMS2 mutations) (9, 14). Additional susceptibility genes are 
retinoblastoma 1 (RB1) and tuberous sclerosis (TSC1 and TSC2) (9). The increased risk of 
glioma among genetic syndromes underlines the genetic basis of glioma development. 
Common molecular alterations in glioma.  As observed in other cancers, gliomas 
form when multiple genes become altered or mutated. Specifically, tumor suppressor genes 
are lost or mutated while oncogenes are activated thus forming the underlying genetic 
landscape of glioma. 
Codeletion of chromosome arms 1p19q is considered a genetic hallmark of 
oligodendroglioma (15). This genetic aberration is observed in 80-90% of low-grade 
oligodendroglioma and about 60% of anaplastic oligodendroglioma. In contrast, 1p19q 
codeletion is observed in <10% of astrocytic tumors, forming a genetic separation between 
oligodendroglial and astrocytic tumors (15, 16). Importantly, the classic morphology of 
oligodendroglioma, such as perinuclear halos and unique “chicken wire” vascular pattern is 
highly associated with 1p19q codeletion. It is noteworthy to mention that loss of the entire 
1p and 19q is frequently observed. Partial loss of the chromosomes or deletion of 1p alone 
may carry a different prognosis than complete 1p19q codeletion (17, 18). It is well-
documented that 1p19q predicts for increased survival rate and improved chemotherapy 
response (19-22), and it appears now that the 1p19q codeletion is more appropriately used 
as a predictive factor of response (and survival) to radio- or chemotherapies (23). 
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Recently, Parsons et al. (24) reported mutations in the isocitrate dehydrogenase 1 
and 2 genes (IDH1 and IDH2), which are involved in the citric acid cycle. IDH1 and IDH2 
mutations have been reported as strong independent prognostic factors for survival (15). 
Subsequently, mutations in these genes have been identified in >68% of low-grade gliomas 
of both oligodendroglial and astrocytic lineages, in addition to secondary GBM (25-27). 
More than 90% of IDH1 mutations occur in the active site and include R132H. IDH1 
mutations are now considered to be a critical initiating event in glioma. In fact, IDH1 
mutations have been reported to occur prior to TP53 mutation or 1p19q codeletion in serial 
biopsies of the same patient tumor. (28). Another group found that all tumors harboring a 
complete 1p19q codeletion also contained IDH1 or IDH2 mutations (29). Therefore, it is 
suggested that IDH mutations may be a prerequisite for 1p19q codeletion and 
oligodendroglioma development (15).  
In accordance with conventional tumor development, gliomas contain characteristic 
losses or mutations in key tumor suppressor genes, including TP53, CDKN2A, and 
phosphatase and tensin homolog (PTEN) (30). Gliomas are strongly impacted by mutation 
or loss of TP53, which encodes the “guardian of the genome,” p53. TP53 mutations are 
considered to be an early event in glioma development and have been reported in >60% of 
diffuse astrocytomas, in ~40% of mixed oligoastrocytomas, and <5% in oligodendrogliomas 
(31, 32). Notably, TP53 mutations and 1p19q codeletions are mutually exclusive in mixed 
oligoastrocytomas, indicating that these tumors are genetically monoclonal, resembling 
either oligodendroglioma or astrocytoma (31). PTEN is mutated or deleted in a large 
majority of GBMs, which directly affects phosphatidylinositol 3-kinase (PI(3)K) and Akt 
signaling (33). Homozygous deletion occurs in up to 36% of GBM (34), whereas loss of 
both copies rarely is observed in anaplastic and low-grade glioma (35, 36). Mutations are 
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also common in primary GBM, but rare in low-grade glioma (37). Promoter methylation, 
however, is observed in low-grade, anaplastic glioma, and secondary GBM and is 
associated with decreased PTEN protein levels (38); therefore, promoter methylation is also 
likely to play a role in low-grade glioma development. Further, PTEN expression levels and 
genetic losses are important prognostic factors for tumor grade and survival (33). The 
CDKN2A gene encodes 2 distinct proteins, p16INK4a, which prevents phosphorylation of 
RB1, thereby preventing G1/S cell cycle transition; and p14ARF, which binds to MDM2, 
thereby stabilizing p53 and preventing cell cycle progression. Similar to PTEN, CDKN2A 
genetic aberrations increase according to tumor grade. Homozygous deletion of INK4a and 
ARF is observed in 49% and 52% of GBM, respectively (34), whereas homozygous deletion 
of INK4a or ARF have been found in 25% of anaplastic oligodendroglioma, but absent in 
oligodendroglioma (39-41). Watanabe et al. (39) reported promoter hypermethylation of 
p14ARF in 21% of oligodendroglioma and in 15% of anaplastic oligodendroglioma; 
p16INK4a promoter hypermethylation was observed in only one anaplastic 
oligodendroglioma case. These data suggest a role of promoter hypermethylation in the 
transformation process and selection of homozygous deletion of INK4a and ARF in 
subsequent progression processes (39).   
Receptor tyrosine kinases (RTK) are frequently overexpressed or mutated in glioma, 
and include epidermal growth factor receptor (EGFR), Platelet-derived growth factor 
receptor (PDGFR), ERBB2, and c-MET (30). Ligand binding results in activation of 
downstream Ras and PI(3)K signaling cascades that promote cell proliferation, invasion, 
and growth. Among these, EGFR is the most prevalent alteration, affecting ~45% of GBMs 
(34). Genomic amplification is the most frequently observed aberration (34) and usually co-
occurs with point mutations and deletions in both the extracellular and cytoplasmic 
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domains. One such example is EGFR variant III (EGFRvIII), which lacks exons 2-5 of the 
extracellular domain, causing constitutive activation of the receptor (42, 43). PDGF 
signaling is altered in both low-grade glioma and 13% of GBM by amplification or mutation 
of the receptor, or overexpression of PDGF ligands (34, 44). Less frequently, mutation of 
ERBB2 (part of the EGFR family) and amplification of MET are observed in 13% and 4% of 
GBMs, respectively (34). 
         The Cancer Genome Atlas (TCGA) research network launched a collaborative effort 
to investigate integrative large-scale molecular alterations in GBM by incorporating DNA 
copy number, DNA methylation, and gene expression (34). Overall, frequent genetic 
alterations occurred in three critical signaling pathways: 1) RTK signaling was altered in 
88% (included amplification of EGFR, PDGFRA, MET, and Akt; mutations of EGFR, 
ERBB2, NF1, RAS, PI3K, PTEN, and FOXO; homozygous deletion of PTEN and NF1); 2) 
p53 signaling was altered in 87% (included amplification of MDM2 and MDM4; homozygous 
deletion and mutation of CDKN2A(ARF) and TP53); and 3) RB signaling was altered in 
78% (included homozygous deletion and mutation of CDKN2A(INK4A), CDKN2B, 
CDKN2C, RB1; amplification in CDK4, CCND2, CDK6). Subsequent work by Verhaak et al. 
(30) analyzed TCGA GBM genomics data and reported distinct subtypes of glioma based 
on molecular signatures: proneural, neural, classical, and mesenchymal. EGFR alterations 
defined the classical subype; NF1, the mesenchymal subtype; and PDGFRA/IDH1, the 
proneural subtype. They further demonstrated that these subtypes were important in 
response to aggressive therapies, with classical and mesenchymal groups having a 
statistically significant prolonged survival and while there was no difference in survival 
among the patients of the proneural group  (45). Other investigators have also undertaken 
efforts to sub-classify GBM via transcriptional profiling, DNA sequence and copy number, 
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proteomic markers, and DNA methylation (46-52). These studies have been useful in 
identifying prognostically significant gene signatures and in sub-dividing GBM into distinct 
classes, reflecting the complexity of GBM (53).  
Prognostic indicators are critical in order to optimally treat patients. One such 
important prognostic marker and molecular alteration in glioma is promoter methylation of 
O6-methylguanine-DNA methyltransferase (MGMT), which results in its epigenetic silencing 
(54). MGMT encodes a DNA repair enzyme that removes alkyl groups from the O6 position 
of DNA. The standard of care involves DNA alkylating agents such as nitrosourea or 
temozolomide, which impedes gene transcription and triggers apoptosis. Decreased levels 
of MGMT via promoter methylation would prevent tumor cells from repairing DNA alkylation 
and subsequently induce cell death. This is the most probable reason why MGMT promoter 
methylation is a strong response predictor to chemotherapies (55-57). Recent studies 
reported a favorable predictive response to radiotherapy alone (58), independent of either 
alkylating chemotherapy or radiotherapy (21, 59). 
Histologic analysis remains the gold standard of glioma diagnosis (60). Features 
including cell density, microvascular proliferation, mitotic activity, necrosis, and nuclear 
atypia are utilized to distinguish glioma grade. However, morphological analyses are often 
subjective and do not distinguish the molecular alterations in the cell. For example, we now 
know that primary and secondary GBM have marked molecular differences (8); however, 
they are morphologically indistinguishable and are treated as a single disease. As 
researchers continue to uncover molecular pathogenesis of glioma, future diagnoses will 
most likely include molecular classifiers. 
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Figure 1. Genomic alterations in glioma involve 3 key signaling pathways. TCGA 
research network performed large scale genomics analysis of GBM and revealed that 
alterations occurred in 3 major signaling pathways: in the RTK/Ras/PI3K pathway, in the 
p53 signaling pathway, and in the RB signaling pathway. This figure was used with 
permission and originally published by Riddick and Fine (61). 
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Therapeutics.  Malignant gliomas are incurable. Treatment remains palliative, 
consisting of surgical resection, external-beam radiation, and chemotherapy. Surgery is the 
front-line defense depending on the tumor location and is an important factor since the 
amount of tumor resection strongly predicts patient prognosis and survival (62). To ensure 
that the maximum amount of tumor is removed without affecting critical functions, surgeons 
utilize cortical and subcortical stimulation during surgery (63). A tumor infiltrating the 
primary motor cortex or corpus callosum may allow for only partial resection (7).  The 
infiltrative nature of glioma cells makes complete tumor resection virtually impossible, as 
individual glioma cells pervade surrounding normal tissue leading to tumor recurrence in 
new anatomical locations. 
The standard of care for newly diagnosed GBM includes concurrent radiation and 
temozolomide treatment with continued temozolomide. This regimen increased median 
survival from 12.1 months with radiotherapy alone to 14.6 months with radiation plus 
temozolomide; the 2-year survival rate was increased from 10.4% to 26.5% with 
temozolomide (57). Temozolomide was the first chemotherapy drug demonstrated to 
significantly increase GBM patient survival rates (7). Until this report, carmustine was 
administered adjuvantly following radiation, although large randomized clinical trials 
demonstrated a significantly increased survival benefit compared to radiation alone. Despite 
the moderate success of temozolomide, tumors inevitable recur. There is no standard 
treatment option for recurrent GBM; generally temozolomide is re-administered, and select 
patients may undergo additional surgery (7). 
Low-grade gliomas are treated less aggressively. Surgery is the front-line therapy, 
similar to GBM. Although the role of chemotherapy in low-grade glioma is not entirely clear, 
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typically patients are treated with temozolomide (64). Oligodendroglioma and mixed 
oligoastrocytoma have demonstrated the most favorable response to temozolomide, with 
1p19q combined loss dictating the highest response (65).  
The explosion of the genomic and high throughput era has provided the opportunity 
to tailor treatment to individual tumors. Further, targeting specific molecules that play a key 
role in tumor development and progression should produce an enhanced response versus 
non-targeted cytotoxic therapies. Molecular targeted therapies should be less toxic to 
normal cells, as they theoretically target tumor cells alone. Since the majority of GBMs have 
EGFR alterations, inhibitors against EGFR are an attractive target for therapy; however, 
inhibition of EGFR alone does not yield promising results. Similar results were observed in 
a clinical trial evaluating monotherapy of the PDGFR inhibitor, Imatinib (66). Dr. Ron 
DePinho’s group later reported that activation of multiple RTKs was creating signaling 
redundancy, leading to the ineffectiveness of single RTK inhibition (45). Many clinical trials 
have assessed effectiveness of targeted agents, primarily against RTKs as well as vascular 
endothelial growth factor (VEGF), Akt, Src, mTOR, and integrins (67). Most current clinical 
trials are adding novel agents to the standard of care treatment. Thus far, few have yielded 
promising results; however, cilengitide (an integrin αv inhibitor) and bevacizumab (VEGF 
inhibitor) are currently being evaluated in Phase III randomized trials in combination with 
temozolomide and radiation (7). Select clinical trials are stratifying patients based on MGMT 
promoter methylation to determine its potential prognostic and predictive value (7), given 
that retrospective studies have reported better response to chemotherapy in MGMT 
promoter methylated cases. Other clinical trials have evaluated tumor cell vaccines, 
including an EGFRvIII-targeted vaccine (68) and an autologous dendritic cell vaccine (69). 
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Other trials are assessing oncolytic viruses (70) and herpes simplex virus-thymidine kinase 
gene therapy (7). 
Mouse models of glioma.  Mouse models are vital for glioma research. They 
provide means to evaluate a broad spectrum of hypotheses in a more biologically relevant 
manner. Cell culture experiments are performed with relative ease and are important and 
necessary to examine detailed molecular events that are required to form the basis of 
animal model experiments. However, appropriate mouse models are needed to reflect the 
heterogeneity and complexity of glioma in a living organism. Highly relevant biological 
endpoints such as tumor grade and size, vasculature (which plays critical role in tumors), 
and survival can all be evaluated in mouse models, but not in cell culture. 
Xenografts are the most common type of mouse model and are also the most time 
and cost efficient. Xenograft experiments involve the implantation of cultured human cancer 
cell lines, either subcutaneously or orthotopically into immunocompromised mice. There are 
several advantages to this type of model, such as retaining the ability to manipulate the 
cells prior to implantation. Subcutaneous xenografts offer easy access to the tumor so that 
tumor growth (or shrinkage) may be measured over time with calipers without the labor-
intensive and costly MRI or other imaging modalities. Additionally, drugs can be more easily 
injected directly into the tumor, precluding the obstacle of drug delivery due to the blood-
brain-barrier. Orthotopic xenografts into the brain allow interaction of glioma cells with brain 
stromal microenvironment and are more likely to reflect a physiologically relevant setting, 
but the compromised immunity of these mice does not reflect the true microenvironment. 
Although xenografts are advantageous, there are several disadvantages. In general, they 
don’t closely recapitulate human glioma due to the use of cell lines that have been 
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maintained in a very different environment and are likely to have acquired mutations over 
time and diverged from their original state (71). Further, orthotopic xenografts don’t have 
the distinct diffuse growth patterns that are characteristic of human glioma; xenografts 
typically produce larger tumors with defined borders. Finally, it is evident that better models 
are required, since drug development testing has yielded limited predictive values (72). 
Genetically engineered mouse models (GEMM) possess much potential for 
delineating the molecular pathogenesis of glioma development and progression, examining 
the cell(s) of origin, as well as for preclinical testing of drug candidates. GEMMs enable the 
study of glioma in a more physiologically relevant environment in immunocompetent mice, 
with the brain stroma and microenvironment intact. These models are valuable because 
they allow one to determine the functional roles of key molecules and signaling pathways 
leading to tumor formation and progression in a living organism. Several studies have 
reported that the molecular characteristics of tumors derived from glioma GEMMs closely 
resemble the human counterpart tumors (73-76). 
         Conventional GEMMs include transgenic and knockout mice. Transgenic mice 
express transgenes under the control of a specific promoter, which directs expression of the 
oncogene to a certain cell population or tissue. Tumor suppressor genes may be eliminated 
via conventional gene knockouts, in which one or both alleles are knocked out in every cell 
(77).  Further genetic manipulation can be achieved by knocking out genes conditionally 
using Cre/loxP technology, in which loxP recombination sequences are inserted (flanking) 
on either side of the gene (floxed) (78). Cre-recombinase then mediates recombination and 
effectively eliminates the gene’s function. Floxed mice are crossed with Cre-transgenic 
mice, which results in recombination. Cell lineage-specific gene knockout may be achieved 
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by placing Cre under promoters such as the glial fibrillary acidic protein (GFAP) promoter, 
which directs expression of glial precursors and astrocytes. Alternatively, studies have been 
performed in which Cre was delivered stereotactically into the brain via adenoviral or 
lentiviral vectors. 
Combined transgenic or knockout mice are utilized to study the combinations of 
important genetic lesions. This approach requires labor-intensive germline mutagenesis 
and extensive breeding schemes. An alternative method involves viral somatic gene 
transfer which is generally injected directly into the brain. Initially, murine retrovirus 
(MoMuLV)-mediated delivery of the PDGFB oncogene was utilized to successfully generate 
glioma (79). A similar approach involves using the avian retrovirus Replication-Competent 
Avian leukosis virus long terminal repeat with a Splice acceptor (RCAS), to enable gene 
delivery (80). Transgenic mice have been engineered to express the RCAS receptor, tv-a, 
under the control of specific promoters, including GFAP, nestin (directs expression of 
neural/glial stem cells), or most recently 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) 
(directs expression of oligodendrocyte progenitor cells) (81). These transgenic mice are 
referred to as Gtv-a, Ntv-a, or Ctv-a, respectively. RCAS viral particles carrying the 
transgene are injected into the brains of newborn Gtv-a, Ntv-a, or Ctv-a mice. RCAS infects 
only cells that express the tv-a receptor, thereby directing transgene expression to a 
specific cell population (80, 82). RCAS vectors have also been modified to incorporate a 
Tetracycline (tet) inducible component (83). An RCAS vector containing the reverse 
tetracycline transcriptional transactivator in addition to an RCAS vector (that places the 
gene of interest under the control of the tet response element) are injected, enabling timed 
expression of the gene of interest upon exposure to the tamoxifen analog, doxycycline. The 
RCAS/tv-a model is advantageous since combinations of oncogenes may be delivered 
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simultaneously, affording relative ease of examining oncogene cooperation. Further, RCAS 
infection and subsequent oncogene expression is restricted to a few cells within the injected 
geographical area, compared to the widespread transgene expression in traditional 
transgenics. This restricted expression of oncogenes more closely recapitulates the human 
disease, in which it is generally accepted that tumor formation occurs in a single cell of 
clonal origin (84).  
Most GEMMs have focused on the key signaling pathways that have been reported 
in human glioma, such as loss or mutation of tumor suppressors p53, PTEN, NF1, and 
INK4a/ARF; and gain of function oncogenes EGFR, PDGF (PDGFR), genes in the PI3K 
pathway, and the ras gene family, HRAS and KRAS (84). Typically a single mutation or 
genetic alteration is insufficient to initiate glioma development, however, there are a few 
exceptions including PDGFB, HRAS and KRAS, and inactivation of RB (85). As previously 
mentioned, PDGFB delivered via MoMuLV led to oligodendroglioma (79). Similarly in the 
RCAS/Ntv-a model, PDGFB consistently yields high-penetrance low-grade glioma 
resembling oligodendroglioma (86-89). An activating mutation in Ras (V12Ras) induces 
astrocytoma with histology and grade dependent on gene dosage (74). Finally, inactivation 
of Rb via truncated SV40T antigen under the GFAP promoter led to 100% tumor 
penetrance of low-grade astrocytoma by 10-12 months (90). 
Combined loss of two or more tumor suppressor genes is sufficient to induce 
glioma. Loss of both NF1 and p53 is an established model of astrocytoma and spans all 
tumor grades (73, 91). Loss of a tumor suppressor gene combined with expression of an 
oncogene may also cooperate to induce glioma. While EGFRvIII alone was not able to 
induce glioma in the RCAS/tv-a system, EGFRvIII combined with loss of INK4a/ARF 
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produced glioma-like features (82). Further, activated Kras with loss of PTEN led to glioma 
(92), as did the loss of INK4a/ARF with either v-erbB (activated variant of EGFR) (93) or 
PDGFB (86, 94). Typically, upon inactivation of an additional tumor suppressor gene, tumor 
latency is decreased and histological grade is increased (84). 
Oncogene cooperation has also been widely studied, particularly in the RCAS-tv-a 
model, due to the facilitation of injecting various combinations of oncogenes 
simultaneously.  Akt combined with either activated Ras (88, 95) or Raf (96, 97) induced 
high-grade glioma, including GBM. Additional oncogenic cooperation has been reported 
with PDGFB and IGFBP2; Kras, IGFBP2, and Akt (88); and Kras, Akt, and c-myc (98). 
          Investigating the specific glial cell type leading to glioma has recently been 
investigated (99). Initial reports came from Eric Holland’s group where they observed 
differences in glioma incidence and histology between Gtv-a and Ntv-a mice injected with 
Kras and Akt. High-grade gliomas developed in Ntv-a mice, however, no tumors developed 
in either Gtv-a (95) or Ctv-a mice (100), indicating that glial cell subtype plays an important 
role in the tumorigenic potential of various genetic alterations. Other cell types that have 
been investigated are neural and glial progenitor cells that inhabit the subventricular zone 
(SVZ) (101), along with neural stem cells (102, 103). Many studies have reported stem cells 
as the cell of origin, given the evidence that cells with transgene expression and/or tumor 
suppressor gene inactivation in and around the SVZ develop glioma, whereas the same 
genetic mutations in cells in other areas others don’t. Lentiviral vectors carrying oncogenic 
Ras or activated Akt (under the control of Cre) induced GBM when injected into the SVZ, 
but tumors were rarely observed upon injection into areas such as the cortex (104). Further, 
injection of adeno-Cre into the SVZ of mice with disrupted NF1; p53; NF1 and p53; PTEN 
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and p53 resulted in 100% penetrance when injected into SVZ, but not when injected into 
cortex or striatum (105). Another study found that mutated cells migrated away from the 
SVZ, suggesting that these stem cells were responsible for glioma development (73). There 
are other reports, however, that dispute this theory. A recent study examined the inhibitor of 
DNA-binding (ID) genes which maintain self-renewal and multipotency of adult neural stem 
cells. Cells with low expression of ID1, which had high proliferative ability and low self-
renewing potential, actually formed tumors with a higher penetrance than cells with high ID1 
expression, which had both high proliferative ability and high self-renewing potential. 
Disruption of the ID genes had minimal effects on animal survival, but knockdown of Olig2 
(committed oligodenrocyte lineage) had a significant survival effect in cells with low ID1 
expression (106). This study indicated that self-renewal potential does not impact tumor 
growth, demonstrating that glioma initiating cells cannot be identified merely by self-
renewal, a hallmark of cancer stem cells. 
Mouse models are also of critical importance in preclinical testing, in particular those 
involving molecular targeted therapies (107). Glioma mouse models have been reported to 
have a similar disrupted blood-brain-barrier as humans, which is important given the 
challenge of efficient drug delivery in glioma (108). These models may also be monitored 
similar to humans. McConville and coworkers (109) reported that gliomas generated from 
the RCAS/tv-a model could be monitored (and graded) via MRI following temozolomide 
treatment. Although no animal model will perfectly represent the human counterpart 
disease, GEMMs can help us to better understand the underlying pathogenesis of glioma 
and develop logically devised therapeutics. 
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Insulin-like growth factor binding protein 2 
Introduction.  Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) is one of 
six proteins that comprise the IGFBPs, which bind IGFs (IGF-I and IGF-II) with high affinity 
(110). IGFBP2 is located on chromosome 2 region q33-q34 (111) and is highly expressed 
during fetal development, expressed at low levels after birth, and highly expressed again 
throughout puberty (112). IGFBP2 is the second most abundant IGFBP in serum, following 
IGFBP3 (111), and is the major IGFBP in both cerebral spinal fluid and the brain (113). 
IGFBP2 expression closely corresponds with IGF-II expression in specific anatomical 
regions in the brain. Further, IGFBP2 and IGF-II are frequently observed at locations 
separate from the cells that express these proteins; therefore, it has been suggested that 
IGFBP2 plays an important role in transporting IGF-II (114). IGFBP2 appears to be involved 
in various CNS conditions, as there is increased IGFBP2 expression during wound repair, 
in both activated microglia (indicative of immune response) and astrocytes, in damaged 
neurons, and in malignancies (115). 
Transgenic mice expressing IGFBP2 under control of the robust cytomegalo virus 
promoter resulted in a postnatal weight reduction, due primarily to affected skeletal 
composition (116). IGFBP2 mouse knockout studies revealed no overall weight changes, 
although the liver and spleen weights were increased and decreased, respectively (117). 
Subsequent studies of IGFBP2-/- mice indicated bone abnormalities (118). Other IGFBPs 
were found to compensate for the loss of IGFBP2 and likely allowed for functional 
redundancy resulting in fewer developmental defects. 
Role in IGF system.  The role of IGFBP2 in the IGF system is complex. IGFs are 
potent mitogens that, upon receptor binding, induce cell proliferation and promote anti-
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apoptotic signals. Type I and type II IGF receptors (IGF-IR and IGF-IIR) differ in structure 
and function (110). IGF-IR is responsible for transducing IGF signaling and forms a 
tetramer composed of two α and two β subunits. The α subunits are extracellular and bind 
both IGF-I and IGF-II, thereby initiating IGF-IR kinase activity and subsequent activation of 
the Ras and PI3K/Akt pathways (119). In contrast, IGF-IIR is a monomer with no tyrosine 
kinase activity. The extracellular domain binds only IGF-II, but may also bind mannose 6-
phosphate proteins and transforming growth factor β. IGF-IIR has been proposed as a 
possible tumor suppressor gene, since it binds and degrades IGF-II (120). In this manner, 
IGF-IIR acts as a competing decoy receptor, which reduces IGF-IR activity. 
In accordance with the other IGFBPs, IGFBP2 binds both IGFs (although IGF-II with 
stronger affinity) (121). This interaction regulates the bioavailability of IGFs and may either 
enhance or inhibit IGF functions.  IGFBP2 can perform this role by transporting IGFs to 
specific cell types or tissues, by stabilizing IGFs thus preventing their degradation, by 
positioning IGFs in proximity to the receptors via extracellular matrix (ECM) binding, by 
sequestering IGFs, and finally by transporting IGFs away from their respective receptor 
(110, 115, 122). IGFBPs are also susceptible to proteolysis, which results in IGF release. 
Rorive and colleagues (123) demonstrated that the IGFBP2/IGF-II complex could be 
proteolyzed by matrix metalloproteinase-9 (MMP-9), thereby releasing IGF-II.  This was 
found to contribute to enhanced growth and motility of LN229 astrocytoma cells. Generally, 
IGFBP2 is thought to have an inhibitory function toward IGFs (122). Overexpression of 
IGFBP2 has been reported to decrease cell proliferation in human embryonic kidney cells; 
this effect was abrogated upon addition of exogenous IGF-I (124). In a similar study, the 
addition of IGFBP2 abolished the IGF-I proliferation effect (125). Further, growth was 
increased upon knockdown of IGFBP2 in intestinal epithelial cells (126), and the growth 
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effect in a transgenic mouse line containing high IGF-I levels was reversed upon crossing to 
IGFBP2 transgenic mice (127). 
IGF-independent functions.  Beyond the IGF-dependent functions, IGFBP2 also 
performs multiple independent functions (not involving IGFs).  These functions occur via 
structural domains in the C-terminus, including the heparin binding domain (HBD) and 
Arginine-Glycine-Aspartic acid (RGD), a known integrin-binding domain (128). Binding of 
ECM components glycosaminoglycans, heparin, and proteoglaycans have been reported 
(129-132). A more recent study demonstrated that ECM binding is mediated via the HBD, 
thereby regulating neuroblastoma growth and invasion (125). Similarly, Kawai et al. (128) 
demonstrated that the HBD was responsible for maintaining bone mass. 
The integrin binding function of IGFBP2 is the most established IGF-independent 
role. Interaction with integrin α5β1 and αvβ3 are mediated via the RGD domain. Cell 
surface binding in a Ewing’s sarcoma cell line was specific for integrin α5β1, which 
decreased cell adhesion and increased cellular migration (133). Our group also observed 
an RGD-dependent interaction between IGFBP2 and integrin α5β1 that led to increased 
glioma cell migration via activation of Rac (134) and JNK (135). In contrast, an interaction 
between IGFBP2 and integrin αvβ3 in the breast cancer cell line MCF-7 resulted in a 
negative effect on migration and tumor growth (136). These functional differences may 
reflect integrin- and cell-specific mechanisms, although this interaction was not dependent 
on the RGD domain. This may suggest that a specific IGFBP2/integrin interaction via the 
RGD domain is critical in mediating cell migration. 
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IGFBP2 in cancer.  Elevated IGFBP2 expression has been observed in multiple 
malignancies, including GBM (137-140), ovarian (141, 142), pancreatic (143), gastric (144), 
prostate (145), colon (146), breast (147, 148), and various sarcomas (149, 150). IGFBP2 
levels increase according to tumor grade in various cancers and serve as an independent 
prognostic factor (151-153). Importantly, IGFBP2 has been suggested to be a biomarker, as 
it’s been found in cerebrospinal fluid from patients with pediatric medulloblastoma and 
ependymoma, as well as pediatric acute lymphoblastic leukemia (154, 155). Beyond 
correlative studies where IGFBP2 has consistently been linked with tumor progression, the 
most direct evidence that IGFBP2 is a bona fide oncogene was reported by our group, 
where we found that IGFBP2 could directly promote glioma progression in the RCAS/Ntv-a 
model of PDGFB-induced glioma (88). 
Migration and invasion are the most characterized phenotypes associated with 
IGFBP2. IGFBP2-mediated invasion has been reported in glioma (156), ovarian (157), and 
human bladder cancer cells, the latter contributing to lymph node metastasis (158). A cDNA 
microarray analysis revealed up-regulation of a variety of cell adhesion, migration, and 
invasion genes in primary human GBM cells (159) and in IGFBP2 over-expressing 
neuroblastoma SK-N-SHEP cells (160). IGFBP2 has been reported to promote invasion in 
GBM via CD24 (161), and overexpression in SNB19 GBM cells led to upregulation of genes 
including MMP-2, integrins α5 and α6, fibronectin, and thrombospondin (156). This study 
demonstrated that MMP-2 is an important mediator of IGFPB2-induced invasion and 
revealed significant correlation between IGFBP2 and MMP-2 expression (156). Parallel 
evidence was detected in human GBM tumor cells following bevacizumab treatment. In a 
subset of GBMs that did not respond positively to bevacizumab, the marked infiltrating cells 
near regions of angiogenesis were strongly immunoreactive to IGFBP2 and MMP-2 in 
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immunohistochemstry studies (162). Similarly, in our INK4a/ARF-/- PDGFB-induced glioma 
mouse model, endogenous lGFBP2 was elevated and localized to the tumor invasive front, 
again providing compelling evidence that IGFBP2 promotes tumor invasion in vivo (94). 
Finally, migration and invasion inhibitory protein (MIIP), a protein involved in inhibiting 
migration, antagonizes IGFBP2 resulting in abrogation of IGFBP2-mediated glioma cell 
invasion (163). Interestingly, the chromosomal location of MIIP is often lost in cancers, 
providing a potential mechanism by which IGFBP2 promotes an oncogenic phenotype. 
In accordance with its oncogenic function, IGFBP2 has been linked to important 
tumor suppressor genes. An inverse relationship between IGFBP2 protein expression and 
PTEN has been demonstrated (128, 164-167), as well as INK4A and ARF (94). The PTEN 
inverse relationship was suggested to be functional, as loss of IGFBP2 abrogated Akt-
driven transformation (166). In prostate cancer cells, IGFBP2 induced phosphorylation of 
PTEN (indicating inactivation), which was dependent on IGFBP2/integrin binding (167). 
Consistently, Perks et al. (165) demonstrated that IGFBP2, when free of IGF-II, can 
suppress PTEN in an integrin-dependent manner. Our lab also demonstrated that inhibition 
of IGFBP2 via an antisense approach promoted survival in INK4A/ARF-/- mice with 
PDGFB-initiated glioma, indicating that IGFBP2 was responsible, in part, for mediating 
effects of INK4a and ARF loss (94). 
Angiogenesis is a crucial aspect of cancer and has been included as a cancer 
hallmark (168). IGFBP2 has also been linked to angiogenesis, a characteristic feature of 
GBM, in which increased IGFBP2 led to up-regulation of VEGF and transactivation of its 
promoter (160). This effect was dependent on IGFBP2 nuclear localization, supporting an 
IGF- and integrin-independent mechanism. In support of increased VEGF transcriptional 
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activity, both Wang et al. (156) and Azar et al. (160) found that IGFBP2 expression led to 
an increase in hypoxia inducible factor 1 α (HIF1α), a known transcriptional activator of 
VEGF. Recently, IGFBP2 was found to regulate endothelial cell recruitment via 
enhancement of IGF-I/IGF-IR binding in a breast cancer metastasis model (169). Therefore, 
it appears that IGFBP2 promotes angiogenesis through both IGF-dependent and IGF-
independent mechanisms. 
Cancer stem cells are postulated to be a small population of cells responsible for 
maintaining the tumor bulk and a major contributing factor in tumor relapse (170). New 
research has identified IGFBP2 as an important factor in the maintenance of stem cells. 
The first report demonstrated that IGFBP2 could strongly influence expansion of mouse 
hematopoietic stem cells (HSC) ex vivo (171). Similar results were observed in glioma stem 
cells (172), epidermal progenitor cells (173) and human cord blood HSCs, in which IGFBP2 
could promote ex vivo expansion and transplantation into NOD/SCID mice (174). IGFBP2 
mouse knockout studies revealed decreased HSC cycling, survival, and repopulation 
capabilities. The HSCs in IGFBP2-null mice displayed decreased Bcl-2 (indicative of 
apoptosis) and increased expression of cell cycle inhibitor proteins. Interestingly, these 
effects were dependent on the C-terminus of IGFBP2, but independent of both the RGD 
domain and IGF-1R signaling (175). Furthermore, secreted IGFBP2 also has the capability 
to recruit hematopoietic stem and progenitor cells, potentially contributing to tumor 
heterogeneity and severity (176). 
IGFBP2 is an attractive therapeutic target, as its oncogenic potential is implicated in 
a diverse array of malignancies. Although no IGFBP2 inhibitors are clinically available, 
antisense approaches to IGFBP2 inhibition have demonstrated anti-tumor effects, providing 
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persuasive evidence that IGFBP2 is a valid potential therapeutic target. A second 
generation IGFBP2 antisense oligonucleotide drug candidate, OGX-225, reduced tumor 
volume in a breast cancer (MDA-MB-231) mouse xenograft model (147), and an IGFBP2 
antisense approach significantly prolonged survival in PDGFB-driven glioma in INK4A/ARF-
/- mice (94). An immunotherapy approach was recently performed where either IGFBP2 
peptide immunization or adoptive transfer of IGFBP2-competent T-cells resulted in 
inhibition of tumor growth in an MMTVneu transgenic breast cancer mouse model (177). An 
additional incentive to therapeutically target IGFBP2 is based on mounting evidence that 
IGFBP2 contributes to chemotherapy resistance. As mentioned previously, IGFBP2 likely 
contributes to the increased invasiveness of GBM cells following anti-VEGF therapy 
(bevacizumab) in humans (162). In breast cancer cells, IGFBP2 has been proposed as an 
antiestrogen-resistant marker (178), given the evidence that IGFBP2 contributes to 
trastuzumab resistance via ErbB2 stimulation in an SKBR3 breast cancer mouse model 
(179). Breast cancer cell lines with high IGFBP2 expression, both in vitro and in vivo, were 
resistant to paclitaxel-induced suppression of tumor growth or cell viability; in contrast, cells 
with low IGFBP2 expression or treated with antisense against IGFBP2 were sensitive to 
paclitaxel (147). The antiestrogen RU 58,688 agent led to increased IGFBP2 expression in 
a dose-dependent manner in antiestrogen-resistant breast cancer cells (180). Similarly, in 
prostate cancer, IGFBP2 expression was increased following androgen ablation, leading to 
enhanced tumor cell growth (181). 
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Integrins 
Introduction.  Integrins are a family of heterodimeric proteins consisting of one α 
and one β subunit that form a non-covalent association. Eighteen α and 8 β subunits 
individually dimerize to form 24 heterodimeric members (182). Integrins were originally 
named in light of their ability to link the ECM to the cytoskeleton. Although originally 
identified as an anchor point for the cell, subsequent research has unveiled a much more 
complex role of integrins in cell migration, invasion, proliferation, and survival (183). Mouse 
knockout studies have revealed the essential role of integrins in development and normal 
adult physiology; including haemotasis, immune function, tissue maintenance, and repair 
(184, 185). In particular, loss of integrins α5, αv, α4, α9, or integrins β1 and β8 exhibit the 
most severe phenotype, where integrin α5 null mice result in embryonic lethality at E10-11 
and integrin β1 null mutants die soon after implantation (185, 186).  
Integrin ligands. Integrin ligands comprise a large variety of proteins, the most 
predominant being the ECM proteins. These include vitronectin, fibronectin, collagen, 
laminin, fibrinogen, fibrillin, tenascin, and osteopontin (187). Integrins may also bind 
receptors on other cells, soluble plasma proteins, cell adhesion molecules, and 
microorganisms (183). ECM binding plays a critical role in cell migration by providing the 
traction necessary for cell movement. Adherent cells require anchorage of the cell for cell 
survival (188, 189); the term “anoikis,” means “homelessness,” and refers to a type of 
programmed cell death resulting from inadequate cell ECM attachment (188). 
Most integrins have the ability to bind multiple ligands with great specificity. The α 
subunit provides ligand recognition and is therefore responsible for appropriate ligand 
binding (187). The specificity may be divided into four main subgroups based on structural 
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interaction: 1) integrins that bind RGD-containing ligands include αV integrins, two β1 
integrins, and αIIbβ3. A vast array of proteins contain the RGD domain, such as the major 
ECM proteins fibronectin, vitronectin, and fibrinogen (187). Not all RGD-containing proteins 
permit integrin binding, as the surrounding sequences may affect binding by blocking the 
RGD sequence which must be available for binding (190); 2) LDV-binding integrins include 
α4β1, α4β7, α9β1, all β2 integrins, and αEβ7. The LDV recognition sequence is structurally 
similar to the RGD-binding integrins and includes an alternatively spliced portion of 
fibronectin (185), in addition to intracellular adhesion molecules (ICAMs) and MadCAM 
adhesion molecules (191); 3) A-domain β1 integrins are laminin and collagen-binding and 
include α1, α2, α10, or α11 combined with β1. The A-domain is a triple-helical peptide that 
relies upon a GFOGER motif for ligand recognition (192); 4) non-αA-domain integrins are 
the major laminin-binding constituents and include α3β1, α6β1, α7β1, and α6β4 (187). 
Integrin signaling pathways. Integrins mediate many important cell signaling 
pathways and have a unique ability to perform bidirectional signaling. Extracellular integrin 
ligand binding induces a conformational change that transmits information into the cell, 
known as outside-in signaling. In addition, signals initiated intracellularly induce another 
integrin conformational change, leading to increased ligand binding affinity. This is known 
as inside-out signaling. 
Integrin ligand binding induces integrin clustering, resulting in recruitment of large 
complexes of proteins near the membrane (193). These complexes are referred to as focal 
complexes which connect the ECM to the cytoskeleton. This creates tensional forces 
resulting in subsequent morphological changes permissible for cell movement (194, 195). 
Integrins themselves possess no enzymatic activity, and thus rely upon multiple 
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cytoskeletal proteins, adapter proteins, and protein kinases to transduce signals 
appropriately. These proteins form a large complex includes at least 156 proteins and is 
referred to as the “adhesome” (196). Focal adhesion kinase (FAK) and Src were among the 
first phosphotyrosine proteins identified to play a role in integrin signaling (183). Upon 
ligand binding, integrin clustering is induced and FAK is recruited to the focal adhesion 
complex, where it binds paxillin and talin (197, 198). FAK undergoes autophosphorylation, 
which creates docking sites for SH2 domain-containing proteins, including the enzymes 
Src-family kinases (SFK), PKC, Jnk, PKA, Ras, Raf, Erk, and PI3K. These signaling 
pathways result in cell survival, growth, and motility (198). In particular, the GTPase family 
of proteins (Rho, Rac, and Cdc42) become activated and mediate actin polymerization 
leading to formation of the focal complexes (lamellipodia and filopodia) required for cell 
motility (199). Adapter proteins such as talin, vinculin, paxillin, α-actinin, tensin and the IPP 
complex (integrin-linked kinse-pinch-parvin), also play a major role by creating signaling 
platforms and organizing signaling networks both spatially and temporally (198). 
 Integrin signaling is also often coupled with growth factor receptor (GFR) signaling 
(200). Specifically, EGFR, PDGFR, VEGFR, and Met (hepatocyte growth factor) cooperate 
with integrin activation to transduce signals within the cell. Growth factors can alter integrin 
avidity and amplify integrin signaling, while integrin engagement can further activate the 
aforementioned GFRs (183). In fact, integrin activation is required for ERK signaling (201, 
202). Futhermore, evidence suggests that integrins and GFRs can modulate expression of 
one another (203, 204). This relationship is remarkably important, as both integrins and 
growth factor signaling are major participants in cancer-related functions. 
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  Integrin activation. Integrins exist in various conformations, which reflect their 
affinity and activation state. Integrins are typically found on the cell surface in a “resting 
state,” described by a bent conformation with low binding affinity. In contrast, the activated 
integrin adopts an extended conformation, with high ligand binding affinity (205).   
         The unique integrin structure governs its function. The overall structure consists of 
the extracellular portion or “legs”, which account for the majority of the protein, a 
transmembrane domain, and a short cytoplasmic tail. More specifically, the extracellular 
portion of the α subunit has a β propeller head followed by one thigh and two calf domains. 
The β subunit consists of a plexin-semaphorin-integrin (PSI) domain, which is a hybrid 
domain that contains a β-I domain, four epidermal growth factor (EGF) molecules, a β-tail, a 
transmembrane domain, and a cytoplasmic tail (206). Upon activation, the integrin shifts 
conformation from a bent state to an intermediate conformation, characterized by 
transmembrane and leg separation between the α thigh subunits and the β EGF subunits.  
Finally, complete separation of the leg, transmembrane and cytoplasmic tail domains 
occurs, resulting in an upright and extended conformation (207). In addition to electron 
microscopy studies and recent FRET analyses, the availability of conformation-sensitive 
antibodies has enabled detection of activated integrins and has greatly aided in the current 
molecular understanding of integrin activation (183). 
         Integrins monitor the extracellular environment and serve as mechanosensors that 
become activated via tensional forces and mechanical stress (193). Regardless of whether 
signaling is initiated outside or inside the cell, the β cytoplasmic tail is crucial in transducing 
integrin signaling. Key intracellular proteins bind this region, and include talin, kindlins, and 
filamin (184, 208-210). Among these, talin is well characterized and is sufficient to activate 
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β1 and β3 integrins (211, 212). Talin exists in both an inactive (folded) and active 
(extended) form. Its structure includes a smaller head and a helical rod (213). The head 
contains a FERM (band four-point one, ezrin, radixin and moesin) domain that is required to 
bind the cytoplasmic tail of β1 (214). Talin may be activated via a guanine nucleotide 
exchange factor (GEF)/GTP-protein cascade, which is modulated through G-protein 
coupled receptor (GPCR)-mediated increase in Ca2+ and diacyl glycerol (DAG). This 
pathway involves RAP1 and RIAM, which binds talin and results in a conformational change 
(206). Talin is then recruited to the plasma membrane where the third FERM subdomain 
(F3) directly binds the integrin β1 cytoplasmic tail (215). This association is thought to 
destabilize integrin transmembrane and cytoplasmic interactions, leading to an extended 
conformational shift (215). Talin may also be activated via cleavage by calpain, which 
exposes the F3 subdomain and enables integrin binding (216). Further, phosphatidylinositol 
(4,5)-biosphosphate (PIP2) levels help mediate an association with the integrin tail (213). 
         Integrin specificity and activation may be controlled through various mechanisms, 
including the regulation of the local amount of talin via PIP2, Rap1, and calpain (206). 
Further, differential β integrin affinities for talin (217) and the phosphorylation state of β 
integrin (particularly β3 integrin) contribute to the degree of integrin activation (206). Integrin 
recycling and trafficking is an additional component that regulates integrin availability and 
activation (218). Integrins continually undergo endo/exocytic trafficking, where they are 
endocytosed and taken back to the membrane or degraded via a lysosomal component 
(219). Integrin trafficking is important for key integrin functions and cooperates with the 
actin cytoskeleton in the formation of new adhesions and lamellipodia (220). Various routes 
and mechanisms are involved in integrin internalization that are either clathrin-dependent or 
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-independent (221). The Rab proteins play a dominant role in the endosomal compartment, 
in addition to ARF6. It has been recently reported that active and inactive β1 integrins are 
recycled via distinct pathways and kinetics (222). Although the net endocytic rates among 
active β1 integrin are higher, inactive β1 integrins are returned to the plasma membrane 
more quickly. The steady-state condition indicates that inactive β1 integrins are more often 
present at the cell membrane, whereas active β1 integrins are mostly in the intracellular 
compartment. The authors suggested this likely indicates that inactive integrins are targeted 
to areas in which they would be available for activation, such as lamellipodial protrusions 
(222).   
 
 
Figure 2. Schematic of integrin activation. Integrins shift from a bent conformation to an 
extended conformation upon either an inside-out activation or by an outside-in mechanism 
that involves extracellular ligand binding. Originally published by Margadant et al. (221). 
Published with permission. 
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Integrins in cancer. Given the essential role of integrins in normal processes such 
as cell migration, invasion, proliferation, and survival, it is not surprising that these functions 
are exploited in the development and progression of various malignancies. Integrins are 
commonly overexpressed in cancer. Specifically, integrins αvβ3, α5β1, and αvβ6 are 
overexpressed and correlated with decreased survival in a variety of tumors; αvβ5, α6β4, 
and α4β1 also are associated with decreased survival, although other integrins also play 
important roles in cancer (223). 
Breast cancer mouse models have made important contributions to the integrin field. 
Conditional integrin β1 knockout in the MMTV-driven polyoma virus middle T antigen 
(PyVmT) mouse revealed that β1 integrins were required for tumor initiation. Tumors with 
disrupted integrin β1 exhibited decreased proliferation and altered activation and subcellular 
localization of FAK (224). Loss of FAK in the PyVmT mouse reduced proliferation of 
transformed cells and prevented malignancy and metastasis (225), indicating that FAK 
plays a crucial role in integrin β1 breast tumor progression. In a mutant K-ras (G12D) 
mouse model of non-small cell lung cancer (NSCLC), loss of integrin α1 attenuated tumor 
incidence and size and promoted longer survival compared to K-ras-derived tumors with 
wild-type integrin α1 (226). These findings suggest a pivotal relationship between integrin 
α1β1 in NSCLCs with mutant K-ras.  Receptor transactivation and crosstalk of RTKs and 
integrins contribute to tumor initiation and progression. Integrins β1 and β4 cooperate with 
ErbB2 in the MMTV-driven PyVmT model of breast cancer; disruption of either β integrin led 
to a marked decrease in metastases, delayed tumor initiation, and down-regulated integrins 
α6 and β5, in comparison to ErbB2-driven tumors with wild-type integrin (227, 228). 
Although many integrins contribute to tumorigenesis and progression, some may serve as 
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negative regulators. Loss of integrin α2β1 in primary epithelial tumor cells led to increased 
cell migration, intravasation, and anchorage-independent growth. Moreoever, metastasis 
was promoted in PyVmT mice with integrin α2β1 and activated ErbB2 (229), while αvβ8 
integrin has been reported to suppress angiogenesis in a mouse model of glioma (230). 
         Altered expression of signaling adapters and ECM components play a major role in 
tumorigenesis. Glioma cells aberrantly express tenascin, vitronectin, hyaluronic acid, and 
osteopontin (231). Many integrin adaptors, such as p130CAS, NEDD9, CRK, p140CAP, 
integrin-linked kinase (ILK), PINCH1/2, and Parvin-β are also overexpressed in various 
tumors, and mouse models of breast cancer have revealed their important contribution to 
integrin signaling (198). MMTV-driven Bcar1 (p130CAS) induces mammary gland 
hyperplasia during pregnancy, and decreases tumor latency when combined with ErbB2 
(232). Knockout of Nedd9 in MMTV-PyVmT mice delayed tumor onset and reduced tumor 
size (233), while expression of CRK under MMTV control led to a low incidence of 
mammary epithelial tumors (234). 
Therapeutic inhibition.  Integrin inhibitors have been pursued in preclinical models 
and clinical trials. Preclinical studies found that integrin inhibitors targeted both tumor and 
tumor-associated cells, such as the vasculature endothelium (223). Several clinical trials 
are ongoing, including function-blocking antibodies against integrin αvβ3 (etaracizumab) 
(235), αv integrin-specific monoclonal antibody (CNTO 95) (236), anti-integrin α5β1 
function-blocking antibody (237), and a small peptide antagonist against integrin α5β1 
(ATN-161) (238). The most successful integrin antagonist has been cilengitide, a cyclic 
RGD peptide that targets integrins αvβ3 and αvβ5 (239). Preclinical studies in an orthotopic 
model of glioblastoma demonstrated its effectiveness in inhibiting tumor growth and 
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angiogenesis (240, 241). Subsequent phase I trials showed that it was well tolerated with 
few toxicities (242, 243). Separate phase II trials were performed in recurrent GBM or newly 
diagnosed GBM. Recurrent GBM demonstrated anti-tumor effects (244), whereas the newly 
diagnosed GBM reported a 69% 6-month progression-free survival (PFS), which rose to 
91% in patients with MGMT promoter methylation (245). Currently, the first phase III trial in 
assessing an integrin antagonist is ongoing.  This trial will evaluate survival among patients 
with promoter-methylated MGMT who are administered cilengitide in combination with 
temozolomide and radiotherapy (223). 
Given the accessibility and tumor-specific overexpression of integrins, they are 
currently being utilized as a target for drug delivery and tumor imaging in preclinical mouse 
models. Examples include MRI-imaging nanoparticles that target specific integrins (246) 
and RGD radio-labeled peptides (247-249). Integrin αvβ3 has been imaged in human 
tumors via scintigraphic imaging using a radiolabeled integrin-targeted peptide (250, 251).  
Radiolabeled peptide (18F-galacto-RGD) with positron emission tomography (PET) has 
also been utilized, which enabled quantitative assessment of integrin αvβ3 (252). 
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Integrin-linked kinase 
Inroduction.  ILK was first discovered as an integrin-interacting protein via a yeast-
two hybrid screen for proteins that interacted with the cytoplasmic tail of integrin β1 (253). 
Subsequent work has extended this interaction to β3 integrins (254). As part of the integrin 
complex, ILK is essential in transducing a variety of signaling pathways that are important in 
both normal physiology and in cancer processes. Under normal conditions ILK is involved in 
cell adhesion, tissue homeostasis, and of particular importance in performing critical cardiac 
functions. Phenotypically, ILK knockout mice are embryonically lethal (E5.5-6.5) (255) and 
display a very similar phenotype as integrin β1 knockouts (186). Conditional loss of ILK in 
specific tissues has revealed various developmental defects, including dwarfism and 
chondrodysplasia upon ILK deletion in chondrocytes (256, 257); dilated cardiomyopathy 
upon ILK loss in cardiomyoctes (258); and impaired vascular development and subsequent 
embryonic lethality upon loss in endothelial cells (259). 
The basic structure of ILK consists of an N-terminal domain containing four ankyrin 
(ANK) repeats, a central plekstrin homology (PH) domain, and a C-terminal kinase domain 
(260). These domains mediate protein interactions in which ILK serves as both an important 
scaffolding protein and as a kinase, thereby activating key cell survival and motility 
pathways. ILK plays a critical role in focal adhesion complexes and is the central protein in 
a tripartite complex.  These proteins include PINCH, which binds the ANK domain, and 
parvin which binds the kinase domain (261). This complex is commonly referred to as ILK-
PINCH-parvin (IPP). Multiple connections to the cytoskeleton are facilitated by α and β 
parvins, which can interact with actin directly; by paxillin, which binds ILK and facilitates an 
actin connection through vinculin and actopaxin binding; and via Mig binding, which 
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mediates an actin linkage through migfilin and filamin (260). Through these interactions, ILK 
links integrins to cytoskeletal components and thus regulates cell spreading and motility. 
ILK also couples integrin and GFR signaling through the tyrosine kinase receptor adapter 
protein, Nck (binds ILK indirectly via paxillin). A complex involving ILK, paxillin, and Nck is 
recruited to EGFR and PDGFR upon receptor stimulation (262). In this manner, ILK can 
further transduce GFR signaling as well as mediate cell motility. 
 
 
Figure 3. ILK is a critical signaling molecule. ILK is both a kinase and an adaptor protein 
that couples integrin and growth factor signaling. Originally published by McDonald et al. 
(260). Used with permission. 
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Kinase or pseudokinase?  ILK serves both as an adapter protein and as a 
serine/threonine kinase. ILK activity is stimulated by integrins, growth factors, and 
chemokines.  In vitro assays have identified at least 12 ILK substrate proteins, including 
integrins β1 (253) and β3 (254) and among the best-documented include phosphorylation 
of GSK-3β at Ser9 and Akt at Ser473. Phosphorylation is mediated by PIP3 binding to the 
PH domain (263) and substrate binding to the kinase domain; disruption of either PIP3 
binding (R211A mutation) or Akt binding (S343A mutation) prevents full Akt activation and 
renders ILK “kinase-dead” (264). Akt requires phosphorylation at both Thr308 and Ser473 
for full activation and thereby regulates multiple cancer-promoting functions such as cell 
proliferation, survival, and angiogenesis (265). ILK phosphorylation of Akt (S473) has been 
reported to require an interaction with Rictor (266). GSK-3β phosphorylation results in its 
inhibition and subsequent stabilization of β-catenin, which translocates to the nucleus in 
conjunction with TCF/Lef to induce transcription of cell proliferation genes such as cyclin D1 
and Myc (261). Additionally, GSK-3β regulates cyclin D1 through cAMP-responsive 
element-binding (CREB) (267). ILK kinase activity is antagonized by PTEN and ILK 
associated protein (ILKAP) (265). PTEN blocks PI3K activity, and thus ILK, by reverting 
PIP3 to PIP2. In support of ILK’s PI3K-dependency, PTEN loss leads to constitutive ILK 
activity in cancer cells (268, 269). ILKAP binds ILK via the N-terminal ANK domain and 
reduces ILK kinase activity and GSK-3β phosphorylation, but does not antagonize Akt 
phosphorylation (270, 271), providing an additional level of specificity and regulation. 
Although multiple investigations have demonstrated ILK kinase activity, much debate has 
been generated regarding the kinase capabilities of ILK. ILK contains significant 
homologies to Ser/Thr protein kinases; however, critics cite the observation that ILK lacks 
classic conserved sequences of typical kinases within the catalytic loop and the DXG motif 
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(272, 273). Further, the catalytic domain sequence diverges across species, suggesting a 
non-essential kinase function (261). Advocates argue that several proteins, including Mik1, 
Vps15p, CASK and haspin, are atypical kinases that were once labeled as pseudokinases, 
but now have been confirmed as catalytically active (274). An additional argument against 
the kinase function was that the ILK enzyme kinetics were unknown; however, a recent 
study reported that the enzyme kinetics were similar to that of classical kinases (275).  
There is ample evidence already cited of ILK kinase activity; however, efforts to elucidate 
the ILK kinase activity have been confounded since various mutations which affect kinase 
activity also perturb important binding partners, making it impossible to determine whether 
decreased substrate phosphorylation was due to the disrupted complex, or in reality due to 
loss of kinase activity of ILK (261). For example, Ser343 in the activation loop has been 
proposed to be autophosphorylated (253). A S343D mutation which mimics phosphorylation 
resulted in constitutive ILK activation, whereas a S343A mutation which is unable to be 
phosphorylated, suppressed ILK signaling (264). In contrast, murine developmental studies 
did not corroborate these findings. The S343A putative kinase inactivating mutation 
exhibited no development defects, suggesting that the ILK kinase function is dispensable in 
embryonic development (276). In ILK null macrophages, Akt Ser473 phosphorylation was 
attenuated (277); however, this same attenuation was not observed in fibroblasts or 
chondrocytes (255-257), indicating there may be cell-type specificities involved. 
         Hannigan et al. (278) suggested that in general, some functions require kinase 
activity and some are kinase-independent, serving as a scaffolding or adapter protein. A 
K220M-mutatation was investigated and found to have a disrupted interaction with α-parvin; 
therefore, the authors concluded that the K220 site was the essential α-parvin binding site, 
as opposed to a true catalytically active site (279). However, it has been reported that ILK 
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kinase activity was attenuated upon α-parvin binding (275). Hannigan’s group hypothesized 
that the attenuated kinase activity likely works to keep ILK in an inactive conformation, and 
that α-parvin binding may be dependent upon ILK kinase activity (278). In support of the 
importance of this site, mice harboring a K220M mutation died shortly after birth and almost 
all animals had impaired renal development and function (274). These data suggest that the 
PI3K-dependency of ILK could be context-specific, as it is not always observed. As 
mentioned previously, there are indications that ILK kinase activity is more important in 
cancer-related processes and cell signaling, whereas in embryogenesis and development, 
the kinase function plays less of a role (278). 
ILK in cancer. The role of ILK in cancer is increasingly recognized. ILK is 
overexpressed in a variety of malignancies and correlates with tumor progression in bladder 
cancer (280), non-small cell lung cancer (281), ovarian (282), colon adenocarcinoma (283, 
284), melanoma (285), prostate (286), and gastric cancers (287). Strikingly, increased ILK 
expression was reported in 100% of Ewing’s sarcoma (288).  Overexpression of ILK was 
initially reported to inhibit adhesion, promote anchorage-independent growth (253), and cell 
cycle progression via increased cyclin D in rat epithelial cells (289). Further, ILK expression 
in epithelial cells was demonstrated to induce tumors in nude mice, highlighting its potential 
as a potent oncogene (290). 
Transgenic mice expressing ILK from the MMTV promoter in mice have revealed a 
direct involvement of ILK in breast cancer development and progression. Overexpression of 
ILK alone led to a 34% incidence of mammary tumors by an average 18 months (291), and 
ILK cooperated with Wnt1 to significantly accelerate tumor development (292). In an ErbB2-
induced mouse model of breast cancer, loss of ILK dramatically delayed tumor onset, and 
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pre-malignant lesions exhibited strong growth defects, indicating its critical role in 
cooperating with GFR in tumorigenesis (293). Mouse models also support an ILK function 
in colon cancer, as loss of ILK resulted in fewer tumors in a colitis-associated model of 
colon cancer (294). 
Similar to IGFBP2, ILK is involved in angiogenesis. ILK was shown to induce VEGF 
expression via HIF-1α in epithelial and prostate cancer cells; inhibition of ILK reversed this 
induction and further, led to inhibition of prostate tumor angiogenesis and tumor growth 
(295). Similar results were obtained in GBM xenografts, where small molecule ILK inhibition 
decreased tumor HIF-1α and VEGF secretion, along with blood vessel mass and tumor 
growth (296). A more recent study found that ILK promoted angiogenesis in melanoma 
xenografts via induction of IL-6 and nuclear factor-kappa B (NF-κB), likely through Stat3-
mediated VEGF transcription (297). 
The epithelial to mesenchymal transition (EMT) has gained significant attention in 
cancer research and describes a phenomenon whereby epithelial cells alter gene 
expression programs toward a mesenchymal phenotype, thus acquiring increased motility 
and enablement of metastasis (298). The morphology of epithelial cells is not amenable to 
motility, with tight cell-cell junctions mediated by E-cadherin; mesenchymal cells do not 
have close linkage to other cells and have a shape amenable to motility (299). EMT gene 
expression programs are typified by various transcriptional factors, including Wnt, β-
catenin, tumor growth factor beta (TGFβ), among others, resulting in decrease of epithelial 
makers such as E-cadherin, and an increase of mesenchymal markers such as vimentin 
(298).  
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ILK overexpression in epithelial cells consistently results in EMT, with decreased E-
cadherin levels and cellular morphological changes resembling fibroblasts (290, 300, 301). 
Importantly, ILK has been shown to induce a full EMT by downregulating epithelial genes, 
including E-cadherin, cytokeratin 18, and MUC1; while upregulating the mesenchymal 
genes LEF1 and vimentin (299). The ILK-mediated EMT phenotype has also been 
observed in the MMTV-ILK mouse model (291). Multiple mechanisms have been reported 
in which ILK induces EMT. First, GSK-3β activity (degradation of β-catenin) is inhibited via 
ILK phosphorylation (302), resulting in nuclear translocation of β-catenin/Tcf, a known 
mediator of EMT via upregulation of mesenchymal genes (303). The Wnt pathway is 
frequently increased in cancer, and also plays a role in EMT by inhibition of GSK-3β and 
increased β-catenin levels (304). This situation results in an excess of β-catenin in the free 
cytoplasmic pool, leading to nucleus translocation with TCF, where it activates transcription 
of mesenchymal genes such as fibronectin (299). Second, ILK modulates expression of an 
E-cadherin transcriptional repressor, Snail, which contains a Snail ILK responsive element 
(SIRE) (305). ILK has been reported to mediate PARP-binding to the SIRE, resulting in 
increased Snail transcription and subsequent decreased E-cadherin (306). ILK 
overexpression also led to an increase of Zeb-1, an additional E-cadherin transcriptional 
repressor (307). Third, interaction of ILK with rictor mediates TGFβ-induced EMT through 
Snail and Slug (308). Finally, overexpression of ILK in breast cancer cell lines resulted in 
significant upregulation of Twist, a known repressor of E-cadherin (309), indicating an 
additional mechanism by which ILK may induce EMT. 
ILK is well documented to promote cell survival and growth; however, researchers 
have recently identified novel mechanisms in these processes. It was first reported that ILK 
is transported to the nucleus via phosphorylation by PAK1, and functions to maintain 
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nuclear integrity (310). Surprising ILK functions were uncovered in the nucleus, where ILK 
associates with tubulin and tubulin-interacting proteins, which assemble mitotic spindles 
during mitosis (311). This function was further developed when Fielding et al. (312) found a 
critical function of centrosome clustering in cancer cells, thereby protecting cells from cell 
death due to supernumerary centrosomes. ILK performed this function with ch-TOG and 
TACC3; inhibiting ILK led to mitotic arrest and cell death in mitosis. This binding function 
could have potential implications in cell division errors and genomic instability. 
Therapeutic targeting.  Cancer cells appear to be more dependent on the kinase 
activity of ILK than their normal counterparts. Pharmalogical ILK inhibition resulted in 
attenuation of Akt phosphorylation in breast cancer cells, whereas this same effect was not 
observed in normal cells, including human breast epithelial cells, mouse fibroblasts, or 
vascular smooth muscle cells. Inhibition of Akt S473 phosphorylation in breast cancer cells 
was accompanied by induction of apoptosis and decreased expression of mammalian 
target of rapamycin (mTOR) (313). This makes ILK an even more attractive therapeutic 
target, as it would potentially be less toxic to normal cells. Indeed, small molecule ILK 
inhibition in a mouse model of renal fibrosis affected the molecular events leading to excess 
collagen production, but did not affect kidney structure or function in healthy mice (314). An 
additional report of a cancer-specific ILK inhibition was found in acute myeloid leukemia 
(AML) initiating cells, where inhibition decreased survival of AML cells while causing 
minimal toxicity in normal bone marrow progenitor cells (315). Inhibition of ILK either by 
RNA interference approaches or by small molecule compounds has been effective in 
eliciting anti-tumor responses. Stable knockdown of ILK in a melanoma xenograft model 
significantly reduced tumor growth, indicating the role of ILK in growth mechanisms (316). 
Another study utilized an antisense therapeutic approach. In vitro transfection of ILK 
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antisense into PTEN-mutant GBM cells induced apoptosis, and daily treatment of ILK 
antisense molecules led to stable disease in established xenografts in Rag-2M mice, as 
opposed to untreated mice which experienced more than 100% tumor volume increase 
(317). Small molecule inhibitors have been developed which compete for ATP binding in 
the active site and have demonstrated ~100-fold selectivity over related kinases (318, 319). 
The ILK inhibitor QLT0267 inhibited growth and reduced invasion and VEGF levels in GBM 
cells (320). Similarly, human squamous cell carcinoma of the head and neck cell lines 
exhibited decreased cell growth and induction of apoptosis upon QLT0267 treatment (321). 
This inhibitor has also provided encouraging outcomes in animal models. ILK inhibition 
resulted in decreased tumor volume, apoptosis in both tumor cells and tumor-associated 
endothelial cells, and reduced vascular density in thyroid cancer xenografts (322). 
Importantly, ILK inhibitors have been administered in conjunction with standard 
chemotherapies and demonstrated synergistic effects. Combined QLT2054 and 
gemcitabine treatment led to a 5.4 fold increase over single agent therapy in induction of 
apoptosis in orthotopic primary pancreatic cancer xenografts (323). Further, ILK inhibition 
with either docetaxel or cisplatin led to increased survival (324) and tumor volume (325) in 
orthotopic models of breast cancer and NSCLC, respectively. Therefore, there is ample 
evidence for the multiple oncogenic functions of ILK and for the promise of its therapeutic 
intervention. 
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Nuclear factor-kappa B    
             Introduction.  NF-κB, or Rel, comprises a family of transcriptional factors involved 
in many biological processes, including inflammation, immunity, and cell survival. Its name 
is derived from initial experiments in which NF-κB bound the enhancer of the 
immunoglobulin κ light-chain gene in activated B cells (326). Subsequent studies have 
revealed that the naming scheme is incorrect, as NF-κB is a pleiotropic transcriptional 
factor present in every cell and is located in both the cytoplasm and the nucleus (327). 
There are two classes of NF-κB family members and each contain an N-terminal 
Rel homology domain (RHD) that mediates DNA binding or dimerization. One class 
includes RelA (p65), RelB, and c-Rel, which are synthesized in their complete forms and 
contain a C-terminal transactivation domain. The other class includes NF-κB1 (or p105) and 
NF-κB2 (or p100), which are synthesized as longer proteins that are subject to ubiquitin-
dependent proteolytic cleavage. These family members lack transactivation domains, but 
contain multiple inhibitory C-terminal ankyrin repeats. Upon proper activation, the proteins 
are cleaved into their shorter, active forms (p105 to p50; p100 to p52) and form either 
hetero- or homodimers (328). The 5 NF-κB proteins can form 15 unique transcription 
factors; 7 of these contain a transcriptional activation domain and thus are transcriptional 
activators, 3 bind DNA but are not transcriptional activators, and 3 do not bind DNA (329). 
The prototypical heterodimer is p65/p50 and consequently, the generic term NF-κB 
generally refers to p65/p50. The multiple heterodimers that form lends itself to the 
regulation of the diverse biological processes controlled by NF-κB. Although NF-κB dimers 
bind to 8-10 base pair regions within κB enhancer elements, dimers differ in their affinity for 
specific DNA sequences (330). Additionally, specificity may be achieved by the cooperation 
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with additional co-activators for induction of full transcription (331), such as the transcription 
factors STAT3, HIF-1α, and AP1 (332). 
NF-κB regulation and activation.  The activation of NF-κB is tightly controlled and 
includes feedback mechanisms to prevent constitutive activation (333). Three specific 
inhibitory proteins, inhibitor of κ B (IκB) α, IκBβ, and IκBε, in addition to the C-terminal 
domains of p105 and p100, closely regulate NF-κB activity via two main mechanisms.  
These mechanisms are known as the canonical (classical) or the non-canonical 
(alternative) pathway (329). In the canonical pathway, the IκB proteins bind NF-κB through 
the RHD, thereby masking the DNA binding sequence and retaining NF-κB in the 
cytoplasm (327). The non-canonical pathway involves the precursor proteins p105 and 
p100, in which the C-terminal portion folds, masking the RHD with the inhibitory ankyrin 
domains (327). A dominant mechanism in termination of NF-κB activity is the immediate 
NF-κB-mediated transcription of its inhibitor, IκBα, which can dislodge NF-κB DNA binding 
(334, 335) and shuttle activated NF-κB out of the nucleus (336, 337). NF-κB activity is also 
modified via extensive posttranslational modification, including ubiquitination, which serves 
as an additional mechanism to terminate NF-κB activity (338). 
NF-κB may be activated by a diverse set of stimuli, including pathogens such as 
bacterial-derived lipopolysaccharide (LPS), proinflammatory cytokines such as tumor 
necrosis factor (TNF) and specific interleukins, growth factors including EGF, various 
environmental hazards (e.g., cigarette smoke) and certain forms of stress, including 
physical, chemical, and cellular stressors (331). The canonical pathway responds to 
pathogens and proinflammatory cytokines, and produces a quick and reversible response, 
independent of protein synthesis. Stimuli bind to appropriate receptors, including toll-like 
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receptors (TLRs), TNF receptors (TNFR), B-cell receptors (BCRs), and T-cell receptors 
(TCRs) (339). Upstream signaling events converge upon the IκB kinase (IKK) complex, 
which includes two catalytic subunits, IKKα and IKKβ, and one regulatory scaffolding 
subunit, IKKγ. The IKKβ subunit directly phosphorylates IκBα at Ser32 and Ser36, leading 
to disruption of NF-κB binding and immediate ubiquitination (340). Ubiquitination usually 
occurs via a β-TrCP complex, which marks IκBα for degradation by the 26S proteasome 
(328). This process then releases NF-κB where it translocates into the nucleus and binds 
the κB enhancer of target genes. In contrast to the canonical pathway, the non-canonical 
pathway produces a slow and chronic NF-κB activation that is dependent upon protein 
synthesis. Additionally, this pathway produces more specific functions, including lymphoid 
development, survival and maturation of B-cells, dendritic cell activation, and bone 
metabolism (339). The non-canonical pathway has some overlapping, but also distinct 
molecules compared to the canonical pathway. Activation is mediated by TNF family 
members and induces NF-κB inducing kinase (NIK), which in turn phosphorylates an IKKα 
homodimer (327). This series of events enables phosphorylation and proteolytic processing 
of p100, thereby removing the inhibitory ankyrin domains and producing the final product 
p52, which binds RelA, RelB, or c-Rel to activate transcription (327). 
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Figure 4. Canonical and non-canonical NF-κB signaling pathways. The canonical and 
non-canonical pathways involve overlapping, but distinct molecules, and contain distinct 
differences. Originally published by Sun (339). Used with permission. 
 
 
Additional mechanisms also exist that induce NF-κB activity independent of IKK or 
IκBα phosphorylation, some of which include direct phosphorylation of p65 by protein 
kinase A (PKA) (341) and GSK-3β (342); and tyrosine phosphorylation of IκBα induced by 
hypoxia and oxidative stress (343) or EGFR activation (344). Further control is governed by 
posttranslational modifications that modulate DNA binding and interaction with co-activators 
or co-repressors. Modifications of p65 are extensive and include phosphorylation, 
acetylation, methylation, and ubiquitination. Specifically, phosphorylation at S276 and S311 
increase DNA binding, and phosphorylation at S276, S468, S529, and S536 induce 
transcriptional activation (332). S536 appears to play a major role, since its phosphorylation 
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is required for p300 interaction and subsequent transactivation; conversely, S536 is subject 
to negative regulation via WIP1 phosphatase activity (345). Acetylation at various sites may 
be either stimulatory or inhibitory, while methylation and ubiquitination are inhibitory (332). 
NF-κB and cancer.  The first indication of an NF-κB role in tumor promotion 
stemmed from the report that a viral form of NF-κB (v-Rel) induced avian reticuloendothelial 
lymphomatosis (346). Given that NF-κB regulates genes involved in cell proliferation, 
survival, angiogenesis, invasion, and metastasis, it is not surprising that multiple lines of 
evidence now demonstrate constitutively active NF-κB in most cancer types (332, 347-349). 
A variety of mechanisms may lead to this aberrant signaling; however, in most solid 
cancers, genetic alterations or altered expression of NF-κB family members are rare (350). 
Some have suggested that the autocrine secretion of tumor-promoting inflammatory 
cytokines is the major contributor of constitutive activation (351). Additionally, loss of TSGs 
and aberrant expression of GFRs and kinases are mechanisms of inducing NF-κB 
constitutive activation. For example, the PI3K/Akt pathway is particularly important in 
activating NF-κB, and is itself activated through many mechanisms, including GFR 
amplification/overexpression and loss of PTEN (332). Finally, pathogen-mediated activation 
of NF-κB is involved in carcinogenesis, including human papilloma virus (HPV) and 
Helicobacter pylori, which are oncogenic pathogens found to constitutively activate NF-κB 
(350). 
Mouse models have provided valuable insights into the functional complexity of NF-
κB in cancer development. TNFα, a potent NF-κB inducer, has been reported as a tumor 
promoter, most likely via NF-κB (352). Genetic ablation of p65, IKKβ, or IKKγ in mouse 
models are embryonically lethal and display degenerative liver phenotype due to apoptosis 
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(353).  However, mice lacking other family members display a less severe phenotype, but 
often have an impaired immune response (327). Conditional ablation of NF-κB family 
members has allowed investigations of direct roles in cancer development and progression. 
These studies have revealed that context and cell-type specificities are major determinants 
of the tumorigenic fate of the NF-κB family members (354). Typically, conditional deletion of 
IKKβ has reduced tumor incidence and development. This effect has been reported in 
intestinal epithelial cells, which decreased tumor incidence (355); in myeloid cells, which 
decreased tumor size (355); and in melanocytes, which inhibited melanoma formation in 
mice (356). In other cell types, such as prostate epithelial cells, IKKβ does not seem to play 
a role in tumor initiation, but is important in tumor progression under inflammatory 
circumstances (357). Recently IKKε, a member of the non-canonical pathway, has been 
identified as a breast cancer oncogene and functions to promote viral signaling pathways 
(358, 359). In contrast, IKKα has been reported as a tumor suppressor in head and neck, 
skin, and lung squamous cell carcinomas. Consistently, loss of IKKα expression 
cooperated with Ras to promote skin carcinogenesis (350, 360). Conditional knockout of 
the regulatory subunit IKKγ in hepatocytes induced spontaneous tumors in all mice, and 
also increased inflammatory cytokine expression (361). A similar phenotype was observed 
with conditional deletion of TAK1, a known activator of the IKK complex (362). 
These studies report divergent functions of NF-κB family members in cancer 
development and progression, and indicate that the cell type plays an important role 
determining the oncogenic phenotype of NF-κB. Multiple factors could influence the 
outcome, including the stimulus involved in NF-κB activation. Along these lines, p65 may 
activate either pro- or anti-apoptotic genes (363). Campbell et al. (364) reported that 
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whereas TNF has been known to activate a p65-mediated anti-apoptotic gene program, 
ultraviolet light (UV) or daunorubicin/doxorubic led to the repression of an anti-apoptotic 
gene program. However, this same consequence was not observed upon doxorubicin 
treatment in other cell types, again indicating the cell-type specificities involved in NF-κB 
functions (365-367). 
NF-κB in glioma.  As with other cancers, NF-κB is constitutively active in glioma 
(368-371). In further support of an NF-κB prominent role in glioma, the gene encoding its 
inhibitor IκBα, NFKBIA, is commonly deleted in GBM (372), and its downregulation is 
associated with poor response to therapy (371). In a large study of 790 GBMs, an important 
relationship between loss of NFKBIA and EGFR was established, since NFKBIA deletion 
and EGFR amplifications were statistically mutually exclusive and had similar clinical 
outcomes (372). Introduction of NFKBIA in glioma cell lines led to sensitization to 
temozolomide, which appeared to be applicable to human tumors, since NFKBIA deletion 
has been shown to be a predictor for poor temozolomide response (371, 372). Further, 
NFKBIA expression and MGMT promoter methylation served as a 2 gene classifier to 
predict response to therapy (372). Another study examined human glioma tissue and 
observed a strong NF-κB correlation with Akt, implying a possible functional link in these 
pathways (348). Indeed, GBM cell lines demonstrated a requirement of Akt for NF-κB 
activation. Both NF-κB and Akt activation levels (phosphorylation) were associated with 
glioma grade in this study, providing further evidence that NF-κB is involved in glioma 
progression. Cell lines studies have demonstrated important roles for NF-κB in various 
tumor-promoting phenotypes. NF-κB was found to play a major role in driving the invasive 
phenotype in GBM (373), in part via IL-8 (369). As described in previous sections, 
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angiogenesis is a prominent hallmark of high-grade glioma. Inhibition of NF-κB in GBM 
cells led to decreased VEGF and IL-8 levels, accompanied by reduced angiogenesis in 
xenograft models (374). The investigations described above strongly suggest a potential 
therapeutic benefit of NF-κB inhibition in glioma, particularly in mediating chemosensitivity. 
NF-κB inhibition has been reported to sensitize glioma cells to both 5-aminolevulinic acid-
based photodynamic therapy (5-ALA-PDT) and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) (375, 376). Another report found that NF-κB activation was high in 
cisplatin-resistant C6 glioma cells. NF-κB inhibition reversed its activation and sensitized 
cells to both cisplatin and doxorubicin (377). NF-κB additionally appears to be important for 
maintaining glioma stem cells (378), since inhibiting this pathway induced glioma-initiating 
cells into senescence (379). 
Therapeutic inhibition.  NF-κB inhibition in cancer has been widely studied in pre-
clinical models, as well as in the clinic. To date, no specific NF-κB inhibitors have been 
developed. Approaches for inhibition include general anti-inflammatory drugs, IKK 
inhibitors, and proteasome inhibitors. The broad anti-inflammatory inhibitors, including non-
steroidal anti-inflammatory drugs (NSAIDs), inhibit NF-κB via an unknown mechanism, but 
have shown anti-tumor responses in vitro and in mouse models (380). Additionally, NSAIDs 
and natural compounds such as curcumin have been investigated as potential 
chemoprevention strategies (350). IKK inhibitors produce a more specific inhibition of the 
canonical NF-κB pathway. Due to animal models which demonstrated tumor inhibition in 
IKKβ knockouts, IKKβ antagonists have been developed and shown to be effective in 
multiple myeloma cells, large B-cell lymphoma, chronic myeloid leukimia, prostate cancer 
cells, and in melanoma xenografts (350). However, these inhibitors have yet to be studied 
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in the clinic, due the non-response in head and neck cancers and incomplete inhibition of 
NF-κB activity (381). This is likely due to the fact that NF-κB activity via the non-canonical 
pathway remains activated by IKKα and other kinases. Proteasome inhibitors, such as 
bortezomib, inhibit NF-κB activity by preventing degradation of IκBα inhibitor. Bortezomib 
has demonstrated positive outcomes in B-cell related cancers and is approved for therapy-
resistant multiple myeloma (382). In contrast, it has shown little to no response in Hodgkin’s 
lymphoma or solid cancers. Phase I studies are ongoing to assess its efficacy in 
combination with cytotoxic therapies. 
Although NF-κB remains an attractive therapeutic target, caution should be taken 
when utilizing NF-κB inhibitors in the clinic, given the diverse outcome in mouse knockout 
studies and preclinical models. A recent report illustrates this concept by comparing the 
differential response of NF-κB inhibition in two separate studies (383-385). NF-κB inhibition 
was assessed in terms of mediating senescence-associated secretory phenotype (SASP) 
induced by cytotoxic therapy. The SASP response results in release of cytokines that arrest 
growth and signal the removal of senescent cells, and is therefore important for an effective 
anti-tumor effect (386, 387). These studies assessed the role of NF-κB inhibition on the 
SASP response. The outcome was based on the underlying genetic aberrations of the 
tumor. In the model proposed by Klein and Ghosh, a beneficial response to NF-κB inhibition 
would be produced in tumors with mutations in NF-κB pathway molecules, as the 
oncogenic function of NF-κB would be counteracted to promote cell death. On the other 
hand, in tumors where expression of survival molecules is independent of NF-κB (e.g., Bcl-
2 expression), functional NF-κB is required to mediate therapy-induced senescence 
response by activating the transcription of genes of SASP (383). In the case, when a 
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genetic mutation is acquired independent of the NF-κB pathway, NF-κB inhibition could 
interfere with cytotoxic chemotherapy. Thus, context is crucial in predicting clinical outcome, 
and should carefully be considered as a stratification factor in future clinical trials. 
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Summary 
IGFBP2 expression is correlated with glioma progression and is an independent 
predictor for survival. We have previously demonstrated that IGFBP2 directly promotes 
glioma progression in the RCAS/Ntv-a mouse model; however, the mechanism of action 
was unclear. We took the following observations into consideration: 1) We and others have 
demonstrated a functional invasive role of IGFBP2 binding to integrin α5β1; 2) It is well 
documented that ILK is a major effector of integrin signaling and GFR signaling; and 3) ILK 
is known to activate NF-κB, and IGFBP2 overexpression in cell lines has led to NF-κB 
upregulation. Given these observations, we hypothesized that IGFBP2 drives glioma 
progression through an integrin/ILK/NF-κB signaling pathway. 
 
Figure 5. Proposed mechanism of IGFBP2-mediated glioma progression. IGFBP2 
binding to integrin leads to recruitment of ILK and is activated in conjunction with GFRs, 
and in turn, leads to the activation of NF-κB which promotes glioma progression by 
activating cancer-promoting transcriptional programs.  
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CHAPTER 2:  Materials and methods 
 
Cell Culture and RCAS Constructs 
SNB19 cells and IGFBP2 stably expressing SNB19 cells were maintained in 
Dulbecco’s modified Eagle’s medium/F-12 medium, supplemented with 10% fetal bovine 
serum (FBS) and 1% antibiotic/antimycotic under 5% CO2 at 37oC. DF-1 cells were 
obtained from the American Type Culture Collection (ATCC) and were supplemented with 
10% FBS and 1% antibiotic/antimycotic and grown under 10% CO2 at 39oC, according to 
ATCC instructions.  RCAS constructs encoding the gene of interest were transfected into 
DF-1 cells via the calcium phosphate method.  RCAS vectors encoding PDGFB and 
IGFBP2 have been previously described (86, 88).  RCAS-IGFBP2(RGE) contains a D306E 
mutation and was subcloned into RCAS from the pcDNA3 vector.  ILK cDNA was obtained 
from Upstate Biotechnology and subcloned into the RCAS vector.  The ILK-KD contains a 
S343A mutation, which has been described previously (264). The RCAS vector containing 
IκBαM has S32,36A mutations and was purchased from Addgene. For the RCAS ex vivo 
infections, whole brains were taken from newborn Ntv-a mice, enzymatically dissociated, 
washed, and plated in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS 
and 1% antibiotic/antimycotic onto dishes under standard tissue culture conditions. 
Conditioned media from DF-1 cells transfected with the relevant RCAS construct were 
added overnight to the primary culture of glial progenitor cells, along with 5 ng/mL 
polybrene. Infections were repeated four times. Cells were treated with increasing nM 
amounts of PS-341 (gift from Dr. Paul Chiao, The University of Texas MD Anderson Cancer 
Center) for 24 hours. 
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Animal Care, RCAS Injection, and Tumor Pathology 
DF-1 cells encoding RCAS viral particles were collected, mixed, and suspended in 1 
x phosphate-buffered saline (PBS), and 2 μL of the cell suspension was subsequently 
injected into the right hemisphere of post-natal day 1 Ntv-a mice using a gas-tight Hamilton 
syringe.  Mice were monitored daily for overall appearance and were euthanized at the first 
sign of distress (including hydrocephalus) or at the end of 13 weeks.  The mice brains were 
removed and fixed in formalin for 24 hours, sectioned, and stained with hematoxylin and 
eosin. Tumors were graded by Greg Fuller, M.D., Ph.D. according to World Health 
Organization criteria. All animal experiments were performed in accordance with The 
University of Texas MD Anderson Cancer Center Institutional Animal Care and Use 
Committee. 
Western Blotting 
Cells were collected after treatment with trypsin, washed, and resuspended in RIPA 
buffer supplemented with protease and phosphatase inhibitors. Equal amounts of lysate 
were loaded onto a 10% polyacrylamide gel, resolved by SDS-PAGE, and transferred to a 
nitrocellulose membrane, followed by incubation with the appropriate antibody. Primary 
antibodies used to detect the appropriate antigens were as follows: phospho-integrin β1 
(Thr788/789) (AB8123, Millipore), integrin β1 (4B7R) (ab3167, Abcam), phospho-FAK 
(Tyr397) (3283, Cell Signaling), FAK (3285, Cell Signaling), ILK (3862, Cell Signaling), 
GAPDH (sc-20357, Santa Cruz Biotechnology), p65 (sc-109, Santa Cruz Biotechnology), 
and p50 (sc-1190, Santa Cruz Biotechnology).   
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Immunofluorescence 
For immunofluorescence analysis, 1 x 105 cells were seeded onto an uncoated 
glass slide cover-slip and cultured in the complete medium under the standard cell culture 
conditions. Cells were allowed to attach overnight and were then fixed in 4% 
paraformaldehyde at room temperature for 10 minutes, followed by permeabilization in 1 x 
PBS containing 0.5% Triton X-100 for 30 min at room temperature. The cells were then 
blocked in blocking solution (1 x PBS containing 10% normal goat serum and 0.05% Triton 
X-100) for at least 4 hr. After brief washing with 1 x PBS, the cells were incubated with a 
mouse monoclonal anti-human Rac1 antibody conjugated with FITC (#610652, BD 
Biosciences) (1:200 dilution in blocking solution) at 40C overnight. After washing, phalloidin 
staining was performed at room temperature for 45 min using phalloidin-TRITC (Molecular 
Probes, Invitrogen) at a concentration of 0.5 mg/ml. For the active form of integrin β1 
staining, the cells were fixed in cold 100% methanol for 30 min at -200C and air dried for 15 
min at room temperature. The integrin β1 staining was performed in the same manner as 
Rac1 staining, except a mouse anti-human integrin β1 (CD29) antibody (#556048, BD 
Biosciences) at 1:500 dilution was used. To visualize the integrin β1, a goat anti-mouse IgG 
conjugated with Alexa Fluor 488 (#A11029, Invitrogen) (1:1000) was incubated with the 
cells at room temperature for 1 hr. Images were captured by phase-contrast fluorescence 
microscopy (ZEISS HBO 100) at a magnification of 63x.  
Flow Cytometry 
Cells (5 x 105) were collected, washed in PBS, and transferred to a 5-mL 
fluorescence-activated cell sorting (FACS) tube, followed by fixation in 3.7% 
paraformaldehyde for 5 min. Cells were washed with PBS three times and incubated for 1 
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hr on ice with primary antibody at a 1:50 dilution in 1% bovine serum albumin (BSA)/PBS. 
Antibodies included were 12G10 (Ab30394, Abcam), HUTS-21 (556048, BD Pharmingen), 
and 4B7R (Ab3167, Abcam). Following incubation with primary antibody, cells were washed 
three times with PBS and incubated with a phycoerythrin (PE)-conjugated secondary 
antibody (goat α-mouse IgG-PE, sc-3738, Santa Cruz Biotechnology) at 1:500 in 1% 
BSA/PBS on ice for 30 min in the dark. Cells were washed three times with 1 x PBS 
containing 0.1% Tween20, resuspended in 1% BSA/PBS, and analyzed by FACS 
(FACSCalibur, BD Biosciences).     
Bioinformatic analysis 
 Microarray experiments were carried out using the Human Whole Genome Oligo 
Microarray Kit from Agilent Technologies,  and the manufacturer’s protocol was followed 
(detailed protocol can be found on the Agilent website: www.Agilent.com).  Briefly, 500 ng 
of total RNA from each sample was used and labeled with either Cy3- or Cy5-CTP. After 17 
hr of hybridization at 650C, the arrays were washed and scanned with Agilent’s dual-laser-
based scanner. Then, Feature Extraction software GE2-v4_91 was used to link a feature to 
a design file and determine the relative fluorescence intensity between the two samples. 
Genes, along with their expression values, were uploaded to Ingenuity Pathway Analysis 
(IPA) v8.6-3003 (http://www.ingenuity.com) to perform pathway analysis. The differentially 
expressed genes were identified in IPA by screening out the genes with expression values 
below a twofold cutoff. The threshold was determined to ensure a sufficient number of 
genes eligible for network and pathway analysis, as required by the IPA software. The 
Ingenuity knowledge base (genes only) was used as a reference set. All data sources, all 
species, excluding uncategorized chemicals, and all tissues and cell lines were used for the 
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analysis. IPA uses computational algorithms to identify pathways that are particularly 
enriched for the input genes, with statistical significance as determined by Fisher’s exact 
test.  
We performed a human glioma analysis of gene expression microarray data from 
the NCI Rembrandt public data repository (http://rembrandt.nci.nih.gov) (388), which is 
composed of 329 tumors: 59 oligodendrogliomas, 102 astrocytomas, and 178 
glioblastomas. Single gene survival analysis of human glioma was separated by midpoint 
expression value. Gene sets for all pathways were obtained from IPA software. The NF-κB 
target gene set was compiled from http://bioinfo.lifl.fr/NF-KB/ and TRANSFAC and 
composed of validated human genes. KEGG analysis was performed with the WebGestalt 
tool (http://bioinfo.vanderbilt.edu/webgestalt/option.php). Homo sapiens genome was used 
for all reference sets.  A hypergeometric statistical method was employed with a Benjamini-
Hochberg multiple test adjustment. The minimum number of genes per pathway was set at 
2.  For GSEA, gene sets were ranked according to Pearson correlation with IGFBP2, and 
an ES was calculated on the basis of the Komogorov-Smirnov statistic. P values were 
calculated by comparing ES to 1000 random permutations. Hierarchical clustering was 
performed on genes in integrin and ILK pathways that were correlated more than 0.5 
(positive or negative). The distance metric was L1, using the unweighted mean distance as 
the linkage criterion. Groups were highlighted manually.  
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siRNA and Migration Assays 
Stably expressing SNB19 cells were collected and plated onto six-well plates and 
subsequently transfected via RNAiMax  (Invitrogen) with 50 nM siRNA directed against ILK 
or a scrambled negative siRNA control (Sigma).  Cells were incubated to confluency for an 
additional 72 hr in 37oC in a humidified chamber with 5% CO2.  A wound was made using a 
sterile 200-µL pipette tip, and cells were returned to the incubator.  The ability of the cells to 
migrate into the wound area was assessed by photographing the wound area at 0, 6, 12, 
and 24 hr after the initial scratch was made.  All photographs were taken from the same 
initial wound area. Each assay was done in triplicate.  Cell migration was quantified using 
ImageJ (NIH software) to trace the wound area. The number of pixels inside the wound 
area was measured at each time point and compared to the initial wound area to calculate 
the percentage of wound closure.   
Rac Activation Assay 
The level of activated Rac was assessed in SNB19 cells stably expressing IGFBP2 
using the Rac activation assay combo kit (STA-404, Cell Biolabs), according to the 
manufacturer’s instructions.  Cells were collected by manual cell scraping into 1 mL of lysis 
buffer with phosphatase and protease inhibitors 48 hours after siRNA transfections. Cell 
were allowed to lyse for 20 min and subsequently centrifuged to remove cellular debris. A 
portion of the supernatant (700μL) was added to 40μL of PAK-1 coated beads and were 
rotated for 1 hr at 4oC. The beads were washed and loaded onto a 10% PAGE gel, 
transferred to a nitrocellulose membrane, and immunobloted for Rac1 (#610650, BD 
Biosciences). Levels of activated Rac were analyzed using ImageJ software by comparing 
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immunoblot band intensity between Rac from the pullodwn to total Rac in whole cell 
lysates. 
EMSA 
Cells were first incubated in a hypotonic buffer (10 mM Hepes pH 7.9, 10 mM KCl, 
0.1 mM EDTA) on ice for 20 min, NP40 was added to a final volume of 0.5% and briefly 
vortexed. Lysates were centrifuged at 14,000 rpm at 4oC for 1 min to remove the 
cytoplasmic fraction. The nuclear pellet was washed in the hypotonic buffer, and nuclear 
extract buffer was added (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 10% glycerol) 
and incubated for 15 min at 4oC with constant vortexing. Finally, extracts were centrifuged 
at 14,000 rpm for 10 min at 4oC. Five micrograms of nuclear extract was incubated with 
DNA binding buffer (100 mM Hepes, pH7.9, 400 mM NaCl, 10 mM EDTA, poly dI-dC, 10 
mM DTT and 32P-ATP-labeled NF-κB consensus probe, 40% glycerol) for 20 min at room 
temperature. Samples were resolved by a 5% polyacrylamide gel, transferred to filter paper, 
and detected via autoradiography. For supershift assays, the incubation was modified 
slightly by the addition of 1 μg of p65 (sc-7151X, Santa Cruz Biotechnology) or p50 (sc-
114X) for 1 hr at 4oC prior to the binding reaction. 
Luciferase Reporter Assay  
1.5 x 105 SNB19 cells were plated onto 6-well plates and co-transfected 24 hours later 
with 500 ng of pGL4-NF-κB firefly luciferase and 20 ng of pGL4-TK Renilla luciferase 
constructs (Promega) via Lipofectamine 2000 (Invitrogen). Dual luciferase reporter assay 
system (Promega) was performed 48 hr after transfections, according to manufacturer’s 
instructions, and luciferase activity was measured with a TD-20/20 luminometer. Each assay 
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was performed in triplicate, and all firefly luciferase values were normalized to renilla luciferase 
readings.  
Statistical Analysis 
 Wound healing and luciferase assay results were analyzed by ANOVA, followed by 
Bonferroni’s multiple comparison test. The log-rank test was used to obtain a p value for the 
significance of Kaplan-Meier curves’ divergence. The statistical significance of the mouse 
tumor data was determined using a 2-ends Fisher’s exact test. A significance level was set 
at P < 0.05 for all tests. 
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CHAPTER 3:  Results 
 
IGFBP2 is clinically linked to the integrin and ILK pathways 
Rationale.  IGFBP2 is highly expressed during fetal development and is 
downregulated following birth (112). However, similar to other developmental proteins, 
IGFBP2 levels are again increased during tumorigenesis (137), indicating that IGFBP2 
likely is an important oncogene. Indeed, IGFBP2 is involved in many critical tumor-
promoting processes, including migration (111), cell proliferation (147), invasion (161), 
angiogenesis (169), maintenance of glioma stem cells (172), and chemoresistance 
mechanisms (179). These phenotypes are also highly clinically applicable since high 
IGFBP2 expression levels correlate with poor prognosis in many cancers (137, 142, 149), 
and the increased serum levels in various malignancies has led to its proposal as a 
potential biomarker (154, 389).  
Genomic studies allow for a bird’s eye view of molecular events inside the cell and 
can be particularly useful in assessing the functional significance of gene perturbations. The 
application of cDNA microarrays following IGFBP2 overexpression has resulted in changes 
in adhesion, cellular migration and invasion, and cell proliferation (156, 390). We sought to 
obtain a clinically oriented global view of the IGFBP2 network by performing comprehensive 
pathway analyses using data from the Repository for Molecular Brain Neoplasia Data 
(Rembrandt) (388). This database was established by the National Cancer Institute as a 
public portal for correlation of molecularly characterized brain tumors with the respective 
clinical parameters. The Rembrandt database contains gliomas of all grades, providing a 
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unique opportunity to harness information on the molecular events involved in glioma 
progression. Pathway analysis was performed via IPA, which contains a curated list of 
genes reported to play a role in known signaling pathways. 
Results.  We obtained gene expression data from all glioma samples available in 
the Rembrandt database and determined which genes were correlated with IGFBP2. The 
gene list was uploaded IPA software to determine which pathways were associated with 
IGFBP2 expression (Appendix Table A1). Many of the top pathways (6 of 25) were related 
to cellular migration and invasion. Particularly, integrin and ILK were among the top 
associated pathways, and we chose to focus these pathways since IGFBP2 has been 
shown to bind integrin α5 and regulate cell motility through this interaction (134) and since 
ILK is a logical player in this pathway given its role in transducing integrin signaling. 
Notably, IGFBP2-correlated genes in the integrin pathway included multiple integrins: 
ITGA4, ITGB1, ITGA2, ITGA5, ITGA3, and ITGB3. The IGFBP2-correlated genes in the ILK 
pathway included MMP9, in accordance with IGFBP2-induced cellular invasion. 
Interestingly, an E-cadherin repressor, SNAI2, was altered among ILK pathway genes, 
indicating a potential EMT function for IGFBP2.  
To determine whether integrin and ILK pathway genes were enriched in samples 
with high IGFBP2 expression, we performed a gene set enrichment analysis (GSEA). This 
method involves a pre-defined gene set (e.g., integrin pathway genes) and determines 
whether the gene set tends to occur at the top or bottom of the list (391). In this case, it 
would indicate whether the integrin pathway genes are significantly positively or negatively 
correlated with IGFBP2. Indeed, the genes in both the integrin and ILK pathways were 
significantly correlated with IGFBP2 (P<0.001; Figure 6 and Appendix Table A2).  
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Figure 6. IGFBP2 is associated with integrin and ILK pathways in human glioma.     
This figure shows GSEA for integrin and ILK pathway genes, based on their correlation with 
IGFBP2 expression. Maximum running enrichment score (RES) for integrin and ILK 
pathway genes are 0.1602 and 0.1182, respectively. Venn diagram represents the number 
of pathway genes that are unique, or shared between integrin and ILK. 
 
To determine the expression patterns of integrin and ILK pathway genes in 
accordance with IGFBP2 expression and glioma grade, we performed unsupervised 
hierarchical clustering. Three major clusters formed, including low, intermediate, and high 
expression (Figures 7 and 8). The clusters were related to IGFBP2 expression and tumor 
grade, with the high expression cluster also containing the highest IGFBP2 expression and 
mostly glioblastoma, indicating a possible positive regulation of integrin and ILK pathway 
genes by IGFBP2. The pathway genes that were not correlated with IGFBP2 expression 
(bottom rows in Figures 7 and 8) clearly demonstrated an opposing pattern with IGFBP2, 
suggesting a possible negative regulation.  
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Figure 7. Integrin pathway genes cluster according to IGFBP2 and tumor grade. 
Hierarchical clustering of integrin pathway genes that are correlated (greater than 0.5 
Pearson correlation) with IGFBP2. Specific molecules assessed in this study are 
highlighted in blue (ILK, ITGA5, and ITGB1). 
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Figure 8. ILK pathway genes cluster according to IGFBP2 and tumor grade. 
Hierarchical clustering of ILK pathway genes that are correlated (greater than 0.5 Pearson 
correlation) with IGFBP2. Specific molecules assessed in this study are highlighted in blue 
(ILK and ITGB1). 
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To determine the influence of integrin and ILK pathway gene expression on patient 
survival, we assessed individual genes, including IGFBP2, ITGA5, ITGB1, and ILK, among 
all tumor histologies (GBM, Astrocytoma, Oligodendroglioma, Mixed). “High” and “Low” 
groups were separated by the midpoint expression value. High expression of each gene 
was associated with significantly poorer survival (Figure 9). This survival trend remained 
upon individual evaluation of each glioma histology (Appendix Figure A1). In addition, 
expression levels of integrin and ILK pathway genes (low-, intermediate-, and high-
expression clusters from Figures 7 and 8) were significantly correlated with patient survival, 
highlighting the clinical significance of the integrin and ILK pathways in human glioma 
(Figure 9).  
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Figure 9. High expression of IGFBP2-related genes is associated with poor 
prognosis. (A) Single-gene Kaplan-Meier survival curves of all glioma samples (n=329). P 
values were calculated using the log-rank test. (B) Kaplan-Meier survival curves based on 
clusters in Figures (X) and (Y). P values were calculated using the log-rank test.  
IGFBP2 regulates downstream pathways via integrin activation 
A 
B 
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Rationale.  IGFBP2 has been reported to interact with α5β1 (133, 134) as well as 
αvβ3 (136); however in our previous study, IGFBP2 did not immunoprecipitate αv (134). 
Further, while addition of anti-α5β1 could decrease IGFBP2 binding to cell surfaces, anti-
αvβ3 antibodies had no effect (133). Although IGFBP2 likely influences other integrins, we 
focused on integrin β1 to investigate integrin pathway, given that integrin β1 comprises the 
most heterodimers and is one of the better known oncogenic integrins involved in cell 
migration, invasion, and metastasis. 
Although the IGFBP2/integrin α5β1 interaction was documented, it was unknown 
whether this interaction could induce integrin activation. Integrin clustering, formation of 
focal adhesions, and subsequent cell signaling transduction are all byproducts of activated 
integrins (185); therefore, detection of integrin activation is important in determining 
functional significance. As described previously, activated integrins shift from a bent 
conformation with a closed headpiece to an upright conformation, including separation 
between the α and β transmembrane portions and cytoplasmic tails (206). Conformation-
specific antibodies have been developed which bind to epitopes exposed only when the 
integrin is in the active conformation. We utilized two separate conformation-specific 
antibodies, both of which detect activated β1 integrin: 12G10 binds to an epitope in the βA 
domain, and HUTS-21 binds an epitope in the hybrid domain (392, 393). An antibody that 
recognizes all integrin β1 conformations, 4B7R, was used as a control. 
To address whether IGFBP2 activates integrin β1 and its downstream pathways we 
compared 2 stably expressing cell lines originating from SNB19: 2 clones expressing a 
mutant form of IGFBP2 that cannot bind integrin (RGD →RGE point mutation; referred to as 
RGE-mutant) and 2 clones expressing wild-type IGFBP2. 
70 
 
Results.  We performed immunofluorescence analysis and flow cytometry 
experiments to assess whether IGFBP2 activates integrin β1. Levels of activated β1 were 
compared among SNB19 parental cells; cells stably expressing IGFBP2; and cells stably 
expressing RGE-mutant IGFBP2. Both parental and RGE-mutant cells exhibited a 
moderate level of activated β1 staining. Activated integrins were localized primarily on focal 
adhesions, indicating the cells were non-motile and engaged with the ECM. In contrast, 
IGFBP2-expressing cells had high levels of staining, localized primarily along the leading 
edge of the cell, indicating their motile nature (Figure 10A). We used an additional 
approach to further confirm that IGFBP2 activates integrin β1 by performing flow cytometry. 
These results mirrored the immunofluorescence data. The parental and RGE-mutant cells 
exhibited low levels of activated integrin, as measured with the HUTS-21 or 12G10 
antibodies, whereas there was a shifted peak in IGFBP2-overexpressing cells, indicating 
that a higher proportion of cells was recognized by these antibodies (Figure 10B). 4B7R 
again served as the control, with similar levels of total β1 integrin among the cell lines, 
indicating that the difference in β1 activation was not merely due to increased expression. 
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Figure 10. IGFBP2 activates integrin β1. (A) Immunofluorescence staining of 12G10, 
HUTS-21, and 4B7R in indicated cells after plating onto fibronectin-coated glass coverslips 
for 18 hr, followed by cold-methanol fixation. Scale bar, 20 μm.  (B) Flow cytometric 
analysis of 12G10 and HUTS-21 (active conformation of β1) or 4B7R (total β1) in the 
indicated cells. 
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To determine the significance of the downstream pathways affected by disruption of 
IGFBP2/integrin signaling, we performed a cDNA microarray analysis comparing SNB19 
RGE-mutant and IGFBP2 wild-type cells. Differentially expressed genes were subjected to 
IPA. Disruption of integrin binding with IGFBP2 (RGE-mutant) led to many significantly 
altered pathways (Appendix Table A3). The integrin pathway was confirmed to be altered, 
and the third top altered pathway was ILK, followed by other pathways involved in migration 
and invasion. GSEA was performed to determine if genes in the selected pathways were 
significantly enriched according to IGFBP2 expression. GSEA may be measured based on 
either differential expression or absolute differential expression. When differential 
expression is used, GSEA emphasizes gene sets in which all of the genes go either up or 
down. Absolute differential expression does not take into account the direction of change, 
but determines only if there is a significant change in gene expression. We performed 
GSEA was based on both differential and absolute differential gene expression using four 
selected Ingenuity pathways, including integrin, ILK, actin cytoskeleton, and glioma 
invasiveness. The absolute differential expression GSEA revealed that each pathway was 
significantly enriched, and the differential expression GSEA showed that  most genes were 
down-regulated, indicating that disruption of IGFBP2 and integrin binding led to de-
activation of cell motility pathways (Figures 11-14).
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Figure 11. Disruption of IGFBP2-integrin interaction alters genes in the integrin pathway. (A) The integrin pathway is 
depicted from Ingenuity pathway analysis showing gene expression changes from SNB19 glioma cells comparing clones 
expressing wild-type IGFBP2 to RGE-mutant IGFBP2. Green and red represent genes represent expression fold changes >2 
or <2, respectively. (B) Integrin pathway genes are significantly enriched according to GSEA analysis. Most genes were 
negatively affected, revealing decreased activity of the integrin pathway.  
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Figure 12. Disruption of IGFBP2-integrin interaction alters the actin cytoskeleton 
pathway. (A) The actin cytoskeleton pathway is depicted from Ingenuity pathway analysis 
showing gene expression changes from SNB19 glioma cells comparing clones expressing 
wild-type IGFBP2 to RGE-mutant IGFBP2. Green and red represent genes represent 
expression fold changes >2 or <2, respectively. (B) Actin cytoskeleton pathway genes are 
significantly enriched according to GSEA analysis. Most genes were negatively affected, 
revealing decreased activity of the actin cytoskeleton pathway.  
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Figure 13. Disruption of IGFBP2-integrin interaction alters the ILK pathway. (A) The 
ILK pathway is depicted from Ingenuity pathway analysis showing gene expression 
changes from SNB19 glioma cells comparing clones expressing wild-type IGFBP2 to RGE-
mutant IGFBP2. Green and red represent genes represent expression fold changes >2 or 
<2, respectively. (B) ILK pathway genes are significantly enriched according to GSEA 
analysis. Most genes were negatively affected, revealing decreased activity of ILK 
signaling. 
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Figure 14. Disruption of IGFBP2-integrin interaction alters the glioma invasiveness 
pathway. (A) The glioma invasiveness signaling pathway is depicted from Ingenuity 
pathway analysis showing gene expression changes from SNB19 glioma cells comparing 
clones expressing wild-type IGFBP2 to RGE-mutant IGFBP2. Green and red represent 
genes represent expression fold changes >2 or <2, respectively. (B) Glioma invasiveness 
pathway genes are significantly enriched according to GSEA analysis. Most genes were 
negatively affected. 
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ILK is required for IGFBP2-induced cell mobility 
Rationale.  ILK binds the cytoplasmic tails of integrins β1 and β3, and is an 
essential effector of integrin and growth factor signaling (265). As such, ILK regulates 
cellular migration and invasion, proliferation, angiogenesis, EMT, and other functions that 
cancer greatly relies upon. Multiple lines of evidence have led us to the hypothesis that ILK 
plays a critical role in IGFBP2-mediated effects. Integrin clustering is known to recruit ILK to 
transduce appropriate signaling. Since IGFBP2 activates integrin β1, ILK is likely recruited 
to the complex. We demonstrated in human glioma samples that ILK pathway genes were 
significantly correlated with IGFBP2 and clustered according to IGFBP2 expression. 
Additionally, perturbation of IGFBP2/integrin binding negatively affected genes in the ILK 
pathway.  
We previously reported that IGFBP2 promotes migration through integrin interaction 
and activation of Rac, a small GTP-binding protein critical for lamellipodia and subsequent 
cell motility (134). We sought to determine whether ILK was critical for cell motility and Rac 
activation induced by IGFBP2. To address this question, we used an siRNA approach to 
knockdown ILK in SNB19 cells stably overexpressing IGFBP2. Wound healing assays were 
performed to assess cell migratory abilities. The assay entails creating a scratch in 
confluent cells and monitoring the wound area over time. The extent of cell migration is 
reflected by the wound closure rate. Rac activation was assessed by immunofluorescence 
of filamentous actin (F-actin) and Rac, since a crucial Rac function involves polymerization 
of actin monomers into F-actin which is necessary for cell tension and movement. The Rac 
activation assay is a pulldown approach based upon the premise that the active GTP-bound 
Rac interacts with PAK.  
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Results.  ILK knockdown resulted in a marked decrease in migration in IGFBP2-
expressing cells compared with control siRNA or parental cells (Figure 15A). IGFBP2-
expressing SNB19 cells migrated into the wound in a significantly higher proportion than did 
parental cells (p<0.01; Figure 15B). In contrast, IGFBP2 cells treated with ILK siRNA 
exhibited a significant decrease in the wound closure rate relative to IGFBP2 cells treated 
with control siRNA (p<0.05; Figure 15B), indicating that ILK is an essential component of 
IGFBP2-induced cell migration. A Western blot analysis confirmed that ILK was sufficiently 
knocked down and further revealed that ILK protein levels were increased in IGFBP2-
overexpressing cells (Figure 15C). 
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Figure 15. ILK is required for IGFBP2-induced cell motility. (A) Wound-healing assay in 
SNB19 parental or IGFBP2-expressing cells transfected with negative control or ILK siRNA. 
Images were captured at the indicated times after the initial wound. Scale bar, 500 μm. (B) 
Graphical representation of wound healing ability after 24 hr, as shown in (A). P values 
represent ANOVA with Bonferroni’s multiple comparison test. *p<0.05, **p<0.01. Error bars 
represent SEM. (C) Western blot analysis of ILK protein levels in SNB19 cell lines.  
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Since we previously reported that IGFBP2/integrin binding led to activation of Rac 
(134), we determined whether ILK is also critical in this pathway. Immunofluorescence 
staining of F-actin and Rac demonstrated that F-actin was localized mostly to focal 
adhesions or throughout the cell membrane in parental cells but concentrated on the 
lamellipodia in IGFBP2 cells. Upon ILK knockdown, the cells’ morphologic characteristics 
shifted to a non-motile phenotype by becoming elongated with fewer lamellipodia, and F-
actin was present mainly in the focal adhesions. Rac was dispersed throughout the 
cytoplasm in parental cells but localized at the leading edge with F-actin in IGFBP2 cells, 
indicating Rac activation. Knockdown of ILK in IGFBP2 cells led to Rac’s movement to the 
cell tail (Figure 16A). To confirm Rac activation in these cells, we performed a Rac 
activation assay. IGFBP2 cells with depleted ILK exhibited significantly less activated Rac 
than did IGFBP2 cells that were untreated or treated with control siRNA (Figures 16A and 
B). These results indicate that ILK plays a direct role in IGFBP2/integrin α5-induced glioma 
cell migration.  
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Figure 16. ILK is required for IGFBP2-induced Rac activation. (A) IGFBP2-expressing 
SNB19 cells transfected with negative control or ILK siRNA for 48 hr, followed by cold 
methanol fixation and immunofluorescence staining of F-actin and Rac. (B,C) Rac 
activation assay in IGFBP2 cells that were untreated or transfected with scrambled or ILK 
siRNA. (C) Quantification of the amount of immunoprecipitated Rac1 normalized to the 
amount of Rac1 in the inputs. 
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IGFBP2 regulates an invasion-related NF-κB transcriptional program 
 Rationale.  NF-κB is one of the most influential transcription factors in cancer, as it 
has been documented to regulate over 150 genes, many of which perform cancer-
promoting functions (327, 394). Similar to IGFBP2, NF-κB is constitutively active in glioma 
and correlates with tumor grade (348). IGFBP2 has been reported to upregulate NF-κB in a 
breast cancer cell line (390), and a previous study by our group revealed that inhibition of 
IGFBP2-induced cell migration via IIp45 (also known as MIIP) led to decreased NF-κB 
expression (163). Additionally, IGFBP2 regulates integrin and ILK signaling, which are both 
known activators of NF-κB (395-397). These observations led us to hypothesize that 
IGFBP2 mediates oncogenic functions through NF-κB. 
 We compiled validated human NF-κB target genes and utilized the Rembrandt 
database to assess whether IGFBP2 expression correlated with the expression of NF-κB 
target genes. To determine whether NF-κB was activated, we first assessed its localization 
by performing nuclear subfractionation and analyzing levels of nuclear NF-κB. Because 
nuclear localization is merely indicative of activation, we also determined the ability of NF-
κB to bind its consensus sequence via electrophoretic mobility shift assays (EMSA), and its 
transactivation potential by performing luciferase gene reporter assays. Finally, we 
assessed whether IGFBP2 expression rendered cells more sensitive to NF-κB inhibition via 
the proteasome inhibitor PS-341 (bortezomib) or to the dominant negative genetic inhibitor, 
IκBαM. Since we had previously found that IGFBP2 (in combination with PDGFB) induced 
glioma progression in a spontaneous mouse model (88), we utilized this system for ex vivo 
NF-κB inhibitor experiments. 
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Results.  We evaluated NF-κB target gene expression from both the SNB19 cell 
line microarray and Rembrandt database. GSEA based upon absolute differential 
expression (Fig. 17, top panel) revealed that NF-κB target genes were significantly 
enriched in stably expressing IGFBP2 cell lines. GSEA based upon differential expression 
(Fig. 17, bottom panel, Table 1) revealed both upregulation and downregulation of NF-κB 
target genes, consistent with the diverse functions of NF-κB target genes. These results 
provide evidence that IGFBP2 regulates NF-κB activity.  
 
 
 
 
Figure 17. Disruption of IGFBP2/integrin significantly alters NF-κB transcriptional 
activity. GSEA plot of NF-κB target genes. Genes ranked according to differential 
expression of SNB19 stably expressing IGFBP2 cells to control cells. 
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NF-κB target gene Expression fold change 
IL11 2.58 
F3 2.29 
PLAU 1.40 
PTX3 0.94 
TNC 0.83 
BCL2L1 0.77 
CCND1 0.72 
CD83 0.71 
CREB3 0.54 
MUC5B 0.51 
NFKB1 0.41 
NFKBIA 0.31 
MICA 0.23 
COL1A2 0.17 
CD44 0.17 
BCL2A1 0.04 
HMOX1 0.01 
PLCD1 -0.07 
IL6 -0.10 
MYC -0.10 
GSTP1 -0.11 
HIF1A -0.13 
SOD2 -0.14 
TPMT -0.29 
NQO1 -0.33 
ING2 -0.35 
AR -0.41 
TNFRSF10B -0.50 
FAS -0.52 
IL15 -0.56 
RELB -0.63 
S100A6 -0.66 
TAP1 -0.93 
BCL3 -1.01 
HLA-G -1.03 
CCL2 -2.95 
SPP1 -3.33 
 
Table 1. Differentially expressed NF-κB target genes resulting from IGFBP2 
overexpression. 
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The Kolmogorov-Smirnov statistic was used to determine whether NF-κB target 
genes were significantly correlated with IGFBP2 expression in human glioma. NF-κB target 
genes were significantly enriched (P<0.01; Figure 18A and Table 2), although not as 
robustly as in the integrin and ILK pathways. Since NF-κB regulates many genes, resulting 
in pleiotropic effects ranging from immune regulation to cellular invasion, we therefore 
evaluated the NF-κB target genes that were positively correlated with IGFBP2. A Kyoto 
Encyclopedia of Genes and Genomes (KEGG) analysis revealed that these genes were 
enriched in migration and invasion-related pathways, such as extracellular matrix-receptor 
interaction and focal adhesion. In contrast, target genes that were not correlated with 
IGFBP2 (Pearson correlation below 0.5) were not enriched in migration and invasion 
pathways, indicating that IGFBP2 likely activates an invasion-related NF-κB transcriptional 
program (Figure 18B).  
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Figure 18. IGFPB2 activates an NF-κB transcriptional program.  (A) GSEA plot from 
human glioma Rembrandt database. NF-κB target genes ranked according to IGFBP2 
correlation. (B) KEGG analysis of genes from (A). Pathways shown are significantly 
enriched in NF-κB target genes that are correlated >0.5 (red bars) or <0.5 (black bars) with 
IGFBP2. Percentage of genes represents the number of NF-κB target genes in the pathway 
relative to the total number of correlated or non-correlated genes. 
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NF-κB target 
gene 
Pearson 
correlation Gene 
Pearson 
correlation Gene 
Pearson 
correlation 
COL1A2 0.767 TGM2 0.284 CD209 -0.116 
PTX3 0.749 HIF1A 0.279 LTB -0.126 
IFNGR2 0.737 IL15 0.272 NR4A1 -0.126 
SOD2 0.708 NOD2 0.268 CRP -0.132 
PLAU 0.671 CCR5 0.258 AGER -0.135 
S100A6 0.643 CXCL9 0.256 GUCY1B3 -0.138 
TNFRSF10B 0.617 IL1RN 0.245 NR4A2 -0.139 
F3 0.612 PTGS2 0.22 IFNB1 -0.141 
BCL3 0.611 IRF2 0.214 SCNN1A -0.15 
MMP9 0.609 NFKB2 0.205 IL13 -0.158 
HMOX1 0.606 VCAM1 0.204 TPMT -0.162 
BRCA2 0.605 IL10 0.185 ELF3 -0.164 
TNC 0.597 REL 0.156 TACR1 -0.175 
HLA-G 0.595 CSF1 0.145 BDKRB1 -0.185 
SPP1 0.594 OLR1 0.141 CCL11 -0.185 
ALOX5AP 0.591 CXCL5 0.14 TAC1 -0.197 
IRF1 0.559 IL1A 0.135 CD40LG -0.211 
CD44 0.555 ING2 0.117 NPY1R -0.217 
TNFAIP3 0.529 IL1B 0.104 MUC5B -0.22 
TAP1 0.526 IL2RA 0.104 IL9 -0.236 
IL8 0.519 CREB3 0.09 FASLG -0.244 
FAS 0.505 PDGFB 0.08 IL2 -0.246 
ICAM1 0.501 AR 0.069 STAT4 -0.247 
TP53 0.458 PTAFR 0.069 IRF4 -0.248 
CCL2 0.457 CD80 0.046 TNF -0.26 
IRF7 0.457 SELP 0.039 IL5 -0.264 
RELB 0.448 TNFRSF9 0.018 OPRM1 -0.27 
MICA 0.439 CCND1 0.007 IL29 -0.277 
BCL2A1 0.425 SELE 0.007 LTA -0.281 
CD74 0.425 CCR7 0.002 ALOX12B -0.333 
NFKB1 0.412 CR2 -0.008 CCL19 -0.358 
SAA1 0.406 CD83 -0.019 CRMP1 -0.37 
STAT5A 0.397 APOC3 -0.022 ABCB1 -0.373 
HAS2 0.393 MYC -0.024 
  BCL2L1 0.355 IFNG -0.025 
  IL6 0.355 IGF1 -0.031 
  GSTP1 0.34 IL11 -0.035 
  NOS2 0.334 CD3G -0.067 
  NQO1 0.328 PLCD1 -0.076 
  TFPI2 0.319 CSF3 -0.078 
  SLC2A5 0.318 IRF8 -0.082 
  GATA3 0.317 IL12B -0.085 
  CCL5 0.312 NFKBIA -0.087 
  CD48 0.307 OPRD1 -0.101 
  IL15RA 0.299 CSF2 -0.105 
   
Table 2. Pearson correlation of NF-κB target genes with IGFBP2 in human glioma. 
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To validate that IGFBP2 activates NF-κB and to determine the role of integrin 
signaling in NF-κB activation, we used SNB19 parental, RGE-mutant, and wild-type 
IGFBP2 cells. A Western blot analysis of the nuclear extracts revealed high levels of NF-κB 
subunits p65 and p50 in wild-type IGFBP2 cells compared with low levels in parental and 
RGE-mutant cells (Figure 19A). NF-κB /DNA binding was additionally assessed via EMSA. 
Parental and RGE-mutant IGFBP2 cells exhibited low levels of DNA binding, whereas 
strong binding was observed in wild-type IGFBP2 extracts. Supershift assays confirmed 
that the binding was specific for p65 and p50 (Figure 19B). Luciferase assays 
demonstrated that NF-κB transcriptional activity was significantly increased in cells 
expressing IGFBP2 versus parental or RGE-mutant cells (p<0.0001; Figure 19C), 
validating that IGFBP2 activates NF-κB through integrin signaling.  
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Figure 19. IGFBP2 induces NF-κB activity. (A) Western blot analysis of p65 and p50 from 
nuclear extracts from the indicated cells. (B) Nuclear extracts from (A) were subjected to 
EMSA using an NF-κB consensus probe. Supershift assays were performed to validate the 
presence of p65 or p50. (C) NF-κB activation, as assessed by luciferase assay, in the 
indicated cells. *p<0.0001, ANOVA with Tukey’s multiple comparison test. Error bars 
represent SEM. 
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We next wanted to test cell viability after NF-κB inhibition in cells expressing high 
levels of IGFBP2 to determine if IGFBP2 rendered cells more sensitive to NF-κB inhibition.  
Primary mouse glial progenitor cells (GPCs) were obtained from Ntv-a transgenic mice at 
postnatal day 1 and treated with conditioned media from DF-1 cells engineered to 
overexpress RCAS particles containing PDGFB or IGFBP2. GPCs were then treated with 
PS-341, a proteasome inhibitor that affects NFκB by preventing the proteasomal 
degradation of its inhibitor, IκBα. Cell viability was measured via Trypan Blue staining, and 
cells were counted 24 hours after PS-341 treatment. Untreated cells and those infected with 
PDGFB alone were unaffected by NF-κB inhibition; in contrast, cells infected with both 
PDGFB and IGFBP2 had significantly reduced cell viability and sensitivity to PS-341, 
indicating that IGFBP2 promotes signaling pathways that activate NF-κB (p<0.001, ANOVA 
with Bonferroni’s posttests) (Figure 20A). To confirm that the reduced viability after PS-341 
treatment was specifically due to NF-κB inhibition, we used the same ex vivo approach but 
with a dominant-negative IκBα mutant (IκBαM) in lieu of PS-341. IκBαM contains S34,36A 
mutations, which prevent phosphorylation and subsequent IκBα degradation, inhibiting NF-
κB activation. GPCs were infected with PDGFB alone or in combination with IGFBP2 or 
IGFBP2 and IκBαM. Measurement of cell viability via MTT assay confirmed that cells 
expressing IGFBP2 exhibited a significantly increased sensitivity to NF-κB inhibition 
(p<0.01, ANOVA with Bonferroni’s posttests) (Figure 20B).  
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Figure 20. Elevated IGFBP2 expression sensitizes cells to NF-κB inhibition.               
Primary glial progenitor cells from Ntv-a mice were infected with RCAS particles expressing 
the indicated gene. (A) Cells uninfected (control) or infected with RCAS-PDGFB alone or 
with IGFBP2 were treated with PS-341 for 24 hr, followed by Trypan Blue staining to assess 
cell viability. *p<0.001, ANOVA with Bonferroni’s posttests. (B) MTT assay 24 hr after 
infection with RCAS-PDGFB, PDGFB with IGFBP2, or PDGFB with IGFBP2 and IκBαM. 
*p<0.01, ANOVA with Bonferroni’s posttests. Error bars indicate SEM.   
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Integrin, ILK, and NF-κB regulate IGFBP2-induced glioma progression 
 Rationale.  We have demonstrated that IGFBP2 activates integrin β1, requires ILK 
for Rac activation and cell motility, and activates NF-κB. We next wanted to test whether 
these pathways play a critical role in glioma progression under physiological conditions, in a 
glioma mouse model which is initially tumor-free. We utilized the RCAS/Ntv-a glial-specific 
transgenic mouse model to test our hypothesis in vivo. This system uses an avian 
retrovirus, RCAS, to infect cells expressing the avian tv-a receptor (80). Ntv-a mice have 
been engineered to express the tv-a receptor under the control of the nestin promoter (82). 
Nestin directs tv-a receptor expression to glial progenitor cells, leaving the remaining 
resident cells unaffected upon RCAS infection. RCAS constructs containing the gene of 
interest are transfected into avian DF-1 fibroblast cells and subsequently injected 
intracranially into Ntv-a mice on postnatal day 1. If the gene or combination of genes is 
oncogenic, mice form gliomas that closely resemble human glioma in their pathogenic 
features, including perinuclear satellitosis, perinuclear halos in oligodendroglioma, vascular 
proliferation, and pseudopalisading necrosis (86, 398). An experimental schematic is 
depicted in Figure 21.
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Figure 21. Experimental procedure for mouse model studies. RCAS constructs carrying 
the gene of interest are transfected into avian DF-1 cells which propagate the retrovirus. 
The cells are then injected into the right hemisphere of postnatal day 1 Ntv-a mice and 
subsequently monitored for tumor formation, upon which the brain is removed, fixed, and 
stained with H&E for pathological analysis. 
 
Using this mouse model, we previously demonstrated that intracranial injection of 
PDGFB led to the development of low-grade diffuse glioma (LGDG) in the majority of mice.  
Co-delivery of IGFBP2 and PDGFB resulted in the development of high-grade diffuse 
glioma (HGDG) in nearly half of the mice (88).  We therefore used this glioma progression 
model to investigate whether IGFBP2/integrin binding, ILK, and NF-κB are physiologically 
active pathways in vivo, and their role in IGFBP2-mediated glioma progression.  
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Results.  To test whether IGFBP2/integrin binding was required for progression, we 
injected RCAS-PDGFB alone or in combination with RCAS vectors encoding either wild-
type IGFBP2 or the RGE-mutant IGFBP2. PDGFB alone led to glioma formation in more 
than 83% of the mice; in 11% of these mice, the gliomas showed vascular proliferation 
and/or foci of necrosis, which qualified them as HGDG lesions.  Co-delivery of wild-type 
IGFBP2 and PDGFB produced gliomas in 72% of the mice, of which 44% were classified as 
HGDG, similar to our previous study (88).  Strikingly, co-delivery of RGE with PDGFB 
resulted in a 78% glioma incidence, but only 4% of these were classified as HGDG, 
indicating that the integrin-binding function of IGFBP2 is critical for its ability to drive glioma 
progression (Figure 22A-D).   
We next tested whether ILK could produce an effect similar to that of IGFBP2 and 
whether kinase-dead ILK (ILK-KD) was capable of blocking IGFBP2-mediated progression.  
Wild-type ILK or ILK-KD (S343A) was injected with PDGFB. Wild-type ILK led to a 
significant increase in HGDG incidence compared to injection of PDGFB alone (from 11%  
to 44% , p=0.006), with the same proportion of anaplastic progression as the PDGFB and 
IGFBP2 combination. In contrast, ILK-KD combined with PDGFB did not produce a 
significant increase in HGDG incidence (14% vs. 11%, p=0.750). When ILK-KD was co-
injected with IGFBP2 and PDGFB, an 18% HGDG incidence was observed, which also was 
not statistically different from PDGFB alone, indicating that, indeed, ILK is a critical 
downstream effector of the IGFBP2 pathway (Figure 22A-D).  
We determined the role of NF-κB in IGFBP2-induced glioma progression by co-
injecting a mutant form of IκBα (IκBαM; S32,36A) with PDGFB and IGFBP2 or PDGFB and 
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ILK. IκBαM inhibited NF-κB activation by retaining it in the cytoplasm. Strikingly, inhibiting 
NF-κB in the IGFBP2 combination produced LGDG tumors in all the mice, suggesting that 
IGFBP2 requires NF-κB to induce progression. Similarly, inhibiting NF-κB in the ILK 
combination also prevented progression (22% grade 3 incidence; p=0.42 vs. PDGFB 
alone). 
Thus, IGFBP2 drives glioma progression through integrin signaling, ILK, and NF-κB; 
genetically blocking any step of the pathway robustly prevents glioma progression, 
highlighting the potential therapeutic value of these findings (Figure 22D).  
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Figure 22.  IGFBP2 drives glioma progression by activating the integrin/ILK/NF-κB 
network. (A) The percentage of mice from each RCAS injection combination with LGDG or 
HGDG tumors. (B) Representative whole-brain sections from each injection combination. 
The dotted line indicates the tumor. (C) Representative H&E sections from tumors 
generated from each RCAS injection combination. Scale bar, 50 μm. (D) Model of IGFBP2-
induced glioma progression. IGFBP2 lies at the top of a signaling cascade that requires 
integrin binding, ILK, and p65/p50 to induce glioma progression (HGDG). Disruption of 
integrin binding to IGFBP2, inhibition of ILK kinase activity, or inhibition of p65/p50 blocks 
IGFBP2’s ability to induce glioma progression (LGDG tumors are produced). 
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RCAS Injection 
Combination 
Tumor 
Incidence 
HGDG 
Incidence 
*p-
value 
PDGFB 83% (35/42) 11% - 
PDGFB/IGFBP2 72% (36/50) 44% 0.003 
PDGFB/IGFBP2 (RGE) 78% (25/32) 4% 0.389 
PDGFB/ILK 79% (37/47) 49% <0.001 
PDGFB/ILK-KD 81% (21/26) 14% 1.000 
PDGFB/ILK-KD/IGFBP2 77% (17/22) 18% 0.669 
PDGFB/IGFBP2/IκBαM 74% (14/19) 0% 0.311 
PDGFB/ILK/IκBαM 90% (18/20) 22% 0.420 
*Fisher's Exact Test, compared to PDGFB 
only group 
   
Table 3. Tumor distribution of Ntv-a mice. 
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CHAPTER 4.  Discussion 
 
Summary 
Gliomas represent one of the most deadly types of cancer. Patients with the most 
commonly diagnosed form of glioma, GBM, typically survive a median of 15 months with 
the standard of care treatment (8). The identification and elucidation of complex oncogenic 
signaling networks is necessary to discover potential therapeutic targets that can be 
translated into clinical treatments. Although IGFBP2 is acknowledged as an important 
oncogene promoting glioma progression, the signaling pathway and mechanism of action 
remained under-characterized. In this current study, we combined transcriptional profiling of 
human glioma, biochemical analysis and perturbation of IGFBP2-associated pathways, and 
a spontaneous glioma mouse model to assess the clinical significance of IGFBP2 in relation 
to the integrin and ILK pathways and to NF-κB transcriptional regulation of invasion-related 
target genes. Our results provide evidence that IGFBP2 lies at the top of a signaling 
cascade involving integrins α5/β1, ILK, and NF-κB. Further, blocking any constituent of this 
network prevented IGFBP2-driven glioma progression in vivo (89). Therefore, we have 
identified novel effectors of IGFBP2 that could open up new avenues for intervention in 
tumors with high IGFBP2 expression, not only for glioma, but also in a broad range of other 
cancer types. 
The role of the IGFBP2 pathway in cell migration and invasion 
Most cancer-related deaths result from the spread of cancer from the initial site to 
distant organs, a phenomenon known as metastasis. The ability of cells to metastasize 
greatly relies upon migration and invasion because cells must be able to both move and 
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invade the surrounding tissue by degrading the ECM. Although primary brain tumors rarely 
metastasize, their ability to invade the surrounding parenchyma is a key feature which 
contributes to the morbidity of the disease. Both oligodendroglioma and astrocytoma 
(including GBM) are referred to as diffuse glioma, and are characterized by individual 
diffusely infiltrative cells. This feature produces an ill-defined tumor border that precludes 
complete surgical resection. As the extent of surgical resection is an important prognostic 
indicator (63), identifying major mechanisms by which cells migrate and invade away from 
the tumor mass is critical to provide more effective treatment. Many proteins are involved in 
these processes, including integrins, ILK, small GTPase proteins such as Rac, MMPs and 
others (399). Given that IGFBP2 has been associated with many of the major migration and 
invasion-promoting molecules, it is not surprising that the main function of IGFBP2 in 
glioma involves promoting cellular migration and invasion (156, 161). Previously, our group 
performed cDNA microarrays in IGFBP2-overexpressing glioma cells and found that 
migration and invasion-related genes were among the most striking differentially regulated 
alterations. In particular, the transcriptional activity of MMP-2 was increased in response to 
IGFBP2 (156). The relationship between IGFBP2 and MMP-2 has also been confirmed in 
human bladder cancer cells, which resulted in enhanced metastatic potential (158). In our 
previous study, we found that tumors that arose from INK4a/ARF loss and PDGFB 
overexpression had elevated endogenous IGFBP2 levels that were localized at the invasive 
front (94). Similarly, stereotactic biopsies of GBMs that progressed following bevacizumab 
treatment displayed a prominent infiltrative growth pattern, accompanied with strong 
IGFBP2 and MMP-2 staining (162), providing compelling evidence that IGFBP2 plays a 
dominant role in tumor invasion in vivo. Current therapies are cytotoxic and do not affect the 
migratory potential of cells. Given that IGFBP2 is a strong promoter of migration and 
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invasion processes, therapeutic targeting of IGFBP2 in combination with standard 
treatments could both eliminate tumor cells and inhibit invasion into surrounding areas.    
Functional significance of the IGFBP2/integrin relationship 
 IGFBP2 contains an integrin-binding RGD motif and has been confirmed to bind 
integrin α5b1. In the current study we confirmed that this interaction induced integrin β1 
activation and affected a variety of pathways, most prominently migration and invasion. 
Integrins bind an array of proteins on either the extracellular domain or cytoplasmic tail. 
Integrin activation may occur by either an outside-in or an inside-out mechanism; however, 
it remains unknown which type of integrin signaling IGFBP2 participates in. IGFBP2 is both 
a secreted and intracellular protein, and there appears to be an active trafficking system for 
IGFBP2 going in and out of cells. We have observed that addition of purified IGFBP2 
protein to the media of low-IGFBP2 expressing cell culture results in import of IGFBP2 into 
the cells. Thus, it is conceivable that IGFBP2 may bind to both extracellular and 
cytoplasmic portions of the integrins. The extracellular portion of integrin binds to matrix 
proteins and is important for cell adhesion. Increased IGFBP2 in the media actually 
increased cell adhesion, suggesting that IGFBP2 does not compete for binding of matrix, if 
in fact IGFBP2 does bind to the extracellular portion of the integrin. The integrin cytoplasmic 
tail binds essential proteins for activation, such as talin and ILK (206). It is plausible that 
IGFBP2 binds the integrin α5 cytoplasmic tail, leading to recruitment of talin and ILK to 
initiate inside-out mediated cellular migration. In previous studies, overexpression of 
IGFBP2 led to upregulation of integrins, including α5, α5, and β1 (134, 156). In our current 
study, microarray analysis comparing RGE-mutant and wild-type IGFBP2 revealed that 
disruption of IGFBP2/integrin binding led to down-regulation of multiple integrins, indicating 
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that IGFBP2 strongly modulates integrin signaling. Additionally, a possible positive 
feedback loop occurs in which IGFBP2 binds and activates integrins, and in turn, induces 
their transcription. 
Although IGFBP2 had been shown to promote cell migration through an integrin α5 
interaction, the full functional significance of this interaction has been unclear. In our study, 
disruption of IGFBP2/integrin binding in glioma cells lines affected multiple pathways, most 
notably the cell motility and invasion pathways. The functional significance of the 
IGFBP2/integrin interaction was not only present in vitro, but was also essential in vivo, as 
evidenced by the fact that RGE-mutant IGFBP2 could no longer cooperate with PDGFB to 
induce glioma progression. These data closely reflected human glioma data, in which 
IGFBP2 expression is intimately linked with genes in the integrin pathway. Importantly, 
activation of this pathway is also significantly correlated with prognosis.  
IGF-independent function of IGFBP2 
 It is now well-recognized that IGFBP2 has both IGF-dependent and IGF-
independent functions (111, 122). IGFBP2 is involved in many important cell processes, 
including cell proliferation; however the proliferative effects are varied and may be mediated 
via IGF-dependent or IGF-independent mechanisms. IGFBP2 has been reported to 
increase proliferation of a number of cancer cell lines, including breast cancer (147) and 
prostate cancer cells (400). In the SNB19 cell lines used for this study, we have not found 
IGFBP2 to increase cell proliferation in vitro (156). In fact, a negative effect of IGFBP2 on 
proliferation has been reported in other studies (124, 126, 127). Our previous study of 
IGFBP2 in the RCAS/Ntv-a model revealed that gliomas arising from IGFBP2 (with PDGFB) 
exhibited increased tumor cell proliferation via phospho-Histone H3 staining (88). Overall, 
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our in vivo system shows a positive proliferative effect from IGFBP2, but our cell culture 
system does not. It appears that IGFBP2 cell proliferation effect is complex and is 
dependent on extracellular environmental conditions.  
The possibility exists that IGFBP2 binding to integrin negatively impacts IGF-
dependent functions. However, IGFBP2-integrin binding in MCF-7 breast cancer cells did 
not affect IGFBP2 binding to IGFs (165). Consistently, a study in neuroblastoma SHEP 
cells reported that mutation of the IGFBP2 RGD (to RGE) had no effect on the affinity of 
IGFBP2 for IGFs (125). Thus, it is unlikely that the RGE-mutant IGFBP2 decreased cell 
migration effects were due to a switch to increased IGF binding. In our work, pathway 
analysis from the microarray experiment did not reveal significant alteration in the IGF 
pathway between cells expressing the RGE mutant and wild-type IGFBP2. Based on these 
observations, we do not believe that an IGF-dependent function is a key player in our 
experimental systems; on the other hand, a recent publication reported that IGFBP2 
recruits endothelia cells via activation of IGF-I/IGF-IR (169). More detailed and extensive 
experiments are required to assess the role of the IGF system in IGFBP2-mediated glioma 
progression. 
Integrin-linked kinase as a key mediator in glioma progression  
Strong ILK expression has been reported in many human malignancies and is 
inversely correlated with survival in melanoma and non-small cell lung, pancreatic, ovarian, 
and prostate cancers, but it had not previously been reported in glioma (260). In this study, 
we demonstrated that IGFBP2 requires ILK to induce Rac activation and subsequent cell 
migration. Our study confirms ILK to be an important factor in glioma progression. In our 
glioma mouse model, we demonstrated that ILK could replace IGFBP2 to drive glioma 
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progression, and that the kinase activity of ILK is required for IGFBP2-mediated glioma 
progression. Thus, it appears that IGFBP2 binds integrin, inducing integrin clustering and 
ILK recruitment, which activates Rac and mediates cell morphological changes that 
facilitate cell movement. Targeting ILK activity in glioma with increased IGFBP2 expression 
may have a clinical benefit, since these functional roles appear to be clinically relevant. We 
found that IGFBP2 expression in human glioma samples significantly associates with 
expression of ILK pathway genes, which is also reflected by the decreased survival duration 
among patients exhibiting elevated expression of both IGFBP2 and ILK.  
Consistent with the observation that IGFBP2 and ILK expression levels were highly 
correlated in human glioma samples, we observed an increase in ILK protein levels in cells 
stably expressing IGFBP2 compared to parental cells. Similarly, a separate study also 
reported that overexpression of IGFBP2 in a breast cancer cell line led to increased ILK 
expression (390). Here we have demonstrated that IGFBP2 activates integrin β1, which is 
consistent with activation of ILK. However, why ILK expression is increased is not yet clear. 
Since putative NF-κB binding sites are present in the ILK promoter, it is conceivable that 
there is a positive regulatory loop whereby IGFBP2 induces NF-κB activation, which then 
binds the ILK promoter to increase ILK expression.  
The role of NF-κB and potential regulatory loop with IGFBP2 
 NF-κB is constitutively active in glioma and has been implicated as in important 
oncogene through a variety of mechanisms. The genetic loss of NFKBIA is one major 
mechanism by which NF-κB is activated (372). In addition, NF-κB appears to cooperate 
with EGFR and Akt in driving glioma progression (156, 372). We demonstrated that IGFBP2 
indeed activates NF-κB, and IGFBP2-expressing cells were more sensitive to NF-κB 
104 
 
inhibition. Disruption of IGFBP2/integrin binding strongly attenuated NF-κB activation, 
indicating that IGFBP2 activates NF-κB through integrin engagement. Blocking NF-κB 
robustly prevented IGFBP2- and ILK-mediated glioma progression, underscoring the 
potential therapeutic benefit of NF-κB inhibition in tumors that highly express IGFBP2. 
Since NF-κB exerts its function at the bottom convergence point of the integrin and ILK 
pathway, inhibiting NF-κB may present the most rationale target in the IGFBP2 signaling 
cascade. However, additional investigation will be required to determine the precise 
mechanism by which NF-κB is activated in this pathway. Since Akt is a direct target of ILK 
and is a known NF-κB activator via IKK phosphorylation, Akt is a logical molecule 
responsible for inducing NF-κB activation in the IGFBP2 pathway. However, caution must 
be used when administering anti-NF-κB therapies, due to the potential hazards of 
immunosuppression with long-term use.    
Not only does IGFBP2 activate NF-κB, but evidence exists that NF-κB also 
regulates IGFBP2. Putative NF-κB binding sites have been identified on the IGFBP2 
promoter in rat alveolar cells, and hyperoxia led to NF-κB activation and subsequent 
induction of IGFBP2 transcriptional activity (401). We have also observed that activated NF-
κB results in increased IGFBP2 protein levels in glioma cells. These findings could indicate 
the presence of a positive feedback loop that perpetuates signaling events contributing to 
progression, in which IGFBP2 would activate NF-κB, which would increase IGFBP2 
transcription. It has also been reported that mitogens induce an INK4a/NF-κB-p65 
interaction, which results in decreased transactivation activity of NF-κB (402). Further, 
INK4a mutations have been reported to attenuate the inhibitory function on the NF-κB 
promoter (403).  In Ntv-a INK4a/ARF-/- mice with PDGFB-driven glioma, increased IGFBP2 
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protein expression was observed after loss of INK4a/ARF, and downregulation of 
endogenous IGFBP2 led to a survival benefit. Therefore, it is plausible to hypothesize that 
loss of INK4a/ARF would increase NF-κB activity, leading to elevated transcription of 
IGFBP2 and, thereby, potentiate glioma progression.    
IGFBP2 represents a physiologically active signaling pathway 
 In this study, we demonstrated that IGFBP2 activates integrin β1 and its 
downstream pathways, requires ILK to induce cell migration, and activates an NF-κB 
invasion-related transcriptional program. The most compelling evidence was obtained from 
in vivo studies that illustrate that these relationships represent true physiologically active 
signaling pathways. Although cell culture experiments and xenografts experiments answer 
key, direct questions, better systems are required to ultimately test the clinical applicability 
and significance of potential therapeutic targets. The RCAS/Ntv-a spontaneous glioma 
mouse model has enabled us to more closely recapitulate human glioma in a 
physiologically relevant setting by transforming normal murine glial cells with combinations 
of clinically relevant oncogenes (404). This study is the first to dissect an entire signaling 
pathway in the RCAS/tv-a system. We validated that IGFBP2-mediated glioma progression 
is driven by an integrin/ILK/NF-κB network and most importantly, we demonstrated that 
genetic inhibition of each pathway component thwarted glioma progression. 
Therapeutic implications 
 This study provides strong evidence that targeted inhibition of the IGFBP2 pathway 
may produce a clinical benefit for patients. The current standard therapy involves the 
alkylating agent temozolomide with concurrent radiotherapy (57).  Although a study has 
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reported that the IGFBP2 antisense drug OGX-225 attenuated tumor growth in a breast 
cancer xenograft model (147), a follow-up investigation has not been performed, and no 
other IGFBP2 inhibitors are available. However, integrin (405), ILK (198, 325), and NF-κB 
(406) are druggable targets that have been used in preclinical studies and clinical trials. 
Particularly, the cyclic RGD-mimetic αv integrin inhibitor cilengitide is in phase III clinical 
trials in glioma, testing its efficacy in combination with temozolomide and radiotherapy in 
newly diagnosed GBM with hypermethylated MGMT promoter (67). Although the results 
have been encouraging, perhaps stratifying patients with the IGFBP2 gene signature would 
elicit a more favorable clinical response. Three β1 inhibitors are currently in clinical trials for 
head and neck tumors and advanced solid tumors, including volociximab, which is a 
humanized monoclonal antibody against integrin α5β1 (407).  The β1 integrin inhibitors may 
be effective in glioma, since we specifically demonstrated its requirement for IGFBP2-
oncogenic function. Small molecule pharmacological inhibition of ILK in glioma xenografts 
has produced favorable outcomes. In U87MG xenografts, ILK inhibition was shown to result 
in significant delayed tumor growth, in addition to decreased angiogenesis and vasculature 
functionality (296, 317). The combined treatment of the ILK inhibitor QLT2054 and 
gemcitabine produced synergistic effects in primary pancreatic cancer xenografts (323), 
and may also perform similarly with temozolomide in GBM patients. To date, no ILK 
inhibitors have been tested in the clinic for any type of cancer. The proteasomal NF-κB 
inhibitor bortezomib has thus far only demonstrated efficacy in multiple myeloma patients 
(382), although it has not been tested on glioma in the clinic. NF-κB inhibitors have 
promoted glioma stem cell senescence and sensitized glioma cells to chemotherapies, 
indicating potential therapeutic benefit (375, 376, 379). Drugs targeting the IGFBP2 network 
could be used either in combination or with current standard therapy.  
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In summary, IGFBP2 is a strong, clinically relevant oncogene that exploits an 
integrin/ILK/NF-κB network to create the major driving force behind glioma progression. We 
are hopeful that by inhibiting the IGFBP2 signaling pathway, this will result in tumor 
regression and a subsequent survival benefit, not only for glioma patients but also for 
patients with a broad range of other cancers. 
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CHAPTER 5.  Future Directions 
  
Translational application of IGFBP2 network inhibition 
 This thesis has provided a basis for various avenues of future research. In 
particular, the RCAS/tv-a mouse model used in this work is an optimal preclinical system to 
test the efficacy of integrin, ILK, and NF-κB inhibitors in tumors with high IGFBP2 
expression. Since previous investigations in our lab revealed that IGFBP2 was responsible, 
in part, for shortened survival in INK4A/ARF-/- mice with PDGFB-driven tumors, current 
studies are ongoing to assess whether IGFBP2 gene ablation will prolong survival or block 
tumor progression. This will provide further evidence of the potential therapeutic benefit of 
IGFBP2 inhibition. As described in the Discussion, various β1 integrin inhibitors are 
available, and may be more effective in tumors with high IGFBP2 expression than the 
current integrin inhibitor cilengitide that is currently in clinical trial, and targets integrin αv. 
We are planning collaborations with Shoukat Dedhar’s laboratory to test the ATP-mimetic 
ILK small molecule inhibitor, QLT0267, in PDGFB-injected mice with IGFBP2 or ILK. Given 
the effectiveness of this inhibitor in xenograft models in glioma and other cancers, anti-
tumor results in our model would provide further framework to test ILK inhibitors in the 
clinic.     
Determining the role of the IGF system in IGFBP2 oncogenic functions 
 Although our current results do not seem to indicate a major IGF-dependency on 
IGFBP2 functions, we cannot rule out the possibility that there is some IGF-dependency. 
We plan to test whether IGFBP2-dependent cell proliferation and cell migration are affected 
by the IGF system. This can be achieved by evaluating the cellular response to varying 
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molar ratios of IGF-I or IGF-II with IGFBP2. Additionally, the effects of the IGF system can 
be eliminated via knockdown of IGF-IR and IGF-IIR. Finally, we plan to test the oncogenic 
capacity of IGF-I and IGF-II in our ex vivo system and mouse model. When injected alone, 
IGFs may not be sufficient to induce transformation. However, if IGFBP2 binding 
potentiates IGF function, as has been observed in some cases, LGDG should develop. In 
contrast, co-injection of IGF-I/II with PDGFB and IGFBP2 should prevent HGDG, if in fact 
IGF/IGFBP2 binding is inhibitory.     
Identification of NF-κB activation mechanism 
We have documented that IGFBP2 activates NF-κB via integrin activation, although 
we have not yet tested the precise mechanism. Since ILK is known to activate Akt, which in 
turn can phosphorylate and activate the IKK complex, it is plausible that Akt is required to 
activate NF-κB. In fact, Makino et al. (397) reported that ILK upregulated IKKα/β and 
activated NF-κB through ILK-dependent Akt phosphorylation. Additionally, we and others 
have found that IGFBP2 activates the Akt pathway (88, 166). We have tested the 
oncogenic capacity of the 3 Akt isoforms in the RCAS/Ntv-a mice, and found that Akt2 and 
Akt3 potently drive glioma progression; therefore, Akt2 and Akt3 are the likely Akt isoforms 
involved in NF-κB activation. To determine whether IGFBP2 requires Akt to induce NF-κB 
activation, Akt2 and Akt3 can be injected either with IκBαM or with dominant negative IKK. 
If Akt requires NF-κB activation to promote glioma progression, the addition or IκBαM or 
dominant negative IKK will prevent development of HGDG. Next, a dominant negative Akt 
should block IGFBP2-induced progression if Akt is a key player in the IGFBP2 pathway to 
activate NF-κB. 
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Figure 23. Proposed mechanism of IGFBP2-mediated NF-κB activation. Future studies 
will examine the involvement of Akt and the IKK complex in the IGFBP2 signaling pathway. 
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Appendix Figure A1. IGFBP2, ITGA5, ITGB1, and ILK Kaplan-Meier survival plots 
according to glioma histology. Data was obtained from the Rembrandt database. P-
values are derived from the log-rank test. 
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Appendix Table A1. Signaling pathways associated with IGFBP2 expression 
Pathways 
 -log(p-
value) 
Ratio Molecules 
 Agrin Interactions at Neuromuscular 
Junction 
7.38E00 3.62E-01 
 GABPB1, ACTA2, LAMC1, JUN, ERBB4, LAMB1, ERBB2, ACTG2, DAG1, ITGA4, ITGB1, PXN, NRAS, RRAS, ACTB, ITGA2, LAMA2, 
ITGA5, ITGA3, ACTG1, ITGB3, PAK3, NRG3, MAPK10, PAK7 
 Integrin Signaling 7.05E00 2.34E-01 
 RAP2B, DIRAS3, ARPC5, PARVB, ARF4, ARPC4, CAV1, ARPC1A, ACTG2, PPP1CA, TSPAN4, ITGA4, CAPN5, AKT2, RRAS, ITGA5, 
RHOJ, MYL12A, RND3, MYL12B, ARPC2, ZYX, PAK7, ACTN4, ITGA7, RAP1B, RAP2A, RALA, TSPAN7, ACTA2, ILK, SHC1, ARF6, 
AKT1, ACTR3, VCL, VASP, ACTN1, ITGB1, PXN, NRAS, RHOC, ACTB, ITGA2, ITGA3, ACTG1, ITGB3, CAPNS1, PAK3 
 Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 
6.29E00 3.67E-01 
 TP53, CDC25C, CKS2, CDK7, WEE1, CCNB2, PLK1, RPRM, CDK1, SKP2, CHEK1, CCNB1, GADD45A, CKS1B, TOP2A, BTRC, BRCA1, 
CHEK2 
 Caveolar-mediated Endocytosis 
Signaling 
5.38E00 2.71E-01 
 ITGB1, ACTB, ITGA2, ACTA2, ITGA5, RAB5B, ITGA3, COPB1, ACTG1, ITGB3, COPB2, DYRK3, FLOT2, HLA-A, FLNA, FLNC, CAV1, 
HLA-B, ACTG2, PTRF, ITGA7, HLA-C, ITGA4 
 Axonal Guidance Signaling 4.93E00 1.69E-01 
 PFN1, MYL6, ARPC5, SEMA6B, TUBB, VEGFA, ARPC4, ABLIM3, PLCB1, TUBA1C, ARPC1A, FZD2, RTN4R, GNG12, ITGA4, AKT2, 
RRAS, ITGA5, MYL9, MYL12A, SRGAP3, SDCBP, MYL12B, ARPC2, FZD6, PAK7, FZD5, PDGFD, EPHA2, GNAL, NRP1, RAP1B, 
LRRC4C, RND1, PLXNA3, SLIT1, UNC5A, PDGFA, FZD1, ABLIM1, EFNB2, SHC1, ACTR3, AKT1, PPP3CB, SMO, ADAM19, PRKCE, 
SEMA4A, ERBB2, SHANK2, SEMA3F, VASP, PPP3CA, BMP1, ITGB1, SEMA3G, PXN, NRAS, CXCR4, ITGA2, PFN2, GNAI1, ITGA3, 
PLXND1, GNG5, GNAI3, PAK3, LINGO1, PRKAG2, SEMA4G, ADAM9, FZD7 
 Actin Cytoskeleton Signaling 4.92E00 1.93E-01 
 FN1, PFN1, MYL6, PDGFA, ARPC5, ACTA2, IQGAP1, FGF13, SHC1, IQGAP2, ACTR3, CYFIP2, ARPC4, FGF12, ARPC1A, ACTG2, 
VCL, PPP1CA, ACTN1, GNG12, IQGAP3, ITGA4, ITGB1, PXN, NRAS, TMSB10/TMSB4X, RRAS, ACTB, ITGA2, PFN2, ITGA5, WASF1, 
ITGA3, ACTG1, MYL9, MYL12A, PAK3, MYL12B, ARPC2, VAV3, CD14, MYH9, PAK7, ACTN4, PDGFD, MSN 
 Cell Cycle Control of Chromosomal 
Replication 
4.82E00 3.87E-01  MCM5, MCM3, CDC45, RPA3, CDK7, CDC6, CDK6, CHEK2, MCM4, DBF4, CDK2, MCM7 
 Molecular Mechanisms of Cancer 4.59E00 1.7E-01 
 RAP2B, DIRAS3, NCSTN, CDKN2C, E2F6, PLCB1, BRCA1, HIPK2, NFKBIB, FZD2, TP53, AKT2, CASP3, RRAS, CDK6, RHOJ, AURKA, 
TCF3, RND3, MAPK10, FZD6, MAP2K3, FZD5, LEF1, PAK7, CFLAR, CDK2, GNAL, CAMK2G, RAP1B, RAP2A, RALA, CTNNA1, 
PSENEN, FZD1, FAS, CHEK1, CASP6, SHC1, SYNGAP1, JUN, AKT1, TGFB2, SMO, PRKCE, CHEK2, BMP1, ADCY2, CDC25C, NRAS, 
HAT1, RHOC, GNAI1, SMAD7, BAX, BAK1, APH1A, FADD, GNAI3, PAK3, RASGRF1, PRKAG2, CASP7, FZD7 
 p53 Signaling 4.56E00 2.6E-01 
 JMY, C12orf5, FAS, BIRC5, CHEK1, CASP6, AKT1, JUN, GADD45A, PPP1R13B, BRCA1, HIPK2, CHEK2, TP53, AKT2, THBS1, 
HDAC1, TNFRSF10B, RPRM, BAX, TP53I3, PCNA, SNAI2, CDK2, SIRT1 
 Regulation of Actin-based Motility 
by Rho 
3.9E00 2.42E-01 
 PFN1, MYL6, RHOC, ACTB, DIRAS3, ACTA2, ARPC5, PFN2, WASF1, RHOJ, MYL9, MYL12A, ACTR3, RND3, PAK3, MYL12B, 
ARPC2, ARPC4, ARPC1A, PAK7, ACTG2, PPP1CA 
 Role of CHK Proteins in Cell Cycle 
Checkpoint Control 
3.8E00 3.43E-01  TP53, E2F6, PCNA, CDC25C, RFC4, HUS1, RFC2, BRCA1, CDK1, CHEK2, CDK2, CHEK1 
 TNFR1 Signaling 3.74E00 2.83E-01  CASP3, TNFAIP3, IKBKE, FADD, TANK, CASP6, TRADD, MADD, JUN, RIPK1, PAK3, CASP2, PAK7, NFKBIB, CASP7 
 Hereditary Breast Cancer Signaling 3.63E00 2.09E-01 
 BARD1, DDB2, CHEK1, POLR2L, AKT1, GADD45A, HDAC11, RFC2, POLR2H, BRCA1, CHEK2, TP53, CDC25C, AKT2, NRAS, HDAC4, 
RRAS, WEE1, HDAC1, CDK6, CDK1, CCNB1, HDAC5, HDAC3, RFC4, POLR2E, BRCA2 
 Virus Entry via Endocytic Pathways 3.44E00 2.2E-01 
 ITGB1, NRAS, RRAS, ACTB, ITGA2, ACTA2, ITGA5, ITGA3, ACTG1, AP2S1, ITGB3, HLA-A, FLNA, FLNC, CLTCL1, CAV1, HLA-B, 
TFRC, PRKCE, ACTG2, ITGA4, HLA-C 
114 
 
    
 Cyclins and Cell Cycle Regulation 3.39E00 2.25E-01 
 TP53, HDAC4, CDK7, WEE1, HDAC1, CDK6, CCNB2, CDKN2C, PPP2R5A, CDK1, SKP2, HDAC5, CCNB1, E2F6, CCNA2, HDAC3, 
HDAC11, TGFB2, BTRC, CDK2 
 Ephrin Receptor Signaling 3.38E00 1.76E-01 
 RAP1B, PDGFA, ARPC5, VEGFA, SHC1, EFNB2, AKT1, ACTR3, GRIN2C, ARPC4, ARPC1A, GNG12, ITGA4, ITGB1, AKT2, PXN, 
NRAS, RRAS, CXCR4, ITGA2, GNAI1, ITGA5, STAT3, ITGA3, GNG5, GRIN3A, GNAI3, SDCBP, ABI1, PAK3, ARPC2, PAK7, PDGFD, 
EPHA2, GNAL 
 ILK Signaling 3.08E00 1.87E-01 
 FN1, MYL6, DIRAS3, ACTA2, ILK, RICTOR, VEGFA, PARVB, TGFB1I1, JUN, AKT1, FLNA, CHD1, ACTG2, ACTN1, ITGB1, PXN, AKT2, 
FBLIM1, CASP3, TMSB10/TMSB4X, RHOC, ACTB, RHOJ, ACTG1, PPP2R5A, ITGB3, MYL9, RND3, FLNC, SNAI2, MAPK10, MYH9, 
LEF1, ACTN4, MMP9 
 Mitotic Roles of Polo-Like Kinase 3E00 2.5E-01  KIF23, CDC25C, ESPL1, CDC20, PTTG1, WEE1, PRC1, CCNB2, PLK1, PPP2R5A, CDK1, CCNB1, HSP90B1, PLK4, KIF11, CHEK2 
 Mechanisms of Viral Exit from Host 
Cells 
2.93E00 2.67E-01  SNF8, CHMP2A, SH3GL3, ACTB, ACTA2, SH3GLB1, PRKCE, LMNB2, ACTG2, SH3GL2, ACTG1, LMNB1 
 Rac Signaling 2.91E00 1.87E-01 
 ITGB1, NOX4, NRAS, RRAS, ITGA2, ARPC5, ITGA5, WASF1, IQGAP1, ITGA3, CDK5R1, IQGAP2, JUN, ACTR3, CYFIP2, PAK3, 
ARPC2, ARPC4, CD44, PAK7, ARPC1A, ITGA4, IQGAP3 
 FAK Signaling 2.82E00 1.96E-01 
 ITGB1, CAPN5, AKT2, PXN, NRAS, RRAS, ACTB, HMMR, ACTA2, ITGA2, ITGA5, ITGA3, ACTG1, AKT1, CAPNS1, PAK3, PAK7, VCL, 
ACTG2, ITGA4 
 Hepatic Fibrosis / Hepatic Stellate 
Cell Activation 
2.7E00 1.9E-01 
 IGFBP4, FN1, MYL6, PDGFA, ACTA2, FAS, VEGFA, COL1A2, TIMP1, CYP2E1, TGFB2, ECE1, TNFRSF11B, IL8, SMAD7, IFNGR2, 
IGFBP5, MMP2, BAX, MYL9, COL1A1, LY96, IGFBP3, MYH9, CD14, IL1RAPL1, MMP9, COL3A1 
 Sphingosine-1-phosphate Signaling 2.68E00 1.93E-01 
 AKT2, ADCY2, CASP3, RHOC, PDIA3, PDGFA, DIRAS3, GNAI1, RHOJ, CASP4, GNAI3, CASP6, PLCE1, AKT1, RND3, CASP2, CASQ1, 
CASP1, S1PR1, PLCB1, PDGFD, SMPD3, CASP7 
 Huntington's Disease Signaling 2.57E00 1.64E-01 
 HSPA6, CASP4, HSPA5, CDK5R1, HSPA4, CASP6, SHC1, POLR2L, JUN, AKT1, HSPA1L, HDAC11, CASQ1, CASP1, PRKCE, PLCB1, 
POLR2H, DNAJB1, GNG12, TP53, CAPN5, AKT2, HDAC4, YKT6, CASP3, SH3GL3, HDAC1, DNM3, BAX, UBE2S, GNG5, HDAC5, 
GRM5, HDAC3, CAPNS1, POLR2E, CASP2, GOSR2, CASP7 
 Inhibition of Angiogenesis by TSP1 2.46E00 2.56E-01  VEGFA, TP53, AKT2, AKT1, JUN, SDC1, CASP3, THBS1, MAPK10, MMP9 
 Amyloid Processing 2.42E00 2.32E-01  CAPN5, AKT2, CSNK1A1, NCSTN, PSENEN, CDK5R1, APH1A, AKT1, CAPNS1, PRKAG2, PRKCE, MAPT, BACE2 
 Clathrin-mediated Endocytosis 
Signaling 
2.41E00 1.74E-01 
 PDGFA, ARPC5, ACTA2, SH3GLB1, SH3GL2, RAB5B, FGF13, VEGFA, ARF6, ACTR3, PPP3CB, FGF12, ARPC4, ARPC1A, ACTG2, 
PPP3CA, SNAP91, ITGB1, ACTB, SH3GL3, ITGA5, DNM3, ACTG1, AP2S1, ITGB3, ARPC2, CLTCL1, TFRC, PDGFD, MYO1E 
 PAK Signaling 2.33E00 1.78E-01 
 ITGB1, PXN, NRAS, MYL6, CASP3, RRAS, PDGFA, ITGA2, ITGA5, ITGA3, MYL9, SHC1, MYL12A, PAK3, MYL12B, MAPK10, PAK7, 
PDGFD, ITGA4 
 Apoptosis Signaling 2.33E00 1.98E-01 
 TP53, CAPN5, NRAS, CASP3, RRAS, LMNA, IKBKE, BAX, FAS, BAK1, CDK1, CASP6, CAPNS1, CASP2, PRKCE, SPTAN1, NFKBIB, 
CASP7, MCL1 
 Death Receptor Signaling 2.27E00 2.15E-01  CASP3, TNFRSF10B, IKBKE, FAS, TANK, FADD, CASP6, TRADD, RIPK1, CASP2, CFLAR, NFKBIB, CASP7, HSPB1 
 Germ Cell-Sertoli Cell Junction 
Signaling 
2.22E00 1.74E-01 
 DIRAS3, ACTA2, ILK, CTNNA1, IQGAP1, TUBB, AKT1, TGFB2, TUBA1C, ACTG2, ACTN1, ITGB1, PXN, NRAS, RHOC, RRAS, ACTB, 
ITGA2, RHOJ, ITGA3, ACTG1, CDH2, PAK3, RND3, MAPK10, ZYX, MAP2K3, PAK7, ACTN4 
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 IL-8 Signaling 2.17E00 1.61E-01 
 ANGPT2, DIRAS3, CXCR1, EIF4EBP1, IRAK1, VEGFA, HMOX1, AKT1, PRKCE, NFKBIB, GNG12, IL8, NOX4, AKT2, NRAS, RHOC, 
RRAS, GNAI1, IKBKE, RHOJ, MMP2, BAX, CSTB, GNG5, GNAI3, ARAF, RND3, MYL12B, MAPK10, MMP9, IRAK4 
 Glioblastoma Multiforme Signaling 2.15E00 1.65E-01 
 TSC1, PDIA3, PDGFA, DIRAS3, FZD1, E2F6, SHC1, AKT1, PLCE1, SMO, PLCB1, FZD2, TP53, AKT2, NRAS, RHOC, RRAS, CDK6, 
RHOJ, TCF3, RND3, FZD6, LEF1, FZD5, PDGFD, CDK2, FZD7 
 Fcγ Receptor-mediated 
Phagocytosis in Macrophages and 
Monocytes 
2.11E00 1.86E-01 
 AKT2, PXN, FCGR2A, ACTB, ACTA2, ARPC5, ACTG1, HMOX1, PLA2G6, ARF6, ACTR3, AKT1, VAV3, ARPC2, ARPC4, PRKCE, 
ARPC1A, ACTG2, VASP 
 Neuregulin Signaling 2.03E00 1.76E-01 
 ITGB1, AKT2, NRAS, RRAS, ITGA2, ITGA5, ITGA3, CDK5R1, TMEFF2, SHC1, HSP90B1, AKT1, NRG3, ERBB4, PRKCE, ERRFI1, 
ERBB2, ITGA4 
 Glioma Invasiveness Signaling 1.99E00 2.17E-01  NRAS, RRAS, RHOC, HMMR, DIRAS3, RHOJ, MMP2, ITGB3, RND3, TIMP1, CD44, PLAU, MMP9 
 Type I Diabetes Mellitus Signaling 1.98E00 1.74E-01 
 SOCS3, CASP3, SOCS2, IFNGR2, IKBKE, IRF1, FAS, IRAK1, FADD, TRADD, RIPK1, HLA-A, HLA-E, MAPK10, HLA-B, FCER1G, 
MAP2K3, HLA-G, NFKBIB, HLA-C, TNFRSF11B 
 TWEAK Signaling 1.94E00 2.31E-01  FADD, CASP6, TRADD, RIPK1, CASP3, IKBKE, NFKBIB, CASP7, TNFRSF12A 
 Neuroprotective Role of THOP1 in 
Alzheimer's Disease 
1.92E00 1.85E-01  HLA-A, HLA-E, HLA-B, PRKAG2, SERPINA3, ECE1, MAPT, HLA-G, MMP9, HLA-C 
 Antigen Presentation Pathway 1.92E00 2.33E-01  PSMB9, CALR, HLA-A, HLA-E, PDIA3, HLA-B, PSMB8, HLA-G, TAP1, HLA-C 
 Phospholipase C Signaling 1.92E00 1.46E-01 
 RAP1B, RALA, MYL6, DIRAS3, RPS6KA3, SHC1, HMOX1, PLCE1, PPP3CB, HDAC11, PLA2G5, PLCB1, PRKCE, PPP1CA, PPP3CA, 
GNG12, ITGA4, ITGB1, ADCY2, HDAC4, NRAS, RHOC, RRAS, FCGR2A, ITGA2, HDAC1, ITGA5, RHOJ, ITGA3, GNG5, HDAC5, 
MYL9, PLA2G6, MYL12A, HDAC3, RND3, MYL12B, FCER1G 
 ATM Signaling 1.92E00 2.22E-01  TP53, CDC25C, JUN, GADD45A, MAPK10, CCNB2, BRCA1, CDK1, CHEK2, CDK2, CHEK1, CCNB1 
 CXCR4 Signaling 1.88E00 1.6E-01 
 MYL6, DIRAS3, AKT1, JUN, PRKCE, PLCB1, GNG12, AKT2, PXN, ADCY2, NRAS, CXCR4, RHOC, RRAS, GNAI1, RHOJ, GNG5, MYL9, 
GNAI3, MYL12A, RND3, PAK3, MYL12B, MAPK10, PAK7, ELMO1, GNAL 
 PI3K/AKT Signaling 1.85E00 1.57E-01 
 TP53, ITGB1, TSC1, CDC37, AKT2, NRAS, RRAS, ITGA2, ILK, ITGA5, IKBKE, ITGA3, PPP2R5A, EIF4EBP1, SHC1, HSP90B1, GYS1, 
AKT1, HLA-B, NFKBIB, ITGA4, MCL1 
 Induction of Apoptosis by HIV1 1.81E00 1.97E-01  TP53, CASP3, CXCR4, IKBKE, BAX, BAK1, FAS, FADD, TRADD, RIPK1, MAPK10, NFKBIB, TNFRSF11B 
 NF-κB Activation by Viruses 1.8E00 1.83E-01  ITGB1, AKT2, NRAS, RRAS, ITGA2, ITGA5, IKBKE, ITGA3, TNFRSF14, ITGB3, AKT1, RIPK1, PRKCE, NFKBIB, ITGA4 
 CDK5 Signaling 1.76E00 1.81E-01 
 ITGB1, LAMA5, ADCY2, NRAS, RRAS, CABLES1, ITGA2, ITGA3, PPP2R5A, CACNA1A, CDK5R1, LAMC1, LAMB1, PRKAG2, MAPT, 
PPP1CA, GNAL 
 HMGB1 Signaling 1.75E00 1.8E-01 
 IL8, AKT2, NRAS, RHOC, RRAS, HAT1, DIRAS3, IFNGR2, RHOJ, AKT1, JUN, RND3, MAPK10, MAP2K3, SERPINE1, TNFRSF11B, 
MYST4, PLAT 
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IL-6 Signaling 1.75E00 1.8E-01 
 IL8, NRAS, RRAS, IKBKE, STAT3, CEBPB, COL1A1, SHC1, JUN, MAPK10, CD14, MAP2K3, IL1RAPL1, TNFAIP6, MAPKAPK2, 
NFKBIB, TNFRSF11B, HSPB1 
 Cdc42 Signaling 1.74E00 1.55E-01 
 RALA, MYL6, ARPC5, IQGAP1, IQGAP2, ACTR3, JUN, HLA-A, ARPC4, HLA-B, ARPC1A, HLA-G, ITGA4, IQGAP3, HLA-C, ITGB1, 
ITGA2, ITGA5, ITGA3, MYL9, MYL12A, PAK3, MYL12B, HLA-E, ARPC2, FCER1G, MAPK10 
 RhoA Signaling 1.69E00 1.79E-01 
 PFN1, MYL6, ACTB, ACTA2, ARPC5, PFN2, WASF1, ACTG1, MYL9, RHPN2, MYL12A, LPAR6, RAPGEF2, ACTR3, MYL12B, ARPC2, 
ARPC4, ARPC1A, ACTG2, MSN 
 Role of BRCA1 in DNA Damage 
Response 
1.67E00 1.97E-01  TP53, E2F6, RFC4, GADD45A, BARD1, RFC2, RBBP8, BRCA2, PLK1, BRCA1, CHEK2, CHEK1 
 Cell Cycle: G1/S Checkpoint 
Regulation 
1.67E00 1.97E-01  TP53, E2F6, HDAC3, HDAC4, HDAC11, HDAC1, CDK6, TGFB2, BTRC, CDK2, SKP2, HDAC5 
 Acute Phase Response Signaling 1.65E00 1.57E-01 
 SOCS3, SERPING1, FN1, SOCS2, SERPINA3, IRAK1, C1R, TRADD, SHC1, HMOX1, JUN, SOD2, AKT1, SERPINA1, OSMR, SERPINE1, 
NFKBIB, TNFRSF11B, AKT2, NRAS, RRAS, C1S, IKBKE, STAT3, CEBPB, TCF3, RIPK1, MAP2K3 
 Notch Signaling 1.62E00 2.09E-01  DLL1, NOTCH3, CNTN1, DTX4, NCSTN, PSENEN, HES1, JAG1, APH1A 
 Leukocyte Extravasation Signaling 1.62E00 1.56E-01 
 RAP1B, MYL6, MMP14, ACTA2, CTNNA1, RAPGEF4, TIMP1, CYBA, PRKCE, ACTG2, VCL, ACTN1, VASP, ITGA4, ITGB1, PXN, 
CXCR4, ACTB, GNAI1, MMP2, ACTG1, F11R, GNAI3, ICAM3, VAV3, MAPK10, CD44, PECAM1, ACTN4, MMP9, MSN 
 Amyotrophic Lateral Sclerosis 
Signaling 
1.54E00 1.51E-01 
 TP53, CAPN5, CASP3, GRIA2, CACNA1C, RAB5B, BAX, CACNA1A, GRIN3A, VEGFA, CACNA1E, CAPNS1, GRID1, GRIN2C, CASP1, 
GRIK2, PPP3CA, CASP7 
 Role of PKR in Interferon Induction 
and Antiviral Response 
1.49E00 1.96E-01  FADD, TP53, AKT1, CASP3, IKBKE, MAP2K3, TRAF5, NFKBIB, IRF1 
 Role of NFAT in Cardiac Hypertrophy 1.48E00 1.4E-01 
 PDIA3, CSNK1A1, SHC1, AKT1, PLCE1, PPP3CB, HDAC11, TGFB2, PLCB1, PRKCE, PPP3CA, GNG12, ADCY2, AKT2, NRAS, HDAC4, 
RRAS, HDAC1, SLC8A3, GNAI1, GNG5, HDAC5, RCAN1, GNAI3, HDAC3, MAPK10, PRKAG2, MAP2K3, CAMK2G 
 Factors Promoting Cardiogenesis in 
Vertebrates 
1.46E00 1.68E-01  NOX4, CDC6, FZD1, TCF3, NOG, FZD6, TGFB2, SMO, PRKCE, LEF1, FZD5, ACVR1C, FZD2, CDK2, BMP1, FZD7 
 Calcium Signaling 1.44E00 1.35E-01 
 RAP1B, RAP2B, RAP2A, MYL6, ACTA2, PPP3CB, GRIN2C, HDAC11, CASQ1, RYR1, TPM4, PPP3CA, CALR, HDAC4, CHRNA9, 
HDAC1, SLC8A3, GRIA2, TPM2, HDAC5, ATP2B2, GRIN3A, MYL9, RCAN1, HDAC3, PRKAG2, MYH9, CAMK2G 
 Cellular Effects of Sildenafil (Viagra) 1.41E00 1.46E-01 
 KCNN3, PDE2A, ADCY2, KCNN2, MYL6, PDIA3, ACTB, ACTA2, CACNA1C, ACTG1, CACNA1A, CACNG2, MYL9, MYL12A, PLCE1, 
CACNA1E, MYL12B, PRKAG2, PLCB1, MYH9, ACTG2, PPP1CA 
 Macropinocytosis Signaling 1.39E00 1.71E-01  ITGB1, NRAS, RRAS, PDGFA, ITGA5, RAB34, ITGB3, ARF6, ABI1, PRKCE, CD14, ACTN4, PDGFD 
 Protein Ubiquitination Pathway 1.35E00 1.42E-01 
 PSMB3, PSMA3, CDC20, PSMA7, DNAJC12, HSPA6, USP54, DNAJC10, PSMB8, HSPA5, TAP1, HSPA4, HSP90B1, HLA-A, HSPA1L, 
HLA-B, DNAJB1, BRCA1, PSMA2, PSMC2, HLA-C, PSMB4, PSMB9, PSME2, DNAJC2, UBE2S, PSMD8, HSPA12A, SKP2, PSMB2, 
DNAJB11, PSMD12, PSMA5, PSMA4, BTRC, USP46, UBE2J2, HSPB1, UBE2I 
 Endoplasmic Reticulum Stress 
Pathway 
1.34E00 2.78E-01  CASP3, XBP1, HSPA5, EIF2AK3, CASP7 
 Gα12/13 Signaling 1.33E00 1.56E-01 
 AKT2, PXN, NRAS, MYL6, RRAS, CDH6, CDH18, IKBKE, CDH11, MYL9, MYL12A, LPAR6, CDH2, JUN, AKT1, MYL12B, VAV3, 
CDH10, MAPK10, NFKBIB 
 Role of Macrophages, Fibroblasts 
and Endothelial Cells in Rheumatoid 
Arthritis 
1.32E00 1.33E-01 
 SOCS3, SFRP2, FN1, PDGFA, PDIA3, CSNK1A1, IL17RC, FZD1, IRAK1, VEGFA, TRADD, AKT1, C5AR1, JUN, PLCE1, PPP3CB, SMO, 
PRKCE, PLCB1, TRAF5, NFKBIB, MAPKAPK2, FZD2, PPP3CA, TNFRSF11B, IL8, AKT2, NRAS, RRAS, IKBKE, CEBPB, STAT3, TCF3, 
RIPK1, CEBPD, FZD6, LEF1, FZD5, MAP2K3, IL1RAPL1, PDGFD, IRAK4, FZD7, CAMK2G 
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 IL-22 Signaling 1.32E00 2.4E-01  SOCS3, AKT2, AKT1, IL10RB, MAPK10, STAT3 
 Tumoricidal Function of Hepatic 
Natural Killer Cells 
1.32E00 2.5E-01  FADD, CASP6, CASP3, BAX, CASP7, FAS 
 Airway Pathology in Chronic 
Obstructive Pulmonary Disease 
1.28E00 3.33E-01  IL8, MMP2, MMP9 
 mTOR Signaling 1.27E00 1.42E-01 
 TSC1, AKT2, NRAS, RHOC, RRAS, DIRAS3, RPS6KA3, FKBP1A, RHOJ, RICTOR, EIF4G1, PPP2R5A, EIF4EBP1, VEGFA, HMOX1, 
AKT1, EIF4G2, EIF3B, RND3, EIF4A1, EIF3I, PRKAG2, PRKCE 
 Myc Mediated Apoptosis Signaling 1.18E00 1.8E-01  FADD, TP53, SHC1, AKT2, AKT1, NRAS, CASP3, RRAS, MAPK10, BAX, FAS 
 Bladder Cancer Signaling 1.12E00 1.63E-01  TP53, IL8, DAPK1, NRAS, RRAS, THBS1, MMP14, MMP2, FGF13, VEGFA, FGF12, CHD1, ERBB2, MMP9, RASSF1 
 G Beta Gamma Signaling 1.12E00 1.28E-01  ADCY2, AKT2, NRAS, RRAS, GNAI1, GNG5, SHC1, GNAI3, AKT1, PRKAG2, CAV1, PRKCE, CAV2, GNAL, GNG12 
 Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid 
Arthritis 
1.09E00 1.33E-01 
 SFRP2, MMP14, CSNK1A1, FZD1, TRADD, JUN, AKT1, PPP3CB, SMO, TRAF5, NFKBIB, FZD2, PPP3CA, TNFRSF11B, BMP1, ITGB1, 
AKT2, SPP1, ITGA2, ITGA5, IKBKE, ITGA3, TCF3, ITGB3, COL1A1, MAPK10, FZD6, FZD5, LEF1, MAP2K3, IL1RAPL1, FZD7 
 Androgen Signaling 1.09E00 1.25E-01 
 CALR, CDK7, GNAI1, GTF2E2, GNG5, SHC1, GNAI3, HSPA4, POLR2L, TGFB1I1, JUN, POLR2E, PRKAG2, POLR2H, PRKCE, DNAJB1, 
GNG12, GNAL 
 Endothelin-1 Signaling 1.09E00 1.37E-01 
 PDIA3, CASP4, CASP6, SHC1, HMOX1, JUN, PLCE1, PLA2G5, CASQ1, CASP1, PLCB1, PRKCE, ECE1, ADCY2, NRAS, CASP3, RRAS, 
GNAI1, PLA2G6, GNAI3, ARAF, CASP2, MAPK10, CASP7, GNAL 
 Regulation of eIF4 and p70S6K 
Signaling 
1.08E00 1.29E-01  ITGB1, AKT2, NRAS, RRAS, ITGA2, ITGA5, ITGA3, EIF4G1, PPP2R5A, EIF4EBP1, SHC1, AKT1, EIF4G2, EIF3B, EIF4A1, EIF3I, ITGA4 
 Oncostatin M Signaling 1.08E00 2E-01  SHC1, NRAS, RRAS, OSMR, STAT3, PLAU, CHI3L1 
 Interferon Signaling 1.08E00 1.94E-01  PTPN2, IFNGR2, PSMB8, BAX, TAP1, BAK1, IRF1 
 MIF Regulation of Innate Immunity 1.06E00 1.6E-01  TP53, PLA2G6, LY96, JUN, PLA2G5, MAPK10, CD14, NFKBIB 
 GABA Receptor Signaling 1.05E00 1.58E-01  GABBR2, GABRG2, GABRB3, GABRG1, GABRB1, SLC6A1, GABBR1, ALDH5A1, AP2S1 
 IGF-1 Signaling 1.03E00 1.5E-01  SOCS3, IGFBP4, PXN, AKT2, NRAS, RRAS, SOCS2, IGFBP5, IGFBP7, STAT3, GRB10, SHC1, JUN, AKT1, IGFBP3, PRKAG2 
 IL-17A Signaling in Fibroblasts 1.02E00 1.75E-01  JUN, CEBPD, IL17RC, IKBKE, CEBPB, NFKBIZ, NFKBIB 
 Cardiac Hypertrophy Signaling 1.01E00 1.31E-01 
 MYL6, PDIA3, DIRAS3, CACNA1E, AKT1, JUN, PLCE1, PPP3CB, TGFB2, PLCB1, MAPKAPK2, PPP3CA, GNG12, ADCY2, NRAS, 
RHOC, RRAS, GNAI1, CACNA1C, RHOJ, CACNA1A, GNG5, MYL9, GNAI3, MYL12A, RND3, MYL12B, MAPK10, PRKAG2, MAP2K3, 
GNAL, HSPB1 
 ERK/MAPK Signaling 1.01E00 1.32E-01 
 RAP1B, DUSP6, RAPGEF4, EIF4EBP1, ELF4, SHC1, PLA2G5, PRKCE, PPP1CA, ITGA4, ITGB1, PXN, NRAS, RRAS, ITGA2, ITGA5, 
STAT3, MKNK2, ITGA3, PPP2R5A, PLA2G6, PAK3, ARAF, PRKAG2, DUSP4, PAK7, HSPB1 
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Type II Diabetes Mellitus Signaling 1.01E00 1.12E-01 
 PKM2, SOCS3, AKT2, SOCS2, ACSL6, IKBKE, CEBPB, KCNJ11, TRADD, AKT1, PRKAG2, ABCC8, MAPK10, PRKCE, SLC27A3, 
NFKBIB, SMPD3, TNFRSF11B 
 Mismatch Repair in Eukaryotes 1E00 1.67E-01  PCNA, RFC4, RFC2, POLD1 
 Atherosclerosis Signaling 9.91E-01 1.4E-01  IL8, PDGFA, CXCR4, F3, TNFRSF14, TNFRSF12A, COL1A2, COL1A1, PLA2G6, PLA2G5, PDGFD, COL18A1, MMP9, ITGA4, COL3A1 
 fMLP Signaling in Neutrophils 9.9E-01 1.33E-01 
 NOX4, NRAS, RRAS, ARPC5, GNAI1, GNG5, GNAI3, ACTR3, PPP3CB, ARPC2, ARPC4, PRKCE, PLCB1, ARPC1A, NFKBIB, GNG12, 
PPP3CA 
 Wnt/β-catenin Signaling 9.74E-01 1.44E-01 
 SFRP2, FRAT1, ILK, CSNK1A1, FZD1, AKT1, JUN, TGFB2, SMO, RUVBL2, FZD2, ACVR1C, TP53, AKT2, CSNK1G2, HDAC1, TCF3, 
PPP2R5A, CDH2, CD44, FZD6, BTRC, LEF1, FZD5, FZD7 
 Glutamate Receptor Signaling 9.71E-01 1.45E-01  GRM5, SLC1A6, SLC1A4, GRID1, GRIN2C, GRIA2, GRIP1, GRIK2, GNG5, GRIN3A 
 Reelin Signaling in Neurons 9.65E-01 1.59E-01  ITGB1, MAPK8IP2, ITGA2, ITGA5, ITGA3, RELN, CDK5R1, ITGB3, APBB1, AKT1, MAPK10, MAPT, ITGA4 
 Ovarian Cancer Signaling 9.59E-01 1.41E-01 
 TP53, AKT2, NRAS, RRAS, MMP2, FZD1, TCF3, VEGFA, AKT1, FZD6, PRKAG2, SMO, CD44, BRCA2, LEF1, FZD5, BRCA1, FZD2, 
MMP9, FZD7 
 IL-17 Signaling 9.53E-01 1.62E-01  IL8, AKT2, AKT1, JUN, NRAS, RRAS, TIMP1, MAPK10, IL17RC, MAP2K3, CEBPB, MAPKAPK2 
 VEGF Signaling 9.47E-01 1.41E-01  PXN, AKT2, NRAS, RRAS, ACTB, ACTA2, ACTG1, VEGFA, SHC1, AKT1, ACTN4, VCL, ACTG2, ACTN1 
 Angiopoietin Signaling 9.42E-01 1.49E-01  AKT2, ANGPT2, TNIP1, AKT1, NRAS, PAK3, RRAS, IKBKE, PAK7, NFKBIB, BIRC5 
 Protein Kinase A Signaling 9.36E-01 1.28E-01 
 RAP1B, AKAP12, AKAP8, MYL6, PDIA3, AKAP11, GYS1, PLCE1, PPP3CB, FLNA, HLA-B, SMO, TGFB2, PRKCE, PLCB1, RYR1, 
PPP1CA, NFKBIB, PPP3CA, GNG12, VASP, PXN, PDE2A, ADCY2, GNAI1, PYGL, AKAP6, TCF3, GNG5, MYL9, GNAI3, MYL12A, 
ADD3, FLNC, MYL12B, KDELR2, KDELR3, PRKAG2, PDE8B, LEF1, KDELR1, CAMK2G 
 CREB Signaling in Neurons 9.31E-01 1.24E-01 
 PDIA3, SHC1, POLR2L, AKT1, PLCE1, GRID1, GRIN2C, PRKCE, PLCB1, POLR2H, GRIK2, GNG12, ADCY2, AKT2, NRAS, RRAS, 
GNAI1, GRIA2, GNG5, GRM5, GNAI3, POLR2E, PRKAG2, GNAL, CAMK2G 
 NRF2-mediated Oxidative Stress 
Response 
9.07E-01 1.35E-01 
 PPIB, ACTA2, GCLC, DNAJC10, CLPP, HMOX1, SOD2, AKT1, JUN, ABCC1, PRKCE, ACTG2, GCLM, DNAJB1, TXN, GSTK1, NRAS, 
RRAS, ACTB, MAFF, ACTG1, ERP29, MGST2, DNAJB11, MAP2K3, EIF2AK3 
 Synaptic Long Term Potentiation 8.92E-01 1.4E-01 
 RAP1B, NRAS, RRAS, PPP1R1A, GRIA2, CACNA1C, GRIN3A, GRM5, PPP3CB, GRIN2C, PRKAG2, PRKCE, PLCB1, PPP1CA, PPP3CA, 
CAMK2G 
 Semaphorin Signaling in Neurons 8.86E-01 1.73E-01  ITGB1, RND1, RND3, PAK3, RHOC, DIRAS3, RHOJ, PAK7, NRP1 
 Endometrial Cancer Signaling 8.86E-01 1.58E-01  TP53, AKT2, AKT1, NRAS, RRAS, CTNNA1, ILK, LEF1, ERBB2 
 Colorectal Cancer Metastasis 
Signaling 
8.82E-01 1.28E-01 
 DIRAS3, MMP14, FZD1, BIRC5, VEGFA, JUN, AKT1, SMO, TGFB2, FZD2, GNG12, TP53, ADCY2, AKT2, NRAS, CASP3, RHOC, 
RRAS, ADRBK2, RHOJ, MMP2, STAT3, BAX, TCF3, GNG5, RND3, MAPK10, PRKAG2, FZD6, FZD5, LEF1, MMP9, FZD7 
 Circadian Rhythm Signaling 8.77E-01 1.71E-01  PER3, GRIN2C, VIPR2, BHLHE40, CRY2, GRIN3A 
 Hypoxia Signaling in the 
Cardiovascular System 
8.74E-01 1.62E-01  VEGFA, TP53, P4HB, HSP90B1, AKT1, JUN, UBE2S, NFKBIB, LDHA, UBE2J2, UBE2I 
 Hepatic Cholestasis 8.42E-01 1.16E-01 
 IL8, ADCY2, TJP2, SLC4A2, SLCO1A2, IKBKE, HSD3B7, IRAK1, LY96, JUN, ABCC1, PRKAG2, MAPK10, CD14, PRKCE, IL1RAPL1, 
NFKBIB, ABCC3, IRAK4, TNFRSF11B 
 IL-10 Signaling 8.41E-01 1.41E-01  HMOX1, SOCS3, JUN, FCGR2A, IL10RB, CD14, IKBKE, MAP2K3, STAT3, IL1RAPL1, NFKBIB 
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EIF2 Signaling 8.14E-01 1.29E-01  AKT2, NRAS, RRAS, PPP1R15A, EIF4G1, SHC1, AKT1, EIF3B, EIF4G2, EIF4A1, EIF3I, PPP1CA, EIF2AK3 
 TREM1 Signaling 8.13E-01 1.36E-01  ITGB1, IL8, TREM1, AKT2, AKT1, CASP1, ITGA5, STAT3, IRAK1 
 IL-1 Signaling 8.05E-01 1.31E-01  ADCY2, GNAI1, IKBKE, GNG5, IRAK1, GNAI3, JUN, PRKAG2, MAPK10, MAP2K3, NFKBIB, GNAL, IRAK4, GNG12 
 Cardiac β-adrenergic Signaling 8.02E-01 1.24E-01 
 AKAP12, PDE2A, ADCY2, AKAP8, PPP1R1A, ADRBK2, SLC8A3, CACNA1C, AKAP6, PPP2R5A, CACNA1A, GNG5, AKAP11, 
CACNA1E, PKIB, PRKAG2, PDE8B, PPP1CA, GNG12 
 HER-2 Signaling in Breast Cancer 7.97E-01 1.48E-01  ITGB1, TP53, TSC1, AKT2, AKT1, NRAS, RRAS, CDK6, PRKCE, MMP2, ERBB2, ITGB3 
 Role of MAPK Signaling in the 
Pathogenesis of Influenza 
7.94E-01 1.54E-01  PLA2G6, AKT2, AKT1, NRAS, CASP3, RRAS, PLA2G5, MAPK10, MAP2K3, BAX 
 Antiproliferative Role of TOB in T 
Cell Signaling 
7.8E-01 1.92E-01  CCNA2, TGFB2, TWSG1, CDK2, SKP2 
 Tight Junction Signaling 7.75E-01 1.34E-01 
 AKT2, TJP2, MYL6, ACTB, ACTA2, CTNNA1, CSDA, ACTG1, PPP2R5A, CPSF4, MYL9, F11R, JUN, AKT1, TGFB2, PRKAG2, MYH9, 
ACTG2, VCL, SPTAN1, VASP, TNFRSF11B 
 CD40 Signaling 7.62E-01 1.43E-01  TANK, JUN, MAPK10, TNFAIP3, IKBKE, MAP2K3, STAT3, TRAF5, MAPKAPK2, NFKBIB 
 Chronic Myeloid Leukemia Signaling 7.53E-01 1.33E-01  TP53, AKT2, NRAS, HDAC4, RRAS, HDAC1, CDK6, IKBKE, HDAC5, E2F6, AKT1, HDAC3, HDAC11, TGFB2 
 SAPK/JNK Signaling 7.53E-01 1.37E-01  TP53, NRAS, RRAS, MAPK8IP2, GNG5, FADD, SHC1, TRADD, JUN, RIPK1, GADD45A, MAPK10, FCER1G, DUSP4 
 Regulation of IL-2 Expression in 
Activated and Anergic T 
Lymphocytes 
7.41E-01 1.35E-01  JUN, NRAS, PPP3CB, RRAS, BCL10, VAV3, MAPK10, TGFB2, IKBKE, MALT1, NFKBIB, PPP3CA 
 α-Adrenergic Signaling 7.34E-01 1.24E-01  ADCY2, NRAS, RRAS, SLC8A3, GNAI1, PYGL, GNG5, GNAI3, GYS1, HLA-B, PRKAG2, PRKCE, GNG12 
 Lipid Antigen Presentation by CD1 7.32E-01 1.74E-01  CALR, ARF6, PDIA3, FCER1G 
 DNA Methylation and 
Transcriptional Repression Signaling 
7.32E-01 1.74E-01  HDAC1, SAP30, DNMT1, SAP18 
 Coagulation System 6.97E-01 1.58E-01  PROS1, SERPINA1, PLAU, SERPINE1, F3, PLAT 
 Nucleotide Excision Repair Pathway 6.97E-01 1.71E-01  POLR2L, RPA3, ERCC1, POLR2E, CDK7, POLR2H 
 Prolactin Signaling 6.94E-01 1.38E-01  SHC1, SOCS3, JUN, NRAS, RRAS, SOCS2, PRKCE, NMI, STAT3, CEBPB, IRF1 
 DNA Double-Strand Break Repair by 
Homologous Recombination 
6.84E-01 1.76E-01  LIG1, BRCA2, BRCA1 
 Aryl Hydrocarbon Receptor Signaling 6.79E-01 1.19E-01 
 TP53, CDK6, BAX, FAS, CHEK1, CCNA2, HSP90B1, JUN, MGST2, TGFB2, ALDH16A1, CHEK2, ALDH5A1, ALDH6A1, CDK2, AHR, 
MCM7, HSPB1, GSTK1 
 CD27 Signaling in Lymphocytes 6.62E-01 1.4E-01  SIVA1, JUN, CASP3, MAPK10, IKBKE, MAP2K3, TRAF5, NFKBIB 
 Glucocorticoid Receptor Signaling 6.43E-01 1.15E-01 
 HSPA6, GTF2E2, CD163, HSPA5, HSPA4, SHC1, HSP90B1, POLR2L, AKT1, JUN, HSPA1L, PPP3CB, ANXA1, TGFB2, POLR2H, 
SERPINE1, NFKBIB, PPP3CA, TAF12, IL8, SRA1, AKT2, NRAS, RRAS, CDK7, IKBKE, STAT3, CEBPB, POLR2E, MAPK10, PRKAG2, 
NR3C2, PLAU, UBE2I 
 TNFR2 Signaling 6.42E-01 1.47E-01  TANK, JUN, TNFAIP3, IKBKE, NFKBIB 
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PI3K Signaling in B Lymphocytes 6.4E-01 1.26E-01 
 AKT2, ATF3, NRAS, PDIA3, RRAS, IKBKE, MALT1, PLEKHA4, AKT1, JUN, PLCE1, PPP3CB, BCL10, VAV3, PLCB1, NFKBIB, PPP3CA, 
CAMK2G 
 Maturity Onset Diabetes of Young 
(MODY) Signaling 
6.29E-01 1.29E-01  CACNA1E, GAPDH, CACNA1C, CACNA1A 
 CD28 Signaling in T Helper Cells 6.18E-01 1.21E-01  AKT2, ARPC5, IKBKE, MALT1, ACTR3, AKT1, JUN, PPP3CB, BCL10, ARPC2, ARPC4, FCER1G, MAPK10, ARPC1A, NFKBIB, PPP3CA 
 P2Y Purigenic Receptor Signaling 
Pathway 
6.18E-01 1.19E-01  ADCY2, AKT2, NRAS, PDIA3, RRAS, GNAI1, GNG5, ITGB3, GNAI3, AKT1, JUN, PLCE1, PRKAG2, PLCB1, PRKCE, GNG12 
 Cytotoxic T Lymphocyte-mediated 
Apoptosis of Target Cells 
6.18E-01 1.36E-01  FADD, CASP6, HLA-A, CASP3, HLA-E, HLA-B, FCER1G, HLA-G, CASP7, FAS, HLA-C 
 Intrinsic Prothrombin Activation 
Pathway 
6.02E-01 1.47E-01  COL1A2, COL1A1, PROS1, COL18A1, COL3A1 
 Role of Tissue Factor in Cancer 5.97E-01 1.32E-01  TP53, ITGB1, IL8, P4HB, AKT2, NRAS, CASP3, RRAS, RPS6KA3, ITGA3, F3, ITGB3, VEGFA, AKT1, PLCB1 
 Melatonin Signaling 5.95E-01 1.3E-01  GNAI3, PLCE1, ARAF, PDIA3, GNAI1, PRKAG2, PRKCE, PLCB1, MAP2K3, CAMK2G 
 Acute Myeloid Leukemia Signaling 5.94E-01 1.34E-01  AKT2, AKT1, NRAS, ARAF, RRAS, KIT, LEF1, MAP2K3, STAT3, TCF3, EIF4EBP1 
 Graft-versus-Host Disease Signaling 5.79E-01 1.4E-01  HLA-A, HLA-E, HLA-B, FCER1G, HLA-G, FAS, HLA-C 
 GM-CSF Signaling 5.72E-01 1.34E-01  SHC1, AKT2, AKT1, NRAS, PPP3CB, RRAS, STAT3, PPP3CA, CAMK2G 
 VDR/RXR Activation 5.71E-01 1.36E-01  SERPINB1, SPP1, GADD45A, PDGFA, IGFBP3, TGFB2, PRKCE, CD14, IGFBP5, HES1, CEBPB 
 Basal Cell Carcinoma Signaling 5.71E-01 1.37E-01  TP53, SMO, FZD6, LEF1, FZD5, FZD1, TCF3, FZD2, FZD7, BMP1 
 Granzyme B Signaling 5.68E-01 1.88E-01  CASP3, LMNB2, LMNB1 
 Glioma Signaling 5.53E-01 1.16E-01  TP53, AKT2, NRAS, RRAS, PDGFA, CDK6, CDKN2C, SHC1, E2F6, AKT1, PRKCE, PDGFD, CAMK2G 
 Autoimmune Thyroid Disease 
Signaling 
5.5E-01 1.15E-01  HLA-A, HLA-E, HLA-B, FCER1G, HLA-G, FAS, HLA-C 
 Nitric Oxide Signaling in the 
Cardiovascular System 
5.49E-01 1.1E-01  VEGFA, PDE2A, HSP90B1, AKT2, CACNA1E, AKT1, CAV1, PRKAG2, CACNA1C, CHRM1, CACNA1A 
 IL-3 Signaling 5.47E-01 1.35E-01  SHC1, AKT2, AKT1, JUN, NRAS, PPP3CB, RRAS, PRKCE, STAT3, PPP3CA 
 Small Cell Lung Cancer Signaling 5.47E-01 1.12E-01  TP53, AKT2, AKT1, CKS1B, CDK6, IKBKE, TRAF5, NFKBIB, CDK2, SKP2 
 Activation of IRF by Cytosolic 
Pattern Recognition Receptors 
5.47E-01 1.25E-01  TANK, FADD, JUN, RIPK1, PPIB, MAPK10, IKBKE, IRF3, NFKBIB 
 Aldosterone Signaling in Epithelial 
Cells 
5.44E-01 1.18E-01 
 ICMT, PDIA3, DNAJC12, HSPA6, DNAJC10, DNAJC2, HSPA5, HSPA12A, HSPA4, HSP90B1, PLCE1, HSPA1L, DNAJB11, ACCN2, 
PLCB1, PRKCE, NR3C2, DNAJB1, HSPB1, AHCY 
 Insulin Receptor Signaling 5.31E-01 1.22E-01 
 FOXO4, SOCS3, TSC1, AKT2, NRAS, RRAS, TRIP10, ACLY, GRB10, EIF4EBP1, SHC1, AKT1, GYS1, ACCN2, HLA-B, PRKAG2, 
PPP1CA 
 Thrombin Signaling 5.07E-01 1.17E-01 
 AKT2, ADCY2, NRAS, MYL6, RHOC, PDIA3, RRAS, DIRAS3, GNAI1, RHOJ, GNG5, MYL9, GNAI3, SHC1, MYL12A, PLCE1, AKT1, 
RND3, MYL12B, PLCB1, PRKCE, GNG12, GNAL, CAMK2G 
 IL-17A Signaling in Gastric Cells 5.03E-01 1.6E-01  IL8, JUN, MAPK10, IL17RC 
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 Role of JAK family kinases in IL-6-
type Cytokine Signaling 
5.03E-01 1.48E-01  SOCS3, MAPK10, OSMR, STAT3 
 MIF-mediated Glucocorticoid 
Regulation 
4.97E-01 1.19E-01  PLA2G6, LY96, PLA2G5, CD14, NFKBIB 
 Complement System 4.97E-01 1.43E-01  C1R, SERPING1, C5AR1, C1S, CFI 
    
 Human Embryonic Stem Cell 
Pluripotency 
4.83E-01 1.1E-01  AKT2, PDGFA, SMAD7, FZD1, TCF3, NOG, AKT1, FZD6, TGFB2, SMO, S1PR1, LEF1, FZD5, PDGFD, FZD2, BMP1, FZD7 
 Crosstalk between Dendritic Cells 
and Natural Killer Cells 
4.73E-01 1.24E-01  HLA-A, HLA-E, ICAM3, ACTB, ACTA2, HLA-B, ACTG2, HLA-G, ACTG1, FAS, HLA-C, CAMK2G 
 14-3-3-mediated Signaling 4.72E-01 1.25E-01  TSC1, AKT2, NRAS, RRAS, PDIA3, BAX, TUBB, AKT1, JUN, PLCE1, MAPK10, PRKCE, PLCB1, TUBA1C, MAPT 
 Melanoma Signaling 4.67E-01 1.3E-01  TP53, AKT2, AKT1, NRAS, RRAS, CHD1 
 PTEN Signaling 4.67E-01 1.13E-01  ITGB1, FOXO4, AKT2, NRAS, CASP3, RRAS, ITGA2, ILK, ITGA5, IKBKE, ITGA3, SHC1, AKT1, ITGA4 
 Erythropoietin Signaling 4.57E-01 1.15E-01  SHC1, SOCS3, AKT2, AKT1, JUN, NRAS, RRAS, PRKCE, NFKBIB 
 Role of NANOG in Mammalian 
Embryonic Stem Cell Pluripotency 
4.5E-01 1.23E-01  TP53, AKT2, NRAS, RRAS, STAT3, FZD1, SHC1, AKT1, FZD6, SMO, FZD5, FZD2, BMP1, FZD7 
 Cholecystokinin/Gastrin-mediated 
Signaling 
4.44E-01 1.23E-01  PXN, NRAS, RRAS, RHOC, DIRAS3, RHOJ, SHC1, JUN, RND3, MAPK10, PRKCE, PLCB1, MAP2K3 
 Role of JAK2 in Hormone-like 
Cytokine Signaling 
4.37E-01 1.35E-01  SH2B3, SHC1, SOCS3, SOCS2, STAT3 
 CCR5 Signaling in Macrophages 4.17E-01 9.57E-02  GNAI3, JUN, MAPK10, GNAI1, FCER1G, PRKCE, GNG5, GNG12, FAS 
 Role of RIG1-like Receptors in 
Antiviral Innate Immunity 
4.16E-01 1.22E-01  TANK, FADD, RIPK1, IKBKE, IRF3, NFKBIB 
 Thyroid Cancer Signaling 4.16E-01 1.3E-01  TP53, SHC1, NRAS, RRAS, LEF1, TCF3 
 JAK/Stat Signaling 4.09E-01 1.25E-01  SHC1, SOCS3, AKT2, AKT1, NRAS, RRAS, SOCS2, STAT3 
 Role of Wnt/GSK-3β Signaling in the 
Pathogenesis of Influenza 
4.06E-01 1.23E-01  CSNK1G2, CSNK1A1, SMO, FZD6, LEF1, FZD5, FZD1, TCF3, FZD2, FZD7 
 PPAR Signaling 4.05E-01 1.13E-01  SHC1, SRA1, HSP90B1, JUN, NRAS, RRAS, PDGFA, IKBKE, IL1RAPL1, PDGFD, NFKBIB, TNFRSF11B 
 Chemokine Signaling 3.98E-01 1.22E-01  GNAI3, JUN, NRAS, RRAS, CXCR4, GNAI1, PLCB1, PPP1CA, CAMK2G 
 Role of Oct4 in Mammalian 
Embryonic Stem Cell Pluripotency 
3.93E-01 1.33E-01  TP53, CASP6, SPP1, SH3GLB1, BRCA1, PHB 
 Role of NFAT in Regulation of the 
Immune Response 
3.9E-01 1.05E-01 
 AKT2, NRAS, FCGR2A, RRAS, CSNK1G2, CSNK1A1, GNAI1, IKBKE, GNG5, RCAN1, GNAI3, AKT1, JUN, PPP3CB, FCER1G, PLCB1, 
NFKBIB, GNG12, PPP3CA, GNAL, ORAI1 
 4-1BB Signaling in T Lymphocytes 3.75E-01 1.18E-01  JUN, MAPK10, IKBKE, NFKBIB 
 Sonic Hedgehog Signaling 3.75E-01 1.21E-01  SMO, PRKAG2, CDK1, CCNB1 
 GNRH Signaling 3.71E-01 1.03E-01  ADCY2, NRAS, RRAS, GNAI1, DNM3, GNAI3, JUN, PAK3, PRKAG2, MAPK10, PRKCE, PLCB1, MAP2K3, PAK7, CAMK2G 
 p38 MAPK Signaling 3.68E-01 1.23E-01  MKNK2, FAS, IRAK1, FADD, PLA2G6, TRADD, PLA2G5, TGFB2, MAP2K3, IL1RAPL1, MAPKAPK2, IRAK4, HSPB1 
AMPK Signaling 3.66E-01 9.64E-02  TSC1, AKT2, CHRNA9, PFKL, PPP2R5A, EIF4EBP1, AKT1, GYS1, PFKFB4, PRKAG2, CPT2, HLA-B, MAP2K3, ACACA, AK4, AK2 
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 April Mediated Signaling 3.6E-01 1.16E-01  JUN, MAPK10, IKBKE, TRAF5, NFKBIB 
 OX40 Signaling Pathway 3.56E-01 1.11E-01  JUN, HLA-A, HLA-E, MAPK10, HLA-B, FCER1G, TRAF5, HLA-G, NFKBIB, HLA-C 
 Role of IL-17A in Psoriasis 3.53E-01 1.54E-01  IL8, IL17RC 
 LPS-stimulated MAPK Signaling 3.46E-01 1.1E-01  JUN, NRAS, RRAS, MAPK10, PRKCE, CD14, IKBKE, MAP2K3, NFKBIB 
 Leptin Signaling in Obesity 3.46E-01 1.1E-01  SOCS3, ADCY2, AKT2, AKT1, PLCE1, PDIA3, PRKAG2, PLCB1, STAT3 
 HGF Signaling 3.45E-01 1.14E-01  RAP1B, ELF4, PXN, AKT2, AKT1, JUN, NRAS, RRAS, MAPK10, PRKCE, STAT3, CDK2 
 Relaxin Signaling 3.41E-01 1.01E-01  RAP1B, PDE2A, ADCY2, AKT2, GNAI1, GNG5, VEGFA, GNAI3, AKT1, JUN, PRKAG2, PDE8B, NFKBIB, GNG12, MMP9, GNAL 
 Non-Small Cell Lung Cancer 
Signaling 
3.36E-01 1.01E-01  TP53, AKT2, AKT1, NRAS, RRAS, CDK6, ERBB2, RASSF1 
 Polyamine Regulation in Colon 
Cancer 
3.34E-01 1.03E-01  SAT1, PSME2, OAZ1 
 Neuropathic Pain Signaling In Dorsal 
Horn Neurons 
3.32E-01 1.11E-01  GRM5, KCNN3, KCNN2, PLCE1, PDIA3, GRIN2C, GRIA2, PRKAG2, PRKCE, PLCB1, CAMK2G, GRIN3A 
    
 TGF-β Signaling 3.26E-01 1.12E-01  JUN, NRAS, RRAS, HDAC1, SMAD7, TGFB2, MAP2K3, SERPINE1, ACVR1C, TGIF1 
 B Cell Activating Factor Signaling 3.17E-01 1.11E-01  JUN, MAPK10, IKBKE, TRAF5, NFKBIB 
 Production of Nitric Oxide and 
Reactive Oxygen Species in 
Macrophages 
3.13E-01 9.63E-02 
 RAP1B, AKT2, RHOC, DIRAS3, IFNGR2, RHOJ, IKBKE, PPP2R5A, IRF1, AKT1, JUN, RND3, CYBA, MAPK10, PRKCE, NFKBIB, 
PPP1CA, TNFRSF11B 
 Toll-like Receptor Signaling 3.11E-01 1.09E-01  LY96, JUN, CD14, MAP2K3, IRAK4, IRAK1 
 p70S6K Signaling 3.01E-01 1.08E-01  AKT2, NRAS, RRAS, PDIA3, GNAI1, PPP2R5A, SHC1, GNAI3, AKT1, PLCE1, PRKCE, PLCB1, MAPT, BCAP31 
 FcγRIIB Signaling in B Lymphocytes 2.97E-01 8.47E-02  SHC1, AKT1, NRAS, RRAS, MAPK10 
 Assembly of RNA Polymerase II 
Complex 
2.94E-01 1.07E-01  TAF12, POLR2L, POLR2E, CDK7, POLR2H, GTF2E2 
 HIF1α Signaling 2.94E-01 1.11E-01  VEGFA, TP53, AKT2, AKT1, JUN, NRAS, RRAS, MMP14, MAPK10, MMP2, LDHA, MMP9 
 Role of JAK1, JAK2 and TYK2 in 
Interferon Signaling 
2.81E-01 1.11E-01  PTPN2, IFNGR2, STAT3 
 G Protein Signaling Mediated by 
Tubby 
2.8E-01 9.76E-02  PLCB1, TUB, GNG5, GNG12 
 Neurotrophin/TRK Signaling 2.75E-01 1.04E-01  SHC1, AKT1, JUN, NRAS, RRAS, SPRY1, SPRY2, MAP2K3 
 Ceramide Signaling 2.73E-01 1.03E-01  AKT2, AKT1, JUN, NRAS, RRAS, S1PR1, SMPD3, PPP2R5A, TNFRSF11B 
 Renal Cell Carcinoma Signaling 2.61E-01 1.08E-01  VEGFA, AKT2, AKT1, JUN, NRAS, PAK3, RRAS, PAK7 
 IL-9 Signaling 2.6E-01 1E-01  SOCS3, SOCS2, BCL3, STAT3 
 Extrinsic Prothrombin Activation 
Pathway 
2.54E-01 1E-01  PROS1, F3 
 Cell Cycle Regulation by BTG Family 
Proteins 
2.41E-01 1.11E-01  E2F6, PRMT1, CDK2, PPP2R5A 
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Appendix Table A2. Pearson correlation of integrin pathway genes with IGFBP2 
Integrin Pathway 
Gene Pearson Gene Pearson Gene Pearson Gene Pearson Gene Pearson Gene Pearson Gene Pearson 
ZYX 0.784 ITGB3 0.513 MAP2K2 0.312 DNAJC15 0.18 GNAS 0.053 PAK1 -0.114 MRAS -0.304 
RHOJ 0.751 UBE2I 0.504 CDC34 0.308 HSP90AA1 0.18 ITGA8 0.05 TSPAN1 -0.116 GIT1 -0.312 
MYL12A 0.748 RALA 0.496 GNA15 0.305 FYB 0.176 DNAJC9 0.033 MYL2 -0.122 PNCK -0.312 
HSPA4 0.746 AKT2 0.495 GNB4 0.296 ITGAM 0.175 DNAJC19 0.03 GNAQ -0.132 CAMK2A -0.319 
GNG5 0.732 UBE2J2 0.493 ASAP1 0.292 PIK3R5 0.171 GSK3B 0.027 UBE2L3 -0.133 UBE2R2 -0.321 
SHC1 0.723 ARF5 0.488 RHOD 0.291 UBE2V2 0.171 MAP2K1 0.027 ITGB6 -0.136 SNCA -0.332 
PFN1 0.714 UBE2F 0.488 WIPF1 0.288 MYLK 0.162 GNA14 0.022 CRKL -0.142 PTK2 -0.334 
TSPAN4 0.713 PXN 0.482 ITGAE 0.287 DNAJC8 0.161 UBE2G1 0.015 FYN -0.142 PIK3C2G -0.337 
ITGA7 0.699 UBE2A 0.48 UBE2D4 0.285 RHOF 0.161 ROCK1 0.013 MYL7 -0.151 DOCK1 -0.338 
ITGA5 0.697 AKT1 0.473 ACTC1 0.283 PTGES3 0.152 UBE3B 0.012 PIK3R4 -0.157 GNG13 -0.338 
HSP90B1 0.696 ARF1 0.468 GNB1 0.282 NEDD4L 0.151 PIK3R2 0.01 DNM1 -0.158 DCTN1 -0.342 
GNG12 0.69 UBE2D3 0.462 RHOT2 0.281 PIK3CD 0.151 DNAJB5 -0.002 RHOV -0.162 CAMK4 -0.368 
DIRAS3 0.675 SMURF1 0.454 PAK2 0.278 ACTA1 0.15 MYL5 -0.003 GNAT1 -0.163 GNB3 -0.371 
ITGB1 0.671 CTTN 0.451 GNB2L1 0.271 GRB2 0.142 MAP3K11 -0.006 RHOT1 -0.164 AIP -0.404 
VAV3 0.67 NFE2L2 0.45 GNB1L 0.267 GNG7 0.141 RRAS2 -0.008 SRC -0.164 HSPB8 -0.404 
RAP2B 0.668 ITGB2 0.449 PIK3R3 0.267 DNAJC17 0.138 BCAR3 -0.009 DNAJC5B -0.165 MAPK8 -0.417 
HSPA5 0.664 RHOQ 0.449 GSN 0.25 MAPK1 0.137 ARHGAP26 -0.01 PTPN11 -0.167 UBE2E2 -0.429 
DNAJB11 0.661 ITGB8 0.448 DNAJB9 0.247 DNAJC13 0.132 GNAT2 -0.01 MYLK2 -0.17 DNAJC6 -0.432 
MYL12B 0.66 RAP1A 0.44 PIK3C3 0.246 TSPAN2 0.129 HSP90AB1 -0.01 ARF3 -0.172 NR3C1 -0.434 
DNAJB1 0.659 GNG11 0.429 TSPAN6 0.241 UBE2E1 0.126 DNAJC7 -0.011 GNB5 -0.172 PTEN -0.444 
PPP1CA 0.654 DNAJC14 0.424 VAV1 0.239 DNAJC4 0.125 CALML5 -0.021 ITGAD -0.172 ARHGAP5 -0.45 
ITGA3 0.649 UBA1 0.42 RALB 0.229 RAPGEF1 0.125 DNAJB7 -0.021 CAMK2B -0.173 PIK3R1 -0.451 
RHOC 0.648 NCK2 0.414 CAMK1 0.227 WASL 0.124 DNAJA4 -0.026 HSPA2 -0.176 GNAZ -0.455 
ARF4 0.64 PARVA 0.411 ITGA6 0.217 ITGA10 0.121 UBE2B -0.028 PAK6 -0.184 GAB2 -0.457 
ACTA2 0.639 LCP2 0.409 UBE2L6 0.213 PPP1CC 0.121 PICK1 -0.031 PIK3CB -0.185 RND2 -0.475 
ACTG1 0.615 ITGAV 0.396 UBE2N 0.213 DNAJC16 0.12 HTT -0.037 TSPAN3 -0.194 TNK2 -0.49 
DNAJC10 0.608 GNA12 0.395 PIK3R6 0.203 RAF1 0.12 RHOB -0.037 DNAJB2 -0.204 SH3GL3 -0.498 
PARVB 0.603 PPP1CB 0.395 RHOG 0.202 RHOH 0.12 HSPA14 -0.066 AKT3 -0.21 PFN2 -0.502 
ILK 0.6 VAV2 0.389 DNAJC11 0.201 UBE2J1 0.119 RHOU -0.07 GLS -0.213 PPARA -0.511 
ARF6 0.599 ITGB5 0.386 HSPA8 0.199 HIP1 0.118 DNAJB8 -0.075 DNAJB13 -0.214 DNAJB12 -0.531 
GNAI3 0.599 CTSD 0.382 UBE2E3 0.199 WAS 0.112 FNBP1 -0.076 ATM -0.216 GNAI1 -0.535 
UBE2S 0.597 CRK 0.38 ITGB4 0.198 UBE2G2 0.103 TSPAN5 -0.08 PPP1R12B -0.22 TSPAN7 -0.536 
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ACTB 0.59 DNAJC3 0.373 ATP5B 0.197 ITGA9 0.099 DNAJB14 -0.081 MYLK3 -0.223 HSPA1L -0.538 
NRAS 0.587 TLN1 0.373 GNA11 0.197 DNAJC1 0.094 PIK3CA -0.081 KRAS -0.227 WASF1 -0.542 
ACTG2 0.581 UBE2M 0.372 DNM2 0.196 PLCG2 0.088 ITGB7 -0.087 GNG3 -0.242 PAK3 -0.569 
HSPA6 0.578 UBD 0.371 PIK3CG 0.196 DNAJA1 0.086 PIK3C2B -0.087 ITGA2B -0.246 GNAL -0.585 
VASP 0.572 IRS2 0.37 HRAS 0.195 ITGAX 0.086 UBE2D1 -0.087 GRM7 -0.255 PAK7 -0.604 
ITGA4 0.568 LIMS1 0.366 SMURF2 0.195 BRAF 0.085 GNA13 -0.09 BIRC6 -0.266 RAP2A -0.605 
RAP1B 0.565 SDHB 0.356 NCK1 0.193 GNG2 0.085 DNAJB4 -0.092 CAMK1G -0.267 CAMK2G -0.612 
RND3 0.557 RHOA 0.347 PFN4 0.191 UBE3A 0.085 ILKAP -0.092 BCAR1 -0.268 DNM3 -0.66 
RRAS 0.541 DNAJA3 0.339 ABL1 0.187 DNAJC5 0.081 OPN1SW -0.095 DNAJC18 -0.268 DNAJC12 -0.705 
VCL 0.531 GNAI2 0.337 ITGA11 0.187 GRB7 0.071 DNAJA2 -0.097 GNG4 -0.284 
  ITGA2 0.529 UBE2H 0.33 NEDD4 0.186 AR 0.069 PPP1R12A -0.097 MAP2K4 -0.284 
  CAV1 0.526 HSPA9 0.324 ITGAL 0.185 UBE2D2 0.066 CAMK2D -0.103 DNAJC5G -0.288 
  AHR 0.523 PAK4 0.32 UBE2Q1 0.183 PIK3C2A 0.055 DNAJC21 -0.105 TLN2 -0.289 
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Appendix Table A3. Pearson correlation of ILK pathway genes with IGFBP2 
 
ILK Pathway 
Gene Pearson Gene Pearson Gene Pearson Gene Pearson Gene Pearson Gene Pearson Gene Pearson Gene 
VEGFA 0.837 UBE2I 0.504 RHOD 0.291 PPP2CA 0.165 FLNB 0.03 CAMK2D -0.103 ITGA2B -0.246 HSPA1L 
FLNA 0.754 AKT2 0.495 ITGAE 0.287 DNAJC8 0.161 GSK3B 0.027 DNAJC21 -0.105 NACA -0.251 CAMK2G 
RHOJ 0.751 UBE2J2 0.493 UBE2D4 0.285 RHOF 0.161 ACTN3 0.024 TESK1 -0.105 GRM7 -0.255 PPP2R5A 
HSPA4 0.746 UBE2F 0.488 ACTC1 0.283 PTGES3 0.152 PPP2R5C 0.021 TNNT3 -0.107 TNF -0.26 DNM3 
ACTN1 0.742 PXN 0.482 GNB1 0.282 NEDD4L 0.151 UBE2G1 0.015 PPP2CB -0.111 BIRC6 -0.266 DNAJC12 
GNG5 0.732 UBE2A 0.48 RHOT2 0.281 PIK3CD 0.151 UBE3B 0.012 MYH13 -0.119 CAMK1G -0.267 RICTOR 
TPM4 0.718 FLNC 0.475 HIF1A 0.279 ACTA1 0.15 MYH6 0.01 MYL2 -0.122 DNAJC18 -0.268 
 ITGA7 0.699 AKT1 0.473 GNB2L1 0.271 GNG7 0.141 PIK3R2 0.01 MYH2 -0.129 MYH3 -0.271 
 ITGA5 0.697 UBE2D3 0.462 GNB1L 0.267 MTOR 0.14 CCND1 0.007 IRS1 -0.13 EP300 -0.273 
 HSP90B1 0.696 TCF3 0.461 PIK3R3 0.267 DNAJC17 0.138 DNAJB5 -0.002 SH2B2 -0.13 TNNT2 -0.275 
 MYH9 0.695 SMURF1 0.454 ATF4 0.255 MAPK1 0.137 MYL5 -0.003 UBE2L3 -0.133 PDPK1 -0.283 
 CASP3 0.692 PPP2R1B 0.451 SNAI1 0.254 GSK3A 0.136 TNNI3 -0.007 MYH4 -0.134 DNAJC5G -0.288 
 TGFB1I1 0.689 NFE2L2 0.45 GSN 0.25 DNAJC13 0.132 HSP90AB1 -0.01 ITGB6 -0.136 PPP2R3A -0.293 
 FBLIM1 0.677 ITGB2 0.449 DNAJB9 0.247 CTNNB1 0.127 DNAJC7 -0.011 ARHGEF6 -0.143 CREB3L4 -0.303 
 DIRAS3 0.675 RHOQ 0.449 PIK3C3 0.246 UBE2E1 0.126 CALML5 -0.021 TNNI1 -0.143 TNNT1 -0.303 
 ITGB1 0.671 ITGB8 0.448 RSU1 0.246 DNAJC4 0.125 DNAJB7 -0.021 CFL2 -0.151 PPP2R2B -0.304 
 HSPA5 0.664 MYL4 0.441 CAMK1 0.227 ITGA10 0.121 MYC -0.024 MYL7 -0.151 PNCK -0.312 
 DNAJB11 0.661 CREB5 0.43 PTGS2 0.22 DNAJC16 0.12 DNAJA4 -0.026 PIK3R4 -0.157 CAMK2A -0.319 
 DNAJB1 0.659 GNG11 0.429 ITGA6 0.217 RHOH 0.12 UBE2B -0.028 DNM1 -0.158 UBE2R2 -0.321 
 ACTN4 0.654 DNAJC14 0.424 UBE2L6 0.213 UBE2J1 0.119 BCL9 -0.031 MYH10 -0.16 MAP2K6 -0.324 
 MYL6 0.651 UBA1 0.42 UBE2N 0.213 HIP1 0.118 PICK1 -0.031 MYH8 -0.16 SNCA -0.332 
 ITGA3 0.649 NCK2 0.414 PIK3R6 0.203 ATF2 0.115 TNNI2 -0.033 RHOV -0.162 PTK2 -0.334 
 RHOC 0.648 MUC1 0.411 PPM1J 0.202 HNF1A 0.108 PPAP2B -0.035 RHOT1 -0.164 PIK3C2G -0.337 
 ACTA2 0.639 PARVA 0.411 RHOG 0.202 VEGFC 0.106 TAF4 -0.036 SRC -0.164 DOCK1 -0.338 
 MYL9 0.637 ITGAV 0.396 DNAJC11 0.201 UBE2G2 0.103 HTT -0.037 DNAJC5B -0.165 DCTN1 -0.342 
 JUN 0.636 ITGB5 0.386 HSPA8 0.199 ITGA9 0.099 RHOB -0.037 PGF -0.167 CAMK4 -0.368 
 TPM2 0.627 CTSD 0.382 UBE2E3 0.199 TNNC1 0.099 MYH1 -0.043 PPM1L -0.167 GNB3 -0.371 
 ACTG1 0.615 DNAJC3 0.373 ITGB4 0.198 DNAJC1 0.094 FIGF -0.045 PTPN11 -0.167 MYH7B -0.39 
 MMP9 0.609 UBE2M 0.372 ATP5B 0.197 CREB3 0.09 TCF4 -0.048 GNB5 -0.172 AIP -0.404 
 DNAJC10 0.608 UBD 0.371 DNM2 0.196 DNAJA1 0.086 ACTN2 -0.063 ITGAD -0.172 HSPB8 -0.404 
 FN1 0.603 IRS2 0.37 PIK3CG 0.196 ITGAX 0.086 HSPA14 -0.066 CAMK2B -0.173 PPP2R2C -0.415 
 PARVB 0.603 FERMT2 0.367 SMURF2 0.195 GNG2 0.085 RHOU -0.07 HSPA2 -0.176 TCF7L2 -0.424 
 SNAI2 0.601 SDHB 0.356 PPP2R2A 0.194 UBE3A 0.085 MYH11 -0.071 PIK3CB -0.185 UBE2E2 -0.429 
 ILK 0.6 FOS 0.353 ITGA11 0.187 DNAJC5 0.081 DNAJB8 -0.075 PPP2R5B -0.201 DNAJC6 -0.432 
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UBE2S 0.597 PDGFC 0.351 NEDD4 0.186 MYL6B 0.079 FNBP1 -0.076 TCF7L1 -0.201 NR3C1 -0.434 
 ACTB 0.59 RHOA 0.347 ITGAL 0.185 AR 0.069 DNAJB14 -0.081 DNAJB2 -0.204 MYH7 -0.438 
 ACTG2 0.581 DNAJA3 0.339 UBE2Q1 0.183 UBE2D2 0.066 PIK3CA -0.081 FKBP4 -0.204 PTEN -0.444 
 HSPA6 0.578 TPM1 0.335 DNAJC15 0.18 NDEL1 0.061 TNNC2 -0.085 RPS6KA4 -0.205 PIK3R1 -0.451 
 ITGA4 0.568 NOS2 0.334 HSP90AA1 0.18 PPP2R5D 0.059 ITGB7 -0.087 AKT3 -0.21 MYH14 -0.453 
 CHD1 0.562 UBE2H 0.33 PPP2R4 0.178 PIK3C2A 0.055 PIK3C2B -0.087 PROK1 -0.211 GAB2 -0.457 
 RND3 0.557 HSPA9 0.324 VEGFB 0.177 ITGA8 0.05 UBE2D1 -0.087 GLS -0.213 RND2 -0.475 
 LEF1 0.545 PPP2R1A 0.323 ITGAM 0.175 TBP 0.045 TAF9B -0.088 DNAJB13 -0.214 CREBBP -0.486 
 VCL 0.531 CFL1 0.311 PPP2R5E 0.175 PPP2R3B 0.042 DNAJB4 -0.092 ATM -0.216 SH3GL3 -0.498 
 ITGA2 0.529 CDC34 0.308 PIK3R5 0.171 DSP 0.038 ILKAP -0.092 IRS4 -0.216 PPARA -0.511 
 AHR 0.523 CREB1 0.304 UBE2V2 0.171 DNAJC9 0.033 DNAJA2 -0.097 MYL3 -0.231 BMP2 -0.521 
 ITGB3 0.513 GNB4 0.296 MAF 0.165 DNAJC19 0.03 PPP1R12A -0.097 MYL1 -0.236 DNAJB12 -0.531 
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Appendix Table A4. Altered signaling pathways resulting from disruption of IGFBP2-integrin binding. 
Pathways 
 -log         
(p-value) 
Ratio Molecules 
Virus Entry via Endocytic 
Pathways 
9.02E00 2.3E-01 
RAC2,FLNB,ITSN1,RRAS,PIK3R1,ACTA2,HRAS,PLCG1,ITGA5,ITGB8,ACTG1,PRKCZ,ITGB3,HLA-A,FLNA,MRAS,HLA-
B,PRKCE,ACTG2,CXADR,ITGB5,HLA-C,PRKCA 
Molecular Mechanisms of 
Cancer 
8.57E00 1.29E-01 
PRKACB,RAF1,GAB2,RAC2,DIRAS3,PIK3R1,SUV39H1,HRAS,CCND1,PTK2,CAMK2D,MRAS,HIPK2,FZD2,ARHGEF4,RRAS,CDKN2D,ARHGEF17,RHO
J,BCL2L1,RHOQ,ARHGEF16,FZD5,LEF1,FNBP1,CDK2,TCF4,HIF1A,MAP3K5,PRKCZ,ARHGEF19,SHC1,HHAT,FANCD2,BBC3,RHOU,TGFB2,PRKCE,A
RHGEF2,PRKCA,MAPK8,GNAI1,FADD,PRKAR2B,FOXO1,CDKN1A,BMP6,WNT5A,CTNND1 
ILK Signaling 7.67E00 1.66E-01 
MYH10,FLNB,FN1,PIK3R1,DIRAS3,ACTA2,PDPK1,HIF1A,ITGB8,CCND1,PTK2,FLNA,KRT18,RHOU,IRS2,ACTG2,DSP,ITGB5,MUC1,FBLIM1,MAPK8,
VEGFC,RHOJ,ACTG1,ITGB3,RHOQ,SNAI2,MYH9,LEF1,RPS6KA5,PPP2R1B,FNBP1 
IGF-1 Signaling 7.45E00 2.06E-01 
PRKACB,IGFBP6,SOCS3,RAF1,RRAS,PIK3R1,SOCS2,MAPK8,HRAS,PDPK1,IGFBP5,IGFBP7,PRKCZ,IGFBP2,GRB10,PTK2,SHC1,PRKAR2B,FOXO1,IGF
BP3,MRAS,IRS2 
Integrin Signaling 6.9E00 1.52E-01 
RAC2,RAF1,PIK3R1,DIRAS3,ACTA2,HRAS,PPP1CB,ITGB8,MYLK,PTK2,SHC1,MRAS,RHOU,ACTG2,TSPAN4,ITGB5,RRAS,ASAP1,MAPK8,ITGA5,PLC
G1,RHOJ,ACTG1,ITGB3,WIPF1,RHOQ,ARF5,TLN2,ARF3,TSPAN6,ITGA7,FNBP1 
PTEN Signaling 6.74E00 1.77E-01 
RAC2,RAF1,RRAS,FGFR1,PIK3R1,HRAS,PDPK1,ITGA5,FOXG1,CCND1,PRKCZ,PTK2,FGFR3,BCL2L1,SHC1,FOXO1,CDKN1A,KDR,PDGFRA,MRAS,FGF
RL1,MAGI3 
HER-2 Signaling in Breast 
Cancer 
6.56E00 2.22E-01 
RRAS,PIK3R1,NRG1 (includes 
EG:112400),HRAS,PLCG1,ITGB8,MAP3K5,CCND1,PRKCZ,ITGB3,FOXO1,CDKN1A,MRAS,PRKCE,ERBB2,PARD3,ITGB5,PRKCA 
Thrombin Signaling 6.29E00 1.45E-01 
RAF1,F2R,PIK3R1,DIRAS3,HRAS,PDPK1,GNG13,PPP1CB,PRKCZ,MYLK,PTK2,SHC1,CAMK2D,GNG11,MRAS,RHOU,PRKCE,ARHGEF2,GNG4,PRKCA
,ARHGEF4,RRAS,GNAI1,PLCG1,RHOJ,ITPR1,RHOQ,ARHGEF16,ITPR3,FNBP1 
IL-8 Signaling 6.18E00 1.45E-01 
RAC2,RAF1,NAPEPLD,PIK3R1,DIRAS3,HRAS,GNG13,CCND1,PRKCZ,PTK2,HMOX1,GNG11,RHOU,MRAS,PRKCE,GNG4,PRKCA,ANGPT1,RRAS,MA
PK8,GNAI1,VEGFC,RHOJ,BCL2L1,RHOQ,ARAF,KDR,FNBP1 
Agrin Interactions at 
Neuromuscular Junction 
5.94E00 2.32E-01 RAC2,NRG2,RRAS,ACTA2,NRG1 (includes EG:112400),MAPK8,HRAS,ITGA5,ACTG1,ITGB3,PTK2,MRAS,UTRN,ACTG2,ERBB2,AGRN 
α-Adrenergic Signaling 5.66E00 1.7E-01 PRKACB,RAF1,RRAS,GNAI1,GNG13,HRAS,PLCG1,ITPR1,PRKCZ,GNG11,PRKAR2B,ITPR3,MRAS,HLA-B,PRKCE,SLC8A1,GNG4,PRKCA 
Glioma Invasiveness 
Signaling 
5.51E00 2.33E-01 F2R,RRAS,DIRAS3,PIK3R1,HRAS,RHOJ,ITGB3,PTK2,TIMP4,RHOQ,MRAS,RHOU,FNBP1,ITGB5 
Caveolar-mediated 
Endocytosis Signaling 
5.43E00 1.88E-01 FLNB,ARCN1,ITSN1,ACTA2,ITGA5,ITGB8,ACTG1,ITGB3,HLA-A,FLNA,HLA-B,ACTG2,ITGA7,ITGB5,HLA-C,PRKCA 
Cholecystokinin/Gastrin-
mediated Signaling 
5.36E00 1.79E-01 RAF1,RRAS,DIRAS3,MAPK8,HRAS,RHOJ,ITPR1,PRKCZ,PTK2,SHC1,RHOQ,ITPR3,CREM,MRAS,RHOU,PRKCE,MEF2C,FNBP1,PRKCA 
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Role of NFAT in Cardiac 
Hypertrophy 
5.29E00 1.3E-01 
PRKACB,RAF1,LIF,PIK3R1,HRAS,GNG13,IL6,PRKCZ,SHC1,CAMK2D,GNG11,MRAS,TGFB2,PRKCE,GNG4,PRKCA,RRAS,MAPK8,GNAI1,PLCG1,ITPR1
,RCAN1,PRKAR2B,ITPR3,MEF2C,SLC8A1,IL11 
Breast Cancer Regulation 
by Stathmin1 
5.18E00 1.33E-01 
PRKACB,RAF1,PIK3R1,GNG13,HRAS,PPP1CB,PRKCZ,ARHGEF19,SHC1,CAMK2D,GNG11,MRAS,PRKCE,ARHGEF2,GNG4,PRKCA,ARHGEF4,RRAS,G
NAI1,TUBA4A,ARHGEF17,ITPR1,PRKAR2B,ARHGEF16,ITPR3,CDKN1A,PPP2R1B,CDK2 
VEGF Signaling 5.09E00 1.72E-01 RAF1,RRAS,PIK3R1,ACTA2,HRAS,VEGFC,PLCG1,HIF1A,ACTG1,PTK2,SHC1,BCL2L1,FOXO1,KDR,MRAS,ACTG2,PRKCA 
Axonal Guidance 
Signaling 
5.09E00 1.04E-01 
SLIT3,PRKACB,RAF1,RAC2,ITSN1,EPHB2,PIK3R1,HRAS,GNG13,ROBO1,PRKCZ,PTK2,SHC1,GNG11,EFNB1,ABLIM3,MRAS,PRKCE,ERBB2,EFNB3,SE
MA3B,FZD2,RTN4R,GNG4,PRKCA,NGEF,NRP2,RRAS,TUBA4A,GNAI1,ITGA5,VEGFC,SLIT2,DPYSL5,EPHA3,SEMA3A,WIPF1,PRKAR2B,ADAM12,PL
XNB1,FZD5,BMP6,EPHA2,WNT5A,NRP1 
Glioblastoma Multiforme 
Signaling 
4.99E00 1.4E-01 
RAF1,RRAS,PIK3R1,DIRAS3,HRAS,PLCG1,RHOJ,ITPR1,CCND1,SHC1,RHOQ,FOXO1,CDKN1A,ITPR3,PDGFRA,MRAS,RHOU,LEF1,FZD5,FZD2,FNBP1
,CDK2,WNT5A 
G Beta Gamma Signaling 4.96E00 1.45E-01 PRKACB,RAF1,RRAS,GNAI1,GNG13,HRAS,PDPK1,PLCG1,PRKCZ,SHC1,GNG11,PRKAR2B,MRAS,PRKCE,CAV2,GNG4,PRKCA 
Phospholipase C Signaling 4.55E00 1.15E-01 
RAF1,NAPEPLD,DIRAS3,HRAS,GNG13,PPP1CB,PRKCZ,ARHGEF19,SHC1,HMOX1,GNG11,AHNAK,MRAS,RHOU,PRKCE,ARHGEF2,GNG4,PRKCA,AR
HGEF4,RRAS,ITGA5,PLCG1,ARHGEF17,RHOJ,ITPR1,RHOQ,ARHGEF16,ITPR3,MEF2C,FNBP1 
Semaphorin Signaling in 
Neurons 
4.52E00 2.31E-01 PTK2,MET,SEMA3A,RHOQ,DPYSL3,DIRAS3,PLXNB1,RHOU,RHOJ,DPYSL5,FNBP1,NRP1 
VDR/RXR Activation 4.48E00 1.85E-01 IGFBP6,SPP1,IGFBP5,HES1 (includes EG:15205),PRKCZ,COL13A1,FOXO1,RUNX2,CDKN1A,TGFB2,CEBPA,IGFBP3,PRKCE,SEMA3B,PRKCA 
Germ Cell-Sertoli Cell 
Junction Signaling 
4.42E00 1.38E-01 
RAC2,RRAS,PIK3R1,DIRAS3,ACTA2,PVRL3,TUBA4A,MAPK8,HRAS,PDPK1,RHOJ,MAP3K5,GSN,ACTG1,PTK2,RHOQ,MRAS,RHOU,TGFB2,JUP,ACT
G2,FNBP1,CTNND1 
Bladder Cancer Signaling 4.36E00 1.74E-01 RAF1,MMP3,RRAS,THBS1,SUV39H1,MMP14,VEGFC,HRAS,CCND1,FGF13,FGFR3,FGF12,CDKN1A,MRAS,RPS6KA5,ERBB2 
HGF Signaling 4.33E00 1.62E-01 RAF1,RRAS,PIK3R1,MAPK8,HRAS,PLCG1,IL6,MAP3K5,CCND1,PRKCZ,PTK2,MET,CDKN1A,MRAS,PRKCE,CDK2,PRKCA 
Renin-Angiotensin 
Signaling 
4.31E00 1.43E-01 PRKACB,RAF1,RRAS,PIK3R1,MAPK8,HRAS,PLCG1,ITPR1,PRKCZ,PTK2,SHC1,PRKAR2B,CCL2,SHC2,ITPR3,MRAS,PRKCE,PRKCA 
Insulin Receptor Signaling 4.27E00 1.43E-01 PRKACB,RAF1,SOCS3,RRAS,PIK3R1,MAPK8,PPP1CB,HRAS,PDPK1,LIPE,PRKCZ,GRB10,SHC1,PRKAR2B,RHOQ,FOXO1,MRAS,ACCN2,HLA-B,IRS2 
Thrombopoietin Signaling 4.26E00 1.9E-01 GAB2,SHC1,RAF1,RRAS,PIK3R1,MRAS,PRKCE,PLCG1,HRAS,IRS2,PRKCZ,PRKCA 
Prolactin Signaling 4.21E00 1.75E-01 RAF1,SOCS3,RRAS,PIK3R1,SOCS2,PLCG1,PDPK1,HRAS,PRKCZ,SHC1,MRAS,PRKCE,NMI,PRKCA 
Non-Small Cell Lung 
Cancer Signaling 
4.14E00 1.65E-01 RAF1,RRAS,PIK3R1,SUV39H1,PLCG1,PDPK1,HRAS,ITPR1,CCND1,ITPR3,MRAS,ERBB2,PRKCA 
FGF Signaling 4.09E00 1.67E-01 RAF1,PIK3R1,FGFR1,MAPK8,HRAS,PLCG1,MAP3K5,ITPR1,FGF13,FGFR3,MET,FGF12,RPS6KA5,FGFRL1,PRKCA 
Glioma Signaling 4.01E00 1.43E-01 RAF1,RRAS,SUV39H1,PIK3R1,CDKN2D,HRAS,PLCG1,CCND1,PRKCZ,SHC1,CAMK2D,CDKN1A,PDGFRA,MRAS,PRKCE,PRKCA 
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Macropinocytosis 
Signaling 
3.93E00 1.71E-01 RRAS,PIK3R1,PLCG1,ITGA5,HRAS,ITGB8,PRKCZ,ITGB3,MET,MRAS,PRKCE,ITGB5,PRKCA 
Colorectal Cancer 
Metastasis Signaling 
3.91E00 1.12E-01 
PRKACB,TCF4,MMP3,PIK3R1,DIRAS3,MMP14,HRAS,GNG13,IL6,CCND1,GNG11,MRAS,TGFB2,RHOU,FZD2,GNG4,PTGER4,RRAS,MAPK8,VEGFC,
RHOJ,BCL2L1,PRKAR2B,RHOQ,FZD5,LEF1,TCF7L2,FNBP1,WNT5A 
Neuregulin Signaling 3.85E00 1.47E-01 RAF1,NRG2,RRAS,PIK3R1,NRG1 (includes EG:112400),HRAS,PLCG1,ITGA5,PDPK1,PRKCZ,SHC1,MRAS,PRKCE,ERBB2,PRKCA 
Ephrin Receptor Signaling 3.81E00 1.15E-01 
RAC2,RAF1,NGEF,ITSN1,ANGPT1,EPHB2,RRAS,PTPN13,GNAI1,GNG13,HRAS,VEGFC,ITGA5,EPHA3,PTK2,SHC1,WIPF1,GNG11,EFNB1,MRAS,EFN
B3,GNG4,EPHA2 
CXCR4 Signaling 3.72E00 1.24E-01 
RAF1,RRAS,PIK3R1,DIRAS3,MAPK8,GNAI1,GNG13,HRAS,RHOJ,ITPR1,PRKCZ,PTK2,GNG11,RHOQ,ITPR3,MRAS,RHOU,PRKCE,GNG4,FNBP1,PRKC
A 
Prostate Cancer Signaling 3.7E00 1.44E-01 RAF1,RRAS,SUV39H1,PIK3R1,PDPK1,HRAS,CCND1,FOXO1,CDKN1A,MRAS,NKX3-1,LEF1,CDK2,GSTP1 
Actin Cytoskeleton 
Signaling 
3.61E00 1.09E-01 
RAC2,RAF1,MYH10,FN1,F2R,PIK3R1,ACTA2,PPP1CB,HRAS,SSH1,FGF13,MYLK,PTK2,SHC1,FGF12,MRAS,ACTG2,ARHGEF4,RRAS,RDX,ITGA5,GSN
,ACTG1,TIAM2,MYH9,PIP4K2A 
mTOR Signaling 3.57E00 1.14E-01 
NAPEPLD,DDIT4,RRAS,PIK3R1,DIRAS3,HRAS,PDPK1,FKBP1A,VEGFC,RHOJ,HIF1A,RPS4Y1,PRKCZ,HMOX1,RHOQ,MRAS,RHOU,PRKCE,RPS4Y2,RP
S6KA5,PPP2R1B,AKT1S1,FNBP1,PRKCA 
CCR3 Signaling in 
Eosinophils 
3.55E00 1.35E-01 RAF1,RRAS,PIK3R1,GNAI1,PPP1CB,GNG13,HRAS,ITPR1,PRKCZ,MYLK,GNG11,ITPR3,MRAS,PRKCE,CCL26,GNG4,PRKCA 
Erythropoietin Signaling 3.4E00 1.54E-01 SHC1,RAF1,SOCS3,RRAS,PIK3R1,MRAS,PRKCE,PLCG1,PDPK1,HRAS,PRKCZ,PRKCA 
Acute Myeloid Leukemia 
Signaling 
3.37E00 1.59E-01 RAF1,TCF4,RRAS,PIK3R1,HRAS,CCND1,ARAF,CSF2RA,CEBPA,MRAS,LEF1,JUP,TCF7L2 
FAK Signaling 3.37E00 1.37E-01 RAF1,ASAP1,RRAS,PIK3R1,ACTA2,HRAS,PLCG1,ITGA5,PDPK1,ACTG1,PTK2,TLN2,MRAS,ACTG2 
PI3K/AKT Signaling 3.33E00 1.21E-01 GAB2,RAF1,RRAS,PIK3R1,HRAS,PDPK1,ITGA5,MAP3K5,CCND1,PRKCZ,SHC1,BCL2L1,FOXO1,CDKN1A,MRAS,HLA-B,PPP2R1B 
Chemokine Signaling 3.28E00 1.64E-01 PTK2,RAF1,CAMK2D,CCL2,RRAS,MAPK8,MRAS,GNAI1,PLCG1,HRAS,PPP1CB,PRKCA 
Tight Junction Signaling 3.18E00 1.22E-01 
PRKACB,MYH10,TJP2,RAB13,ACTA2,PVRL3,CSDA,SYMPK,ACTG1,PRKCZ,MYLK,F11R,PRKAR2B,MPP5,CEBPA,TGFB2,MYH9,ARHGEF2,ACTG2,PP
P2R1B 
Leukocyte Extravasation 
Signaling 
3.18E00 1.15E-01 
RAC2,MMP3,PIK3R1,MMP14,ACTA2,RDX,GNAI1,MAPK8,ARHGAP4,THY1,PLCG1,ACTG1,PRKCZ,PTK2,F11R,TIMP4,WIPF1,SIPA1,PRKCE,ARHGA
P12,ACTG2,PRKCA,CTNND1 
GNRH Signaling 3.12E00 1.16E-01 PRKACB,RAF1,RRAS,MAPK8,GNAI1,HRAS,DNM3,ITPR1,MAP3K5,PRKCZ,PTK2,CAMK2D,PRKAR2B,ITPR3,MRAS,PRKCE,PRKCA 
Role of Osteoblasts, 
Osteoclasts and 
Chondrocytes in 
Rheumatoid Arthritis 
3.06E00 1.04E-01 
TCF4,MMP3,MMP14,PIK3R1,IL6,MAP3K5,RUNX2,TRAF5,FZD2,ADAMTS4,CTSK,SPP1,MAPK8,ITGA5,GSN,ITGB3,FOXO1,LEF1,FZD5,SFRP1,DKK1,
BMP6,TCF7L2,WNT5A,IL11 
Protein Kinase A Signaling 3.03E00 9.76E-02 
PRKACB,AKAP12,RAF1,MYH10,FLNB,TCF4,LIPE,GNG13,PPP1CB,PRKCZ,MYLK,PTK2,CAMK2D,GNG11,HHAT,FLNA,TGFB2,HLA-
B,PRKCE,GNG4,HIST1H1B,PRKCA,H1F0,GNAI1,PLCG1,ITPR1,ANAPC4,PRKAR2B,CREM,ITPR3,LEF1,TCF7L2 
Biosynthesis of Steroids 3.03E00 4.96E-02 SQLE,FDFT1,DHCR7,IDI1,HMGCR,SC5DL 
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Regulation of Actin-based 
Motility by Rho 
3E00 1.43E-01 RAC2,DIRAS3,ACTA2,PPP1CB,RHOJ,GSN,MYLK,WIPF1,RHOQ,RHOU,ACTG2,PIP4K2A,FNBP1 
EGF Signaling 2.97E00 1.73E-01 SHC1,RAF1,PIK3R1,ITPR3,MAPK8,PLCG1,HRAS,ITPR1,PRKCA 
Cardiac Hypertrophy 
Signaling 
2.95E00 1.02E-01 
PRKACB,RAF1,PIK3R1,DIRAS3,GNG13,HRAS,IL6,MAP3K5,GNG11,TGFB2,RHOU,MRAS,GNG4,ADRA1B,MAPKAPK3,RRAS,GNAI1,MAPK8,PLCG1,
CACNA1C,RHOJ,PRKAR2B,RHOQ,MEF2C,FNBP1 
P2Y Purigenic Receptor 
Signaling Pathway 
2.92E00 1.17E-01 PRKACB,RAF1,RRAS,PIK3R1,GNAI1,GNG13,HRAS,PLCG1,PRKCZ,ITGB3,GNG11,PRKAR2B,MRAS,PRKCE,GNG4,PRKCA 
Factors Promoting 
Cardiogenesis in 
Vertebrates 
2.86E00 1.37E-01 TCF4,PRKCZ,TGFB2,PRKCE,LEF1,FZD5,MEF2C,DKK1,BMP6,FZD2,TCF7L2,CDK2,PRKCA 
Endothelin-1 Signaling 2.85E00 1.09E-01 RAF1,NAPEPLD,RRAS,PIK3R1,GNAI1,MAPK8,HRAS,PLCG1,CASP4,ITPR1,PRKCZ,SHC1,HMOX1,ARAF,SHC2,ITPR3,MRAS,PRKCE,CASP5,PRKCA 
Human Embryonic Stem 
Cell Pluripotency 
2.81E00 1.1E-01 TCF4,S1PR2,PIK3R1,FGFR1,PDPK1,SOX2,FGFR3,TGFB2,MRAS,PDGFRA,LEF1,FZD5,FGFRL1,BMP6,FZD2,TCF7L2,WNT5A 
Growth Hormone 
Signaling 
2.78E00 1.47E-01 SOCS3,PIK3R1,SOCS2,CEBPA,IGFBP3,PRKCE,PLCG1,PDPK1,RPS6KA5,PRKCZ,PRKCA 
NRF2-mediated Oxidative 
Stress Response 
2.78E00 1.09E-01 
RAF1,PRDX1,RRAS,PIK3R1,GSTA4,ACTA2,HSPB8,MAPK8,HRAS,MAP3K5,JUNB,ACTG1,PRKCZ,GSR,HMOX1,MRAS,PRKCE,CDC34,ACTG2,GSTP1,P
RKCA 
Neuroprotective Role of 
THOP1 in Alzheimer's 
Disease 
2.76E00 1.48E-01 PRKACB,PRKAR2B,HLA-A,HLA-E,HLA-B,HLA-G,HLA-C,HLA-F 
Antigen Presentation 
Pathway 
2.76E00 1.86E-01 PSMB9,HLA-A,HLA-E,HLA-B,HLA-G,TAP1,HLA-C,HLA-F 
Crosstalk between 
Dendritic Cells and 
Natural Killer Cells 
2.72E00 1.35E-01 ACTA2,CD83,IL6,ACTG1,HLA-F,TLN2,CAMK2D,HLA-A,HLA-E,HLA-B,ACTG2,HLA-G,HLA-C 
Clathrin-mediated 
Endocytosis Signaling 
2.66E00 1.1E-01 MYO6,F2R,EPHB2,PIK3R1,ACTA2,GAK,VEGFC,DNM3,ITGA5,ITGB8,HIP1,ACTG1,FGF13,ITGB3,MET,FGF12,LDLRAP1,ACTG2,ITGB5 
IL-3 Signaling 2.63E00 1.49E-01 GAB2,SHC1,RAF1,FOXO1,RRAS,PIK3R1,MRAS,PRKCE,HRAS,PRKCZ,PRKCA 
Melanoma Signaling 2.61E00 1.74E-01 RAF1,RRAS,MITF,PIK3R1,CDKN1A,MRAS,HRAS,CCND1 
Synaptic Long Term 
Potentiation 
2.59E00 1.23E-01 PRKACB,RAF1,RRAS,PPP1CB,CACNA1C,HRAS,ITPR1,PRKCZ,PRKAR2B,CAMK2D,ITPR3,MRAS,PRKCE,PRKCA 
Fcγ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 
2.59E00 1.27E-01 GAB2,RAC2,NAPEPLD,PIK3R1,ACTA2,PLCG1,ACTG1,PRKCZ,HMOX1,TLN2,PRKCE,ACTG2,PRKCA 
Endometrial Cancer 
Signaling 
2.58E00 1.58E-01 RAF1,RRAS,PIK3R1,MRAS,PDPK1,HRAS,LEF1,ERBB2,CCND1 
GM-CSF Signaling 2.57E00 1.49E-01 SHC1,BCL2L1,RAF1,CAMK2D,RRAS,CSF2RA,PIK3R1,MRAS,HRAS,CCND1 
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14-3-3-mediated 
Signaling 
2.57E00 1.25E-01 RAF1,RRAS,PIK3R1,MAPK8,TUBA4A,HRAS,PLCG1,MAP3K5,PRKCZ,FOXO1,MRAS,PRKCE,GFAP,AKT1S1,PRKCA 
Oncostatin M Signaling 2.55E00 2E-01 SHC1,RAF1,MMP3,RRAS,MT2A,MRAS,HRAS 
NF-κB Activation by 
Viruses 
2.53E00 1.34E-01 RAF1,RRAS,PIK3R1,MRAS,PRKCE,ITGA5,HRAS,ITGB5,PRKCZ,PRKCA,ITGB3 
Thyroid Cancer Signaling 2.48E00 1.74E-01 SHC1,TCF4,RRAS,MRAS,HRAS,LEF1,CCND1,TCF7L2 
Melanocyte Development 
and Pigmentation 
Signaling 
2.47E00 1.3E-01 PRKACB,SHC1,RAF1,PRKAR2B,MC1R,RRAS,MITF,PIK3R1,MRAS,PLCG1,HRAS,RPS6KA5 
fMLP Signaling in 
Neutrophils 
2.44E00 1.09E-01 RAF1,RRAS,PIK3R1,GNAI1,GNG13,HRAS,ITPR1,PRKCZ,GNG11,ITPR3,MRAS,PRKCE,GNG4,PRKCA 
p70S6K Signaling 2.42E00 1.15E-01 RAF1,F2R,EEF2,RRAS,PIK3R1,GNAI1,HRAS,PLCG1,PDPK1,PRKCZ,SHC1,MRAS,PRKCE,PPP2R1B,PRKCA 
Ovarian Cancer Signaling 2.41E00 1.13E-01 PRKACB,RAF1,TCF4,RRAS,SUV39H1,PIK3R1,HRAS,VEGFC,CCND1,PRKAR2B,MRAS,LEF1,FZD5,FZD2,TCF7L2,WNT5A 
ERK/MAPK Signaling 2.32E00 9.8E-02 
PRKACB,RAC2,RAF1,RRAS,PIK3R1,PPP1CB,HRAS,PLCG1,ITGA5,PTK2,SHC1,PRKAR2B,TLN2,ARAF,DUSP1,MRAS,PRKCE,RPS6KA5,PPP2R1B,PRKC
A 
CREB Signaling in 
Neurons 
2.31E00 9.41E-02 PRKACB,RAF1,RRAS,PIK3R1,GNAI1,GNG13,HRAS,PLCG1,ITPR1,PRKCZ,SHC1,GNG11,CAMK2D,PRKAR2B,ITPR3,MRAS,PRKCE,GNG4,PRKCA 
PAK Signaling 2.3E00 1.12E-01 PTK2,MYLK,SHC1,RAF1,RRAS,PIK3R1,MAPK8,MRAS,PDGFRA,ITGA5,HRAS,EPHA3 
Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 
2.3E00 8.71E-02 
SOCS3,RAF1,TCF4,FN1,MMP3,PIK3R1,HRAS,IL6,CCND1,CEBPG,PRKCZ,CAMK2D,CCL2,MRAS,CEBPA,PRKCE,TRAF5,FZD2,PRKCA,ADAMTS4,RRAS
,PLCG1,VEGFC,LEF1,FZD5,DKK1,SFRP1,TCF7L2,WNT5A 
Androgen Signaling 2.3E00 9.72E-02 PRKACB,GNAI1,GNG13,CCND1,PRKCZ,SHC1,HSPA4,GNG11,PRKAR2B,MRAS,PRKCE,TAF2,GNG4,PRKCA 
CCR5 Signaling in 
Macrophages 
2.23E00 1.06E-01 GNG11,MAPK8,MRAS,GNAI1,PRKCE,PLCG1,GNG13,GNG4,PRKCZ,PRKCA 
Melatonin Signaling 2.23E00 1.3E-01 PRKACB,RAF1,PRKAR2B,CAMK2D,ARAF,GNAI1,PRKCE,PLCG1,PRKCZ,PRKCA 
Neurotrophin/TRK 
Signaling 
2.23E00 1.3E-01 SHC1,RAF1,RRAS,PIK3R1,MAPK8,MRAS,PLCG1,PDPK1,HRAS,MAP3K5 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
2.17E00 1.09E-01 MYH10,FN1,FGFR1,ACTA2,VEGFC,IGFBP5,IL6,MET,LY96,CCL2,KDR,IGFBP3,PDGFRA,TGFB2,LAMA1,MYH9 
Mechanisms of Viral Exit 
from Host Cells 
2.14E00 1.56E-01 CHMP2B,ACTA2,PRKCE,ACTG2,ACTG1,PRKCZ,PRKCA 
PDGF Signaling 2.14E00 1.27E-01 SHC1,RAF1,RRAS,PIK3R1,MAPK8,MRAS,PDGFRA,PLCG1,HRAS,PRKCA 
Chronic Myeloid 
Leukemia Signaling 
2.12E00 1.14E-01 CTBP1,GAB2,BCL2L1,RAF1,RRAS,PIK3R1,SUV39H1,CDKN1A,MRAS,TGFB2,HRAS,CCND1 
IL-15 Signaling 2.1E00 1.34E-01 PTK2,SHC1,BCL2L1,RAF1,RRAS,PIK3R1,MRAS,PLCG1,HRAS 
JAK/Stat Signaling 2.1E00 1.41E-01 SHC1,RAF1,SOCS3,RRAS,PIK3R1,CDKN1A,SOCS2,MRAS,HRAS 
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Butanoate Metabolism 2.1E00 6.92E-02 ACAT2,C1orf93,ALDH1A3,OXCT1,LIPE,SDHC,MYO5B,HMGCS1,ELOVL6 
Pancreatic 
Adenocarcinoma 
Signaling 
2.1E00 1.09E-01 RAF1,NAPEPLD,PIK3R1,SUV39H1,MAPK8,VEGFC,CCND1,HMOX1,BCL2L1,CDKN1A,TGFB2,ERBB2,CDK2 
FcγRIIB Signaling in B 
Lymphocytes 
2.08E00 1.19E-01 SHC1,RRAS,PIK3R1,MAPK8,MRAS,PDPK1,HRAS 
PI3K Signaling in B 
Lymphocytes 
2.07E00 1.05E-01 RAF1,ATF3,RRAS,PIK3R1,PLCG1,PDPK1,HRAS,MALT1,PLEKHA4,ITPR1,PRKCZ,CAMK2D,ITPR3,MRAS,IRS2 
LPS-stimulated MAPK 
Signaling 
2.05E00 1.22E-01 RAF1,RRAS,PIK3R1,MAPK8,MRAS,PRKCE,HRAS,MAP3K5,PRKCZ,PRKCA 
AMPK Signaling 1.98E00 8.93E-02 PRKACB,CPT1A,PIK3R1,LIPE,PDPK1,AK5,PRKAR2B,HLA-B,MRAS,AK4,IRS2,HMGCR,PPP2R1B,ADRA1B,PPAT 
Sphingosine-1-phosphate 
Signaling 
1.97E00 1.07E-01 S1PR2,DIRAS3,PIK3R1,GNAI1,PLCG1,RHOJ,CASP4,PTK2,RHOQ,PDGFRA,RHOU,CASP5,FNBP1 
Apoptosis Signaling 1.88E00 1.15E-01 ENDOG,BCL2L1,RAF1,RRAS,MAPK8,MRAS,PRKCE,PLCG1,HRAS,MAP3K5,PRKCA 
Ceramide Signaling 1.86E00 1.15E-01 CTSD,RAF1,S1PR2,RRAS,PIK3R1,MAPK8,MRAS,HRAS,PPP2R1B,PRKCZ 
Reelin Signaling in 
Neurons 
1.82E00 1.22E-01 PAFAH1B2,ARHGEF4,PIK3R1,CNR1,ARHGEF16,MAPK8,ITGA5,LRP8,ARHGEF2,ITGB3 
Aldosterone Signaling in 
Epithelial Cells 
1.81E00 9.41E-02 RAF1,SACS,PIK3R1,HSPB8,PDPK1,PLCG1,ITPR1,PRKCZ,HSPA4,DUSP1,ITPR3,HSPB11,ACCN2,PRKCE,PIP4K2A,PRKCA 
Fc Epsilon RI Signaling 1.81E00 1.08E-01 RAF1,RAC2,RRAS,PIK3R1,MAPK8,MRAS,PRKCE,PLCG1,PDPK1,HRAS,PRKCZ,PRKCA 
Graft-versus-Host Disease 
Signaling 
1.81E00 1.4E-01 HLA-A,HLA-E,HLA-B,IL6,HLA-G,HLA-C,HLA-F 
Glutamate Metabolism 1.8E00 8E-02 GSR,GNPNAT1,GLUL,MYO5B,PPAT,GFPT2 
p53 Signaling 1.75E00 1.15E-01 BCL2L1,BBC3,THBS1,PIK3R1,SNAI2,CDKN1A,MAPK8,HIPK2,CCND1,CDK2,DRAM1 
HMGB1 Signaling 1.72E00 1.1E-01 RHOQ,CCL2,RRAS,DIRAS3,PIK3R1,MAPK8,MRAS,RHOU,HRAS,RHOJ,FNBP1 
Myc Mediated Apoptosis 
Signaling 
1.71E00 1.31E-01 FADD,SHC1,RRAS,PIK3R1,MAPK8,MRAS,HRAS,PRKCZ 
FLT3 Signaling in 
Hematopoietic 
Progenitor Cells 
1.65E00 1.22E-01 GAB2,SHC1,RAF1,RRAS,PIK3R1,MRAS,PDPK1,HRAS,RPS6KA5 
BMP signaling pathway 1.65E00 1.12E-01 PRKACB,RAF1,PRKAR2B,RRAS,RUNX2,MAPK8,MRAS,HRAS,BMP6 
Role of NANOG in 
Mammalian Embryonic 
Stem Cell Pluripotency 
1.64E00 1.05E-01 SOX2,SHC1,RAF1,LIF,RRAS,PIK3R1,MRAS,HRAS,FZD5,BMP6,FZD2,WNT5A 
Type I Diabetes Mellitus 
Signaling 
1.64E00 9.92E-02 FADD,SOCS3,HLA-A,HLA-E,SOCS2,MAPK8,HLA-B,MYO5B,MAP3K5,HLA-G,HLA-C,HLA-F 
Lysine Degradation 1.6E00 5.76E-02 TMLHE,PLOD2,ACAT2,C1orf93,ALDH1A3,SUV39H1,PIPOX,ELOVL6 
133 
 
Corticotropin Releasing 
Hormone Signaling 
1.58E00 8.82E-02 PRKACB,RAF1,PRKAR2B,CNR1,ITPR3,GNAI1,PRKCE,PLCG1,MEF2C,ITPR1,PRKCZ,PRKCA 
O-Glycan Biosynthesis 1.57E00 1.14E-01 ST6GALNAC6,GCNT1,ST3GAL1,WBSCR17,ST3GAL4 
Huntington's Disease 
Signaling 
1.57E00 8.4E-02 PIK3R1,MAPK8,GNG13,HRAS,PDPK1,DNM3,CASP4,ITPR1,UBE2S,HIP1,PRKCZ,BCL2L1,SHC1,HSPA4,CTSD,GNG11,PRKCE,GNG4,CASP5,PRKCA 
Antiproliferative Role of 
Somatostatin Receptor 2 
1.56E00 1.13E-01 GNG11,RRAS,PIK3R1,CDKN1A,MRAS,HRAS,GNG13,GNG4 
Role of MAPK Signaling in 
the Pathogenesis of 
Influenza 
1.56E00 1.21E-01 RAF1,CCL2,RRAS,MAPK8,MRAS,HRAS,MAP3K5,PRKCA 
CDK5 Signaling 1.56E00 1.06E-01 PRKACB,LAMA5,RAF1,PRKAR2B,RRAS,LAMA1,MRAS,HRAS,PPP1CB,PPP2R1B 
Synthesis and 
Degradation of Ketone 
Bodies 
1.55E00 1.58E-01 ACAT2,OXCT1,HMGCS1 
IL-2 Signaling 1.5E00 1.21E-01 SHC1,RAF1,RRAS,PIK3R1,MAPK8,MRAS,HRAS 
Acute Phase Response 
Signaling 
1.5E00 8.99E-02 ECSIT,RAF1,SOCS3,TCF4,FN1,RRAS,PIK3R1,SOCS2,MAPK8,HRAS,PDPK1,IL6,MAP3K5,HMOX1,SHC1,MRAS 
Production of Nitric Oxide 
and Reactive Oxygen 
Species in Macrophages 
1.49E00 8.02E-02 DIRAS3,PIK3R1,MAPK8,PPP1CB,PLCG1,RHOJ,MAP3K5,PRKCZ,RHOQ,RHOU,PRKCE,PPP2R1B,FNBP1,SIRPA,PRKCA 
NF-κB Signaling 1.48E00 9.09E-02 PRKACB,RRAS,RELB,PIK3R1,FGFR1,MAPK8,HRAS,MALT1,PRKCZ,TAB3,FGFR3,KDR,PDGFRA,MRAS,TRAF5,FGFRL1 
TREM1 Signaling 1.46E00 1.06E-01 CCL2,LAT2,PLCG1,ITGA5,CD83,IL6,CASP5 
Pentose Phosphate 
Pathway 
1.46E00 6.1E-02 RBKS,PGD,PGM2L1,PGM1,TKTL1 
Natural Killer Cell 
Signaling 
1.43E00 9.91E-02 SHC1,RAF1,RAC2,RRAS,PIK3R1,MRAS,PRKCE,PLCG1,HRAS,PRKCZ,PRKCA 
Rac Signaling 1.43E00 8.94E-02 PTK2,RAF1,RRAS,PIK3R1,MAPK8,MRAS,ITGA5,HRAS,PARD3,PIP4K2A,PRKCZ 
Cellular Effects of 
Sildenafil (Viagra) 
1.41E00 8.61E-02 PRKACB,MYH10,ACTA2,CACNA1C,PLCG1,PPP1CB,ITPR1,ACTG1,MYLK,PRKAR2B,ITPR3,MYH9,ACTG2 
IL-9 Signaling 1.36E00 1.25E-01 SOCS3,PIK3R1,SOCS2,IRS2,BCL3 
G Protein Signaling 
Mediated by Tubby 
1.36E00 1.19E-01 GNG11,MRAS,PLCG1,GNG13,GNG4 
SAPK/JNK Signaling 1.36E00 9.8E-02 FADD,SHC1,RAC2,GNG11,RRAS,PIK3R1,MAPK8,MRAS,HRAS,MAP3K5 
MSP-RON Signaling 
Pathway 
1.32E00 1.18E-01 CCL2,PIK3R1,ACTA2,ACTG2,ACTG1,PRKCZ 
Role of JAK2 in Hormone-
like Cytokine Signaling 
1.31E00 1.35E-01 SHC1,SOCS3,SOCS2,IRS2,SIRPA 
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Glycerophospholipid 
Metabolism 
1.31E00 6.52E-02 PPAPDC1A,HMOX1,NAPEPLD,LPCAT2,PPP2R2D,GPD2,BCHE,CHKA,PLCG1,AGPAT9,LPIN2,ELOVL6 
Role of Tissue Factor in 
Cancer 
1.3E00 9.65E-02 BCL2L1,RRAS,PIK3R1,MRAS,VEGFC,HRAS,RPS6KA5,F3,ITGB5,PRKCA,ITGB3 
Cdc42 Signaling 1.3E00 8.33E-02 RAF1,MAPK8,PPP1CB,ITGA5,PRKCZ,HLA-F,MYLK,WIPF1,HLA-A,HLA-E,FNBP1L,HLA-B,PARD3,HLA-G,HLA-C 
Autoimmune Thyroid 
Disease Signaling 
1.29E00 9.84E-02 HLA-A,HLA-E,HLA-B,HLA-G,HLA-C,HLA-F 
Aryl Hydrocarbon 
Receptor Signaling 
1.28E00 8.18E-02 GSTA4,MAPK8,IL6,CCND1,CTSD,ALDH1A3,CDKN1A,TGFB2,NFIB,NRIP1,ALDH16A1,GSTP1,CDK2 
IL-17 Signaling 1.26E00 1.08E-01 CCL2,MMP3,RRAS,PIK3R1,MAPK8,MRAS,HRAS,IL6 
RhoA Signaling 1.26E00 9.65E-02 PTK2,MYLK,NGEF,ACTA2,ARHGAP4,RDX,ARHGAP12,PPP1CB,ACTG2,PIP4K2A,ACTG1 
TR/RXR Activation 1.25E00 9.38E-02 RAB3B,AKR1C3,SREBF2,PIK3R1,THRA,BCL3,HIF1A,DIO2,NRGN 
OX40 Signaling Pathway 1.23E00 9.47E-02 BCL2L1,HLA-A,HLA-E,MAPK8,HLA-B,TRAF5,HLA-G,HLA-C,HLA-F 
Neuropathic Pain 
Signaling In Dorsal Horn 
Neurons 
1.21E00 9.26E-02 PRKACB,PRKAR2B,CAMK2D,PIK3R1,ITPR3,PRKCE,PLCG1,ITPR1,PRKCZ,PRKCA 
PPARα/RXRα Activation 1.19E00 8.06E-02 PRKACB,RAF1,RRAS,MAPK8,PLCG1,HRAS,IL6,ABCA1,SHC1,PRKAR2B,GPD2,TGFB2,MRAS,ITGB5,PRKCA 
ERK5 Signaling 1.19E00 1.09E-01 LIF,RRAS,MRAS,HRAS,MEF2C,RPS6KA5,PRKCZ 
Type II Diabetes Mellitus 
Signaling 
1.17E00 6.88E-02 SOCS3,PIK3R1,SOCS2,MAPK8,PRKCE,PDPK1,IRS2,SLC27A3,MAP3K5,PRKCZ,PRKCA 
RAR Activation 1.16E00 8.02E-02 PRKACB,TRIM24,PIK3R1,MAPK8,PDPK1,MAP3K5,PRKCZ,PRKAR2B,DUSP1,ALDH1A3,TGFB2,IGFBP3,PRKCE,NRIP1,PRKCA 
Role of JAK1 and JAK3 in 
γc Cytokine Signaling 
1.16E00 1.03E-01 SHC1,SOCS3,RRAS,PIK3R1,MRAS,HRAS,IRS2 
Phenylalanine 
Metabolism 
1.14E00 4.5E-02 DHCR24,PRDX5,PRDX1,ALDH1A3,ELOVL6 
B Cell Receptor Signaling 1.14E00 8.33E-02 GAB2,RAF1,RAC2,RRAS,PIK3R1,MAPK8,HRAS,MALT1,MAP3K5,SHC1,BCL2L1,CAMK2D,MRAS 
CNTF Signaling 1.11E00 1.09E-01 RAF1,RRAS,PIK3R1,MRAS,HRAS,RPS6KA5 
Angiopoietin Signaling 1.1E00 9.46E-02 PTK2,ANGPT1,FOXO1,RRAS,PIK3R1,MRAS,HRAS 
Gα12/13 Signaling 1.09E00 8.59E-02 PTK2,RAF1,F2R,RRAS,PIK3R1,MAPK8,MRAS,HRAS,MEF2C,MAP3K5,CDH11 
IL-1 Signaling 1.08E00 8.41E-02 PRKACB,ECSIT,GNG11,PRKAR2B,MAPK8,MRAS,GNAI1,GNG13,GNG4 
Regulation of IL-2 
Expression in Activated 
and Anergic T 
Lymphocytes 
1.07E00 8.99E-02 RAF1,RRAS,MAPK8,MRAS,TGFB2,PLCG1,HRAS,MALT1 
Cyclins and Cell Cycle 1.07E00 8.99E-02 RAF1,SUV39H1,CDKN1A,CDKN2D,TGFB2,PPP2R1B,CCND1,CDK2 
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Regulation 
Nitric Oxide Signaling in 
the Cardiovascular 
System 
1.07E00 8E-02 PRKACB,PRKAR2B,PIK3R1,KDR,ITPR3,CACNA1C,VEGFC,ITPR1 
Role of IL-17F in Allergic 
Inflammatory Airway 
Diseases 
1E00 1.09E-01 RAF1,CCL2,RPS6KA5,IL6,IL11 
Regulation of eIF4 and 
p70S6K Signaling 
9.99E-01 7.26E-02 RAF1,RRAS,PIK3R1,ITGA5,PDPK1,HRAS,EIF2C2,RPS4Y1,PRKCZ,SHC1,MRAS,RPS4Y2,PPP2R1B 
Inositol Phosphate 
Metabolism 
9.94E-01 6.67E-02 INPP4B,ARAF,PIK3R1,MTMR14,MTMR1,MAPK8,MTM1,PRKCE,PLCG1,GRK5,PIP4K2A,CDK2 
Cell Cycle: G1/S 
Checkpoint Regulation 
9.9E-01 9.84E-02 SUV39H1,CDKN1A,NRG1 (includes EG:112400),TGFB2,CCND1,CDK2 
Sulfur Metabolism 9.79E-01 5.08E-02 SULT1A1,PAPSS1,CHST11 
Renal Cell Carcinoma 
Signaling 
9.67E-01 9.46E-02 MET,RAF1,RRAS,PIK3R1,MRAS,HRAS,HIF1A 
Basal Cell Carcinoma 
Signaling 
9.67E-01 9.59E-02 TCF4,LEF1,FZD5,BMP6,FZD2,TCF7L2,WNT5A 
Small Cell Lung Cancer 
Signaling 
9.43E-01 7.87E-02 PTK2,BCL2L1,PIK3R1,SUV39H1,TRAF5,CCND1,CDK2 
Glycine, Serine and 
Threonine Metabolism 
9.43E-01 4.79E-02 C1orf93,PIPOX,CHKA,PHGDH,PLCG1,TARS,ELOVL6 
Xenobiotic Metabolism 
Signaling 
9.4E-01 7.26E-02 
RAF1,RRAS,PIK3R1,GSTA4,MAPK8,HRAS,IL6,MAP3K5,PRKCZ,HS6ST1,HMOX1,CAMK2D,ALDH1A3,SULT1A1,MRAS,PRKCE,CHST11,NRIP1,ALDH1
6A1,PPP2R1B,GSTP1,PRKCA 
Synaptic Long Term 
Depression 
9.37E-01 7.48E-02 RAF1,RRAS,ITPR3,MRAS,GNAI1,PRKCE,HRAS,ITPR1,PPP2R1B,PRKCZ,PRKCA 
Estrogen Receptor 
Signaling 
9.37E-01 8.09E-02 CTBP1,SHC1,RAF1,RRAS,MED30,MRAS,HRAS,NRIP1,MED10,TAF2,G6PC3 
Protein Ubiquitination 
Pathway 
9.24E-01 7.3E-02 PSMB9,SACS,UBE2H,HSPB8,USP54,UBE2S,TAP1,FZR1,USP31,UCHL1,ANAPC4,HSPA4,HLA-A,HSPB11,HLA-B,USP46,CDC34,USP25,HLA-C,UBE2I 
Systemic Lupus 
Erythematosus Signaling 
9.23E-01 7.02E-02 LSM14B,RRAS,PIK3R1,HRAS,PLCG1,IL6,HLA-F,HLA-A,LSM7,HLA-E,CREM,HLA-B,MRAS,HLA-G,HLA-C,PRPF38A 
Glucocorticoid Receptor 
Signaling 
9.12E-01 6.78E-02 PRKACB,RAF1,RRAS,PIK3R1,PBX1,MAPK8,HRAS,IL6,SHC1,BCL2L1,HSPA4,CCL2,DUSP1,CDKN1A,MRAS,CEBPA,TGFB2,NRIP1,TAF2,UBE2I 
Role of NFAT in 
Regulation of the 
Immune Response 
9E-01 7E-02 RAF1,RRAS,PIK3R1,GNAI1,GNG13,PLCG1,HRAS,ITPR1,RCAN1,GNG11,ITPR3,MRAS,MEF2C,GNG4 
PKCθ Signaling in T 
Lymphocytes 
8.96E-01 7.04E-02 RAC2,CAMK2D,RRAS,PIK3R1,MAPK8,MRAS,PLCG1,HRAS,MALT1,MAP3K5 
Galactose Metabolism 8.78E-01 4.67E-02 C1orf93,PGM2L1,PGM1,GANAB,G6PC3 
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HIF1α Signaling 8.55E-01 8.33E-02 MMP3,RRAS,MMP14,PIK3R1,MAPK8,MRAS,VEGFC,HRAS,HIF1A 
Cardiac β-adrenergic 
Signaling 
8.53E-01 7.14E-02 PRKACB,AKAP12,GNG11,PRKAR2B,MRAS,CACNA1C,GNG13,PPP1CB,SLC8A1,PPP2R1B,GNG4 
Cell Cycle Regulation by 
BTG Family Proteins 
8.52E-01 1.11E-01 BTG2,PPP2R1B,CCND1,CDK2 
Calcium-induced T 
Lymphocyte Apoptosis 
8.35E-01 8.57E-02 ITPR3,PRKCE,PLCG1,ITPR1,PRKCZ,PRKCA 
Glycolysis/Gluconeogene
sis 
8.32E-01 5.97E-02 ALDH1A3,PGM2L1,PGM1,ENO2,ACYP1,ACYP2,G6PC3,BPGM 
Communication between 
Innate and Adaptive 
Immune Cells 
8.13E-01 7.34E-02 HLA-A,HLA-E,HLA-B,CD83,IL6,HLA-G,HLA-C,HLA-F 
iCOS-iCOSL Signaling in T 
Helper Cells 
8.02E-01 7.38E-02 GAB2,SHC1,CAMK2D,PIK3R1,ITPR3,PLCG1,PDPK1,PLEKHA4,ITPR1 
CD27 Signaling in 
Lymphocytes 
7.71E-01 8.77E-02 BCL2L1,CD70,MAPK8,TRAF5,MAP3K5 
Role of JAK family kinases 
in IL-6-type Cytokine 
Signaling 
7.64E-01 1.11E-01 SOCS3,MAPK8,IL6 
Keratan Sulfate 
Biosynthesis 
7.47E-01 9.26E-02 HS6ST1,ST3GAL1,SULT1A1,CHST11,ST3GAL4 
ATM Signaling 7.47E-01 9.26E-02 FANCD2,CDKN1A,MAPK8,CDK2,SMC1A 
LPS/IL-1 Mediated 
Inhibition of RXR 
Function 
7.45E-01 6.82E-02 ECSIT,CPT1A,GSTA4,MAPK8,ABCA1,HS6ST1,LY96,ALDH1A3,SULT1A1,CHST11,FABP7,SLC27A3,ALDH16A1,HMGCS1,GSTP1 
Wnt/β-catenin Signaling 7.38E-01 7.47E-02 TCF4,CCND1,SOX2,TLE4,TGFB2,LEF1,FZD5,SFRP1,DKK1,PPP2R1B,FZD2,TCF7L2,WNT5A 
Cytotoxic T Lymphocyte-
mediated Apoptosis of 
Target Cells 
7.32E-01 8.14E-02 FADD,HLA-A,HLA-E,HLA-B,HLA-G,HLA-C,HLA-F 
Docosahexaenoic Acid 
(DHA) Signaling 
7.32E-01 8.16E-02 BCL2L1,FOXO1,PIK3R1,PDPK1 
Antiproliferative Role of 
TOB in T Cell Signaling 
7.28E-01 1.15E-01 TGFB2,CDC34,CDK2 
Valine, Leucine and 
Isoleucine Degradation 
7.25E-01 5.56E-02 BCAT1,ACAT2,ALDH1A3,OXCT1,HMGCS1,ELOVL6 
Glycosphingolipid 
Biosynthesis - Lactoseries 
7.18E-01 7.14E-02 ST3GAL1,ST3GAL4 
T Cell Receptor Signaling 7.07E-01 7.34E-02 RAF1,RRAS,PIK3R1,MAPK8,MRAS,PLCG1,HRAS,MALT1 
IL-4 Signaling 7.05E-01 8.22E-02 SHC1,RRAS,PIK3R1,MRAS,HMGA1,HRAS 
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Lymphotoxin β Receptor 
Signaling 
7.01E-01 8.2E-02 BCL2L1,PIK3R1,RELB,PDPK1,TRAF5 
TGF-β Signaling 6.95E-01 7.87E-02 RAF1,RRAS,RUNX2,MAPK8,MRAS,TGFB2,HRAS 
Glycosphingolipid 
Biosynthesis - 
Ganglioseries 
6.95E-01 5.17E-02 ST3GAL1,ST3GAL4,ELOVL6 
Glycosaminoglycan 
Degradation 
6.95E-01 5.26E-02 HYAL3,SGSH,FGFRL1 
Calcium Signaling 6.89E-01 6.28E-02 PRKACB,MYH10,TPM1 (includes EG:22003),TNNT1,ACTA2,ITPR1,RCAN1,PRKAR2B,CAMK2D,ITPR3,MYH9,MEF2C,SLC8A1 
PXR/RXR Activation 6.85E-01 6.74E-02 PRKACB,SCD,PRKAR2B,CPT1A,FOXO1,IL6 
Starch and Sucrose 
Metabolism 
6.66E-01 3.55E-02 UCHL1,PGM2L1,PGM1,HLA-B,GANAB,G6PC3 
IL-15 Production 6.63E-01 9.38E-02 PTK2,IL6,PRKCZ 
Nicotinate and 
Nicotinamide Metabolism 
6.6E-01 5.88E-02 NNMT,ARAF,NT5E,NT5M,MAPK8,PRKCE,GRK5,CDK2 
Hereditary Breast Cancer 
Signaling 
6.32E-01 6.98E-02 FANCD2,RRAS,PIK3R1,CDKN1A,MRAS,HRAS,RFC1,CCND1,FANCA 
RAN Signaling 6.29E-01 8.7E-02 RCC1,TNPO1 
Extrinsic Prothrombin 
Activation Pathway 
6.29E-01 1E-01 TFPI,F3 
RANK Signaling in 
Osteoclasts 
6.28E-01 7.37E-02 RAF1,MITF,PIK3R1,MAPK8,TRAF5,MAP3K5,GSN 
Mitochondrial 
Dysfunction 
6.11E-01 5.71E-02 MT-COI,GSR,CPT1A,PRDX5,GPD2,MAPK8,SDHC,DHODH,BACE2,PINK1 
Death Receptor Signaling 5.98E-01 7.69E-02 TNFRSF21,FADD,TNFRSF25,MAPK8,MAP3K5 
Methane Metabolism 5.91E-01 2.99E-02 PRDX5,PRDX1 
Induction of Apoptosis by 
HIV1 
5.79E-01 7.58E-02 FADD,BCL2L1,BBC3,MAPK8,MAP3K5 
Estrogen-Dependent 
Breast Cancer Signaling 
5.79E-01 7.14E-02 RRAS,PIK3R1,MRAS,HRAS,CCND1 
Leptin Signaling in 
Obesity 
5.79E-01 7.14E-02 PRKACB,SOCS3,PRKAR2B,FOXO1,PIK3R1,PLCG1 
Selenoamino Acid 
Metabolism 
5.78E-01 4.35E-02 PAPSS1,FTSJ1,SCLY 
LXR/RXR Activation 5.63E-01 6.45E-02 SCD,LY96,CCL2,IL6,HMGCR,ABCA1 
Differential Regulation of 
Cytokine Production in 
Macrophages and T 
5.55E-01 1.11E-01 CCL2,IL6 
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Helper Cells by IL-17A 
and IL-17F 
Parkinson's Signaling 5.55E-01 1.11E-01 UCHL1,MAPK8 
Endoplasmic Reticulum 
Stress Pathway 
5.55E-01 1.11E-01 MAPK8,MAP3K5 
Mitotic Roles of Polo-Like 
Kinase 
5.44E-01 7.69E-02 ANAPC4,PLK2,PPP2R1B,FZR1,SMC1A 
Role of Wnt/GSK-3β 
Signaling in the 
Pathogenesis of Influenza 
5.32E-01 7.41E-02 TCF4,LEF1,FZD5,FZD2,TCF7L2,WNT5A 
Role of CHK Proteins in 
Cell Cycle Checkpoint 
Control 
5.29E-01 8.57E-02 CDKN1A,RFC1,CDK2 
IL-6 Signaling 5.25E-01 7E-02 SHC1,RAF1,RRAS,MAPK8,MRAS,HRAS,IL6 
Granzyme A Signaling 5.22E-01 1E-01 H1F0,HIST1H1B 
Ascorbate and Aldarate 
Metabolism 
5.22E-01 2.5E-02 C1orf93,ALDH1A3 
Stilbene, Coumarine and 
Lignin Biosynthesis 
5.22E-01 2.7E-02 PRDX5,PRDX1 
Inhibition of Angiogenesis 
by TSP1 
5.06E-01 7.69E-02 THBS1,KDR,MAPK8 
PPAR Signaling 4.99E-01 6.54E-02 SHC1,RAF1,RRAS,MRAS,PDGFRA,HRAS,NRIP1 
Phospholipid Degradation 4.89E-01 6.12E-02 PPAPDC1A,HMOX1,NAPEPLD,PPP2R2D,PLCG1,LPIN2 
Chondroitin Sulfate 
Biosynthesis 
4.87E-01 6.15E-02 HS6ST1,SULT1A1,CHST11,DSE 
Coagulation System 4.84E-01 7.89E-02 F2R,TFPI,F3 
Amyloid Processing 4.7E-01 7.14E-02 PRKACB,PRKAR2B,PRKCE,BACE2 
Hypoxia Signaling in the 
Cardiovascular System 
4.64E-01 7.35E-02 UBE2H,HIF1A,CDC34,UBE2S,UBE2I 
Pyruvate Metabolism 4.64E-01 3.68E-02 ACAT2,ALDH1A3,ME3,ACYP1,ACYP2 
Pantothenate and CoA 
Biosynthesis 
4.64E-01 3.17E-02 BCAT1,DPYSL3 
Nitrogen Metabolism 4.63E-01 2.48E-02 CA9,ASRGL1,GLUL 
Allograft Rejection 
Signaling 
4.62E-01 6.25E-02 HLA-A,HLA-E,HLA-B,HLA-G,HLA-C,HLA-F 
cAMP-mediated signaling 4.61E-01 6.39E-02 PRKACB,AKAP12,RAF1,CNR1,GNAI1,RGS4,CHRM3,CAMK2D,PRKAR2B,MC1R,DUSP1,HTR7,CREM,PTGER4 
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G-Protein Coupled 
Receptor Signaling 
4.59E-01 6.04E-02 
PRKACB,RAF1,F2R,PIK3R1,PTHLH,PDPK1,HRAS,CHRM3,HRH1,SHC1,CAMK2D,MC1R,HTR7,MRAS,PRKCE,FZD2,BAI2,PTGER4,ADRA1B,PRKCA,O
XTR,S1PR2,RRAS,CNR1,GNAI1,RGS4,CD97,GPR64,PRKAR2B,DUSP1,FZD5,LGR4 
Polyamine Regulation in 
Colon Cancer 
4.38E-01 6.9E-02 TCF4,SAT1 
Relaxin Signaling 4.34E-01 5.7E-02 PRKACB,GNG11,PRKAR2B,PIK3R1,MRAS,GNAI1,GNG13,GNG4,PRKCZ 
Notch Signaling 4.24E-01 6.98E-02 NOTCH2,LFNG,HES1 (includes EG:15205) 
Aminosugars Metabolism 3.96E-01 4.1E-02 GNPNAT1,C1orf93,CYB5R2,NANS,GFPT2 
Role of BRCA1 in DNA 
Damage Response 
3.92E-01 6.56E-02 FANCD2,CDKN1A,RFC1,FANCA 
IL-22 Signaling 3.91E-01 8E-02 SOCS3,MAPK8 
Tumoricidal Function of 
Hepatic Natural Killer 
Cells 
3.91E-01 8.33E-02 ENDOG,FADD 
Role of PKR in Interferon 
Induction and Antiviral 
Response 
3.89E-01 6.52E-02 FADD,TRAF5,RNASEL 
EIF2 Signaling 3.88E-01 5.86E-02 EIF2AK1,RAF1,RRAS,PIK3R1,PDPK1,HRAS,EIF2C2,PPP1CB,RPS4Y1,SHC1,RPL28,MRAS,RPS4Y2 
p38 MAPK Signaling 3.85E-01 6.6E-02 FADD,MAPKAPK3,DUSP1,TGFB2,MEF2C,RPS6KA5,MAP3K5 
Tyrosine Metabolism 3.84E-01 2.53E-02 ALDH1A3,COMT,FTSJ1,LRTOMT,ELOVL6 
Purine Metabolism 3.84E-01 4.25E-02 TJP2,AMPD1,PAICS,ATP5S,AMPD2,TAP1,NME3,AK5,NT5E,MPP5,IMPDH1,NT5M,PAPSS1,MYH9,AK4,PFAS,PPAT 
Nucleotide Sugars 
Metabolism 
3.83E-01 1.52E-02 C1orf93 
Assembly of RNA 
Polymerase I Complex 
3.83E-01 7.69E-02 TAF1C 
Hepatic Cholestasis 3.79E-01 5.11E-02 PRKACB,LY96,PRKAR2B,TJP2,MAPK8,PRKCE,IL6,PRKCZ,PRKCA 
Glutamate Receptor 
Signaling 
3.78E-01 5.8E-02 GNG11,GLUL,SLC38A1,HOMER3 
Propanoate Metabolism 3.78E-01 3.31E-02 ACAT2,DHCR24,ALDH1A3,SLC27A3 
Glycosphingolipid 
Biosynthesis - 
Globoseries 
3.7E-01 4.76E-02 ST3GAL1,ST3GAL4 
Glutathione Metabolism 3.52E-01 4.4E-02 GSR,PGD,GSTA4,GSTP1 
Dopamine Receptor 
Signaling 
3.49E-01 5.26E-02 PRKACB,PRKAR2B,COMT,PPP1CB,PPP2R1B 
Fatty Acid Biosynthesis 3.49E-01 2.04E-02 SLC27A3 
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Cell Cycle Control of 
Chromosomal Replication 
3.31E-01 6.45E-02 DBF4,CDK2 
Role of Oct4 in 
Mammalian Embryonic 
Stem Cell Pluripotency 
3.14E-01 6.67E-02 SOX2,SPP1,FOXA1 
4-1BB Signaling in T 
Lymphocytes 
2.97E-01 5.88E-02 MAPK8,MAP3K5 
Sonic Hedgehog Signaling 2.97E-01 6.06E-02 PRKACB,PRKAR2B 
CD28 Signaling in T 
Helper Cells 
2.95E-01 5.3E-02 PIK3R1,ITPR3,MAPK8,PLCG1,PDPK1,MALT1,ITPR1 
Valine, Leucine and 
Isoleucine Biosynthesis 
2.93E-01 2.33E-02 BCAT1 
Amyotrophic Lateral 
Sclerosis Signaling 
2.92E-01 5.04E-02 BCL2L1,NEFL,PIK3R1,CACNA1C,GLUL,VEGFC 
β-alanine Metabolism 2.77E-01 3.23E-02 ALDH1A3,DPYSL3,MYO5B 
Sphingolipid Metabolism 2.7E-01 4.42E-02 LASS6,PPAPDC1A,PPP2R2D,UGCG,LPIN2 
Taurine and Hypotaurine 
Metabolism 
2.69E-01 2.22E-02 MYO5B 
Toll-like Receptor 
Signaling 
2.65E-01 5.45E-02 ECSIT,LY96,MAPK8 
Glycerolipid Metabolism 2.6E-01 3.87E-02 PPAPDC1A,PPP2R2D,ALDH1A3,LIPE,AGPAT9,LPIN2 
Histidine Metabolism 2.55E-01 2.59E-02 ALDH1A3,FTSJ1,ELOVL6 
Cysteine Metabolism 2.55E-01 3.45E-02 HS6ST1,SULT1A1,CHST11 
IL-10 Signaling 2.54E-01 5.13E-02 HMOX1,SOCS3,MAPK8,IL6 
TWEAK Signaling 2.28E-01 5.13E-02 FADD,TNFRSF25 
Interferon Signaling 2.28E-01 5.56E-02 IFIT1,TAP1 
Granzyme B Signaling 2.12E-01 6.25E-02 ENDOG 
Mismatch Repair in 
Eukaryotes 
2.12E-01 4.17E-02 RFC1 
Phenylalanine, Tyrosine 
and Tryptophan 
Biosynthesis 
1.97E-01 1.49E-02 ENO2 
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